




The Genetic Basis of Malformation of 
Cortical Development Syndromes: 
Primary Focus on Aicardi Syndrome 
 
Thuong Thi Ha 
B. Sc, M. Bio 
 
Neurogenetics Research Group 
The University of Adelaide 
 
Thesis submitted for the degree of  




Discipline of Genetics and Evolution 
School of Biological Sciences 
Faculty of Science 








Table of Contents 
Abstract 6 





CHAPTER I: Introduction 15 
1.1 Overview of Malformations of Cortical Development (MCD) 15 
1.2 Introduction into Aicardi Syndrome 16 
1.3 Clinical Features of Aicardi Syndrome 20 
1.3.1 Epidemiology 20 
1.3.2 Clinical Diagnosis 21 
1.3.3 Differential Diagnosis 23 
1.3.4 Development & Prognosis 24 
1.4 Treatment 28 
1.5 Pathogenesis of Aicardi Syndrome 29 
1.5.1 Prenatal or Intrauterine Disturbances 29 
1.5.2 Genetic Predisposition 30 
1.6 Hypothesis & Aims 41 
1.6.1 Hypothesis 41 
1.6.2 Research Aims 41 
1.7 Expected Outcomes 42 
 
CHAPTER II: Materials & Methods 43 
2.1 Study Design 43 
2.1.1 Cohort of Study 44 
2.1.2 Inheritance-based Strategy 45 
 2 
2.1.3 Ethics for human and animals 46 
2.2 Computational Methods 46 
2.2.1 Pre-Processing Raw Reads 46 
2.2.2 Sequencing Coverage 47 
2.2.3 Variant Discovery 49 
2.2.4 Annotating Variants 53 
2.2.5 Evaluating Variants 55 
2.3 Biological Methods 58 
2.3.1 Cell Culture 58 
2.3.2 Genomic DNA Sequencing 61 
2.3.3 Plasmid cloning 69 
2.3.4 RNA, whole exome & Whole Genome Sequencing 74 
2.3.5 TOPFlash Assay 75 
2.3.6 Western Blot 76 
2.3.7 Morpholino Knockdown in Zebrafish 79 
 
CHAPTER III: A mutation in COL4A2 causes autosomal dominant porencephaly with 
cataracts. 83 
3.1 Introduction 83 
3.2 Materials & Methods 87 
3.2.1 Exome Sequencing 87 
3.3 Results 88 
3.3.1 Clinical Findings 88 
3.3.2 Overview of filtered variants 93 
3.3.3 Predicted pathogenicity of COL4A2 p.G800E 94 
3.4 Discussion 96 
3.4.1 Phenotypes in human COL4A2-related disorders 96 
 3 
3.4.2 Phenotypes of COL4A2 and COL4A1 mutations in human and mice 96 
3.4.3 Prognosis of THR glycine mutations versus NGMs 97 
3.4.4 Concluding remarks 98 
3.5 Acknowledgement 100 
3.6 Publication 100 
 
CHAPTER IV: Genetical heterogeneity and complexity of Aicardi Syndrome revealed 
through whole exome and whole genome sequencing. 101 
4.1 Introduction 101 
4.2 Results 103 
4.2.1 Clinical summary of Aicardi cohort 103 
4.2.2 Coverage analysis across whole exome sequencing and whole genome sequencing. 108 
4.2.3 Detecting likely pathogenic SNP and Indels across exomes and genomes. 113 
4.2.4 Assessing the HCN1 (p.Cys542Phe) variant via Voltage clamp assay. 118 
4.2.5 Assessing the WNT8B (p.Leu70Pro) variant via TOPFlash assay. 120 
4.2.6 Morpholino-mediated knockdown of AIC candidate genes in zebrafish embryos. 123 
4.3 Discussion 125 
4.3.1 Lack of X-linked pathogenic variants 125 
4.3.2 Variants identified in known neurodevelopmental disorder genes 126 
4.3.3 Variants identified in novel disease genes 131 
4.3.4 Identifying additional carriers of variants in putative Aicardi genes 133 
4.3.5 Early developmental expression of candidate genes 139 
4.3.6 Concluding Remarks 144 
4.4 Acknowledgement 145 
4.5 Publication 145 
 
 4 
CHAPTER V: Contribution of copy number and submicroscopic structural variants to 
Aicardi Syndrome. 146 
5.1 Introduction 146 
5.2 Results 152 
5.2.1 SV Discovery Pipeline versus NA12878 genome 152 
5.2.2 Unfiltered structural variants in Aicardi cohort and Inhouse genomes 157 
5.2.3 Automated Filtering of Structural Variants in Aicardi Probands 158 
5.2.4 Manual evaluation of Structural variants in Aicardi probands 159 
5.3 Discussion 161 
5.4 Concluding Remarks 164 
5.4 Acknowledgement 165 
5.5 Publication 165 
 
CHAPTER VI: Final Discussion & Future Directions 166 
6.1 Significance of Study 166 
6.2 Limitations 168 
6.2.1 X-linked variants 168 
6.2.2 Non-coding variants 169 
6.2.3 Structural variants 170 
6.2.4 Somatic variants 171 
6.2.5 Non-Mendelian inheritance 171 
6.3 Future Directions 172 
6.3.1 Improving variant screening 172 
6.3.2 Future experimental plans 174 
6.3.3 Explaining female-bias incidence 176 
6.4 Conclusion 179 
6.5 Publication 180 
 5 
 
CHAPTER VII: Appendices 181 
7.1 Appendix Code & Data 181 
7.2 Appendix Tables 184 
7.3 Appendix Publications 191 
7.3.1 A mutation in COL4A2 causes autosomal dominant porencephaly with cataracts. 191 
7.3.2 Genetic heterogeneity of Aicardi Syndrome revealed through whole exome and whole 






Aicardi Syndrome is a rare neurodevelopmental disorder recognized by a classical triad of 
chorioretinal lacunae, infantile spasms and agenesis of the corpus callosum. The revised 
diagnostic criteria of Aicardi Syndrome have been broadened to include additional phenotypes 
outside of the classical triad that are frequently observed. Early investigations into the genetics of 
Aicardi Syndrome were predominantly focused on chromosome X for two reasons. Firstly, the 
first chromosomal aberration reported in a suspected Aicardi female was an X/3 translocation. 
Secondly, an X-linked male-lethal cause would best explain the predominance of the disease in 
females, which are represented in more than 99% of cases reported in literature. Despite 70 years 
of genetic and genomic investigations, an X-linked cause has yet to be established. 
 
We performed whole exome and genome sequencing on a cohort of 13 individuals 
diagnosed with or suspected of Aicardi Syndrome. The phenotypes displayed by of our cohort 
were clinically heterogeneous, which enabled us to query whether there are: (1) different genetic 
causes underlying different clinical subsets of Aicardi Syndrome or (2) mutations in a recurring 
gene that is pleiotropic and with variable penetrance or expressivity. We also investigated the 
molecular consequences of candidate genes using protein-specific in vitro assays and/or the 
phenotypic consequences of morpholino-mediated knockdown in zebrafish embryos.  
 
We utilised a list-based approach to enrich for variants in genes associated with eye and brain 
development. To test the efficiency of this list-based approach in finding a genetic diagnosis, we 
performed whole exome sequencing in a family with autosomal dominant disorder comprising of 
porencephaly, focal epilepsy and lens opacities. From the affected individuals in this multi-
generation family, who were negative for mutations in COL4A1, we found a rare variant in 
COL4A2. Mutations in COL4A1 are well described and result in brain abnormalities manifesting 
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with severe neurological deficits. Our findings expanded the phenotypic spectrum associated with 
COL4A2 and highlight the increasing overlap with phenotypes associated with COL4A1.   
 
We applied the same list-based approach to our Aicardi Syndrome cohort study. In five unrelated 
individuals, we identified de novo variants in HCN1, KMT2B, SLF1, SZT2 and WNT8B 
respectively. Next, we assessed the likely pathogenicity of the autosomal variants we identified 
using a combination of: pre-existing in vitro assays (HCN1 and WNT8B), published expression 
and phenotype studies in human or mice and morpholino knockdown in zebrafish (Danio rerio) 
embryos. Our findings show that causes underlying AIC are genetically heterogeneous but 
converge on molecular pathways central to cortical development. We highlighted the importance 
of utilising genetic studies to guide differential diagnosis of syndromes like Aicardi Syndrome 
that involve multiple complex traits. This will lead to better understanding of how these brain 
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CHAPTER I: Introduction 
1.1 Overview of Malformations of Cortical Development (MCD) 
Cortical development is a dynamic and multiplex process; involving the proliferation, 
differentiation, migration and organisation of neuronal cells (Guerrini and Dobyns, 2014). In 
humans, cortical development occurs in a series of overlapping morphological events during the 
first two trimesters of pregnancy (Leventer et al., 2008, Baffet et al., 2016). The process begins 
with the formation of the neural plate at 18 days post conception (dpc), followed by 
differentiation of the early embryonic brain into three divisions (prosencephalon, mesencephalon 
and rhombencephalon at 33 dpc (Barkovich et al., 2005). Next, the proliferation of cortical 
precursor cells starting in the ventricular zone. Between the 10-16th week of gestation, cell 
migration occurs in serial waves starting from the intermediate zone to the marginal zone and 
eventually reaching the cortical plate. By the 22nd week of gestation, radial or tangential 
movements of cortical cells form 6 distinctive layers of the cerebral cortex.  Finally, cortical 
organisation commences with the following molecular processes: neurite extension, 
synaptogenesis and neuronal maturation (Barkovich et al., 2005).  
 
Perturbations at any stage during neurogenesis through to neuronal migration can result in a 
variety of structural abnormalities of the brain, known as Malformations of cortical development 
(MCD) (Baffet et al., 2016). The aetiology of MCDs can be of environmental (in utero infections 
or ischaemia) or genetic inception (Leventer et al., 2008). There are genes that regulate a variety 
of cortical development processes; by both autonomous and extrinsic means (Barkovich, 2005). 
Thus unsurprisingly, variants in more than 100 genes have been identified as the cause of MCD 
in various human syndromes (Guerrini and Dobyns, 2014). MCD can lead to a variety of clinical 
manifestations with the most common being recurrent and intractable seizures; 25-40% of 
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childhood epilepsy are a consequence of MCDs (Leventer et al., 2008). Many MCD syndromes 
have been characterised and diagnosed based on clinical, imaging and genetic screening. 
However, there still remains a subset of unresolved MCD syndromes such as Aicardi Syndrome, 
whereby the genetic origins have yet to be identified.  
  
1.2 Introduction into Aicardi Syndrome 
Aicardi Syndrome (MIM 405060; AIC) is characterized by a classical triad of callosal agenesis, 
chorioretinal lacunae (CRL) and infantile spasms (Figure 1.1) (Aicardi, 2005). There are 
additional cerebral, ocular and musculoskeletal and systemic defects associated with AIC, which 
are subject to interindividual variability. The symptoms of AIC were first clinically noted by 
Krause (1946), who described an infant with intellectual disability, infantile seizures and ocular 
plaques (reminiscent of CRL). AIC was later recognised as an independent neuropathological 
entity from other congenital disorders, based on a series of 15 affected individuals (Aicardi et al., 
1969). The prevalence of AIC is estimated at 4000 cases worldwide (Kroner et al., 2008). In 
addition to previous estimates, more than 1000 cases (Figure 1.2) have been included in serial 
studies to date (Aicardi, 2005, Iwamoto et al., 2008).  
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A  B  
C  
Figure 1.1: Classical Triad of Aicardi Syndrome. A: shows a funduscopic image of typical 
chorioretinal lacunae (triangles); which usually appear in multiple, rounded and white areas 
adjacent to the optic disc (circle) (Ospina et al., 2004). B: shows a brain magnetic resonance 
image of complete agenesis of the corpus callosum (red arrow); which is the absence of the 
structure connecting the two brain hemispheres (Baierl et al., 1988). C: shows an interictal 
electroencephalograph recording of infantile spasms originating from the left hemisphere with 
high-voltage slow waves (blue squares) (Kobayashi et al., 2011).   
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Figure 1.2: Published Cases in Serial Studies between 1969 and 2012. This graph shows the 
number of Aicardi cases included in serial studies between 1969 and 2012. The author and date 
of the published studies are shown on the X axis. The numbers of included cases are labelled on 
top of the corresponding bars. This graph does not show the exact number of all Aicardi cases 
reported in literature. Individual case reports, females with cytogenetically visible findings and 
males with Aicardi syndrome are not included in this graph. There may also be replicate cases in 
studies from 2007 to 2012, where patients are sourced from northern US organisations and 
institutes.  
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The aetiology of AIC remains enigmatic (Aicardi, 2005, Van den Veyver, 2002). Environmental 
factors such as exposure to teratogenic agents or intrauterine disturbances have been refuted in 
the pathology of AIC, suggesting that the disorder is likely to have a genetic basis Donnenfeld et 
al. (1989). AIC is reported almost exclusively in females or rarely in Klinefelter males (Aicardi, 
2005, Chen et al., 2009, Hopkins et al., 1979, Shetty et al., 2014, Zubairi et al., 2009). The 
diagnosis of AIC in 46,XY males have either been disputed or disregarded in literature 
(Chappelow et al., 2008). The gender bias observed in AIC has led many to conclude that an X-
linked, male-lethal, de novo dominant mutation is responsible for the syndrome (van den Veyver, 
2002, Eble et al., 2009, Yilmaz et al., 2007). Approaches used to investigate the pathogenesis of 
AIC include: Array comparative genome hybridisation, skewed X-inactivation studies, candidate 
gene sequencing, whole exome and whole genome sequencing and cytogenetic examinations. 
Despite the investigative efforts thus far, no convincing candidate gene or locus has yet to be 
identified (Eble et al., 2009, Yilmaz et al., 2007, Wieacker et al., 1985, Anderson et al., 2009, 
Hoag et al., 1997, Neidich et al., 1990, Nielsen et al., 1991, Wang et al., 2009, Pai et al., 2013, 




1.3 Clinical Features of Aicardi Syndrome 
1.3.1 Epidemiology 
Based on a cohort of 408 individuals with confirmed or suspected AIC, the incidence of AIC was 
estimated at one in every 99,000 to 183,000 live births in European and US populations 
respectively (Kroner et al., 2008). The emerging reports of individuals with milder forms of AIC 
suggest the prevalence may be higher than predicted, as a majority of earlier reports described 
severe or atypical forms of the disorder (Saddichha et al., 2007, King et al., 1998, Menezes et al., 
1994, Matlary et al., 2004, Grosso et al., 2007, Yacoub et al., 2003, Lee et al., 2004, Prats Vinas 
et al., 2005, Glasmacher et al., 2007). It is unknown whether atypical forms of AIC should be 
considered as distinct syndromes or represent true variant forms allelic to AIC (Bursztejn et al., 
2009, Spennato et al., 2013). 
 
The recurrence risk for family members of a proband with AIC is predicted to be low (Sutton and 
Van den Veyver, 1993). Parents of probands with AIC are mostly asymptomatic and have 
negative family history for ophthalmologic and/or neurological disorders (Donnenfeld et al., 
1989, Glasmacher et al., 2007, Hopkins et al. 2008). There are no known cases of AIC 
transmission from parent to child There are two known and isolated familial cases of AIC; one 
pair of sisters from non-consanguineous parents and one pair of monozygotic twins concordant 
for AIC (Molina et al., 1989, Pons and Garcia, 2008). However, a majority of AIC cases occur 
sporadically, presumed to be the result of a de novo variant, thus siblings are not considered to be 




1.3.2 Clinical Diagnosis 
The original diagnosis of AIC was based on the classical triad (Figure 1.1) and accompanying 
traits including: subependymal heterotopias, costovertebral defects and various neurological 
anomalies (Chevrie and Aicardi, 1986). Further AIC-related anomalies were later revealed 
through advancement in imaging technology (Aicardi, 2005, Hopkins et al., 2008, Chevrie and 
Aicardi, 1986). These anomalies led to the revision of the diagnostic criteria, to include 
frequently recurring phenotypes.  
 
The revised diagnosis also allowed the inclusion of cases that did not meet the classical 
diagnosis; individuals who were missing one or more features of the classical triad (Aicardi, 
2005; Figure 1.1). The accepted criteria for the diagnosis AIC include two major and two 
supporting features (Table 1.1) (Sutton et al., 2005). This criterion is based on commonly 
observed neurological, musculoskeletal and ocular defects. There are other common 
presentations outside of the diagnostic criteria including: intellectual disability, respiratory 
problems, gastrointestinal upsets and craniofacial abnormalities (Aicardi, 2005, Glasmacher et 
al., 2007, Sutton et al., 2005). Due to its phenotypic heterogeneity, the diagnosis for AIC is 
heavily reliant on the accurate assessment of fundus examinations, brain magnetic resonance 




Type of Findings1 Major Features Supporting Features Other Features 
Classical Triad 
(Figure 1.1) 






























Absent or abnormal ribs 
Hand malformations 
Craniofacial 
 Prominent premaxilla 
Upturned nasal tip 
Sparse lateral eyebrows 
Cleft lip  
Cleft palate 
Skin 
  Vascular malformations/ 
malignancies 
Pigmentary lesions 
Table 1.1: Clinical Presentation of Aicardi Syndrome (AIC).   
                                               
1Clinical features were collated from the following papers: Aicardi, 2005; Glasmacher et al., 2007; Fruhman et al., 
2012; Sutton and Van den Veyver, 1993; McMahon et al., 1984; Iwamoto et al., 2008; Sutton et al., 2005 
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1.3.3 Differential Diagnosis 
Chorioretinal Lacunae (CRL) are considered pathognomonic to AIC (Figure 1.1) (Aicardi, 2005, 
Glasmacher et al., 2007, Chevrie and Aicardi, 1986, Fruhman et al., 2012, Sutton et al., 2005). 
Similar chorioretinal defects have been described in patients with Oculoauricular Syndrome 
(MIM 142992), Orofaciodigital Syndrome IX (MIM 258865) and Kniest Dysplasia (MIM 
120140). The lacunae in AIC can be distinguished from other differential diagnosis and 
congenital infections based on their distinctive appearance and anatomical position, which can be 
determined via funduscopic and histological examinations (Table 1.2) (Fruhman et al., 2012, 
Kurugundla et al. 2008). The diagnoses of patients suspected to have AIC are often disputed if 
the CRL are absent or atypical (Ropers et al., 1982, Burch-Smith et al., 2012, Leng and 
Moshfeghi, 2011, Willis and Rosman, 1980).  
 









Female Always Always Bilateral; posterior; little 
pigment; “lacunar” 
Microphthalmia; 











optic atrophy; lenticular 













Occasional No or Rare Uni-/bilateral; posterior of 
peripheral; pigmentary; 









Occasional No Uni-/bilateral; posterior of 
peripheral; pigmentary; 















Table 1.2: Aicardi Syndrome versus Congenital Infections. This table was adapted from 
O’Driscoll et al. (2010).  
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In contrast to CRL, Agenesis of the Corpus Callosum (ACC) and Infantile Spasms (IS) are not 
specific to AIC (Figure 1.1 & Table 1.3) (Paciorkowski et al., 2011, Rosser et al., 2002). For the 
diagnosis of AIC, the absence of ACC can be substituted by the presence of other neurological 
defects such as intracranial cysts, heterotopias or cortical malformations (Aicardi, 2005, Sutton 
and Van den Veyver, 1993). Similarly, IS can be interchanged in the diagnosis of AIC with other 
early-onset epileptic seizures (Aicardi 2005, Chevrie & Aicardi, 1986). AIC requires brain 
magnetic resonance imaging and electroencephalograms for the accurate differential diagnosis of 
syndromes listed in Table 1.3.    
 
1.3.4 Development & Prognosis 
The prognosis for AIC depends on the extent and severity of the clinical findings (Donnenfeld et 
al., 1989, Grosso et al., 2007, Glasmacher et al., 2007, Rosser et al. 2001). In addition to the 
eleven patients noted by Abe et al. (1990), eight more patients were recently reported with 
favourable outcomes (Saddichha et al., 2007, King et al., 1998, Menezes et al., 1994, Matlary et 
al., 2005, Grosso et al., 2007, Yacoub et al., 2003, Lee et al., 2004, Vinas et al., 2005, 
Glasmacher et al., 2007, Kasasbeh et al., 2014). All eight patients had incomplete classical triad 
(Figure 1.1) and relatively mild neurological findings; resulting in less cognitive decline and 
increased life expectancy (Grosso et al., 2007). The oldest known survivor of AIC is a 49-year-
old woman reported by King et al. (1998). The survival estimates for AIC is 62% at 27 years of 
age, which is higher than previously reported (Kroner et al., 2008, Donnenfeld et al., 1989, 
Menezes et al., 1994, Glasmacher et al., 2007). The mean and median age of death is estimated at 





Syndromes2 Genotype Phenotype 
Infantile spasms ARX  
(MIM 300350) 




Cortical atrophy, abnormal WM, calcifications, LGS, autistic features 
common 
FOXG1 Variable dysgenesis of CC, autistic features common 
MEF2C Atrophy, reduced WM, variable subsequent epilepsy, severe cognitive 
impairment, hyperkinesia common 
SLC25A22 Atrophy, dysgenesis of CC, CBLH, EIEE, severe cognitive impairment, 
abnormal results of electroretinogram 
SPTAN1 Cortical atrophy and CBLA, hypomyelination, reduced, WM, thin CC 














LIS, LGS, severe cognitive impairment  
PAFAH1B1 
(MIM 607432) 













LIS, CBLH, LGS, severe cognitive impairment 
Deletion 1p36 
syndrome 
Deletion in 1p36 
(MIM 607872) 
























LIS, mild CBVH, LGS common, severe cognitive impairment 
Table 1.3: Syndromes Associated with Infantile Spasm and Agenesis of the Corpus 
Callosum. This table was adapted from Paciorkowski et al. (2011) to show syndromes 
considered in the differential diagnosis of infantile spasms and agenesis of the corpus callosum of 
Aicardi Syndrome (Rosser et al., 2002).        
                                               
2 Only syndromes with known implicated genes or specific genotypes are included in this table.  
 
Abbreviations: basal ganglia, BG; cerebellar atrophy, CA; diffuse cerebellar hypoplasia, CBLH; corpus callosum, 
CC; early infantile epileptic encephalopathy, EIEE; Lennox-Gastaut syndrome, LGS; lissencephaly, LIS; white 
matter, WM.  
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The increased risk of mortality is attributed to neurological impairments and related defects 
(Menezes et al., 1994). More than 91% of AIC patients develop severe intellectual disability and 
intractable epilepsy (Donnenfeld et al., 1989, Rosser et al., 2001). In a study of 77 patients, 
approximately 80% and 95% of patients were unable to walk and talk respectively (Rosser et al., 
2001).    Furthermore, 67% of patients had seizures daily, which were refractory to anti-epileptic 
drugs. These neurological impairments can lead to reduced immobility, gastrointestinal 
disturbances and respiratory problems (Table 1.4) (Glasmacher et al., 2007, Rosser et al., 2001). 
In a study of 69 patients, approximately 94% were affected by gastrointestinal disturbances; most 
of these health complications occurred after seizures. In study of 18 patients, more than 72% 
experienced recurrent pneumonia that was correlated with seizures (Donnenfeld et al., 1989).  
 
Skeletal and visual defects are also common in AIC; the former is the second most common 
complication following neurological impairments (Aicardi et al., 1969). Individuals with costal 
and/or vertebral defects are prone to developing scoliosis after 12 months of age (Chevrie and 
Aicardi, 1986). Scoliosis and kyphosis were reported in 55% and 18% of affected children 
respectively in study of 69 AIC patients (Glasmacher et al., 2007). The average growth (height 
and weight) of AIC children are relatively similar to the general population; up to the ages of 
seven and ten years. After this age, the average growth of AIC patients is lower; partially 
attributed to scoliosis. Visual impairment in AIC patients is usually associated with optic nerve 
abnormalities and/or microphthalmia (Aicardi, 2005). More than a quarter of AIC children are 




Type of Outcome Common Complications3 Rare Complications  References 
Cardiovascular  ● Mitral valve 
prolapsed 
● Benign heart murmur  
Glasmacher et al., 
2007 
Gastrointestinal  ● Recurrent constipation 
● Reflux 
● Abdominal pain 
● Diarrhoea 
● Occasional/abnormal liver valve 
● Hiatal hernias 
● Bowel obstructions 
Glasmacher et al., 
2007 
Ocular ● Legally blind 
● Blind in one eye 
● Near or far-sightedness 
● Nystagmus 
● Cataracts Glasmacher et al., 
2007 
Developmental ● Intellectual disability 
● Speech impairment 
● Walking difficulties 
 Chevrie and Aicardi, 
1986 
Modgil et al., 2014 
Respiratory ● Chest congestion 
● Upper airway infections 
o pneumonia 
● Aspiration problems 
● Required supplementary oxygen 
● Apnoea   
 Glasmacher et al., 
2007 
Other  ● Urinary refluxa 
● Kidney stonesa  
● Precocious Puberty 
Glasmacher et al., 
2007 
Table 1.4: Prognosis for Aicardi Syndrome. This table summarises the medical complications 
experienced by Aicardi patients.   
                                               
3 Common complications are those reported in 20% or more of patients in the respective study cohort. Rare 
complications are those that occur in one to three patients per study cohort.  
aattribute of anti-epileptic drug, rather than inherent trait of Aicardi Syndrome. 
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1.4 Treatment 
Treatment for AIC is personalized due to the clinical heterogeneity of symptoms and outcomes 
(Hoyt et al., 1978). Seizures and developmental delay/intellectual disability are the central 
symptoms targeted for treatment. Seizures are managed through individual or combined 
treatments of anti-epileptic drugs (AEDs), vagus nerve (VN) stimulation or implantation and/or 
palliative epilepsy surgery (Figure 1.6). The latter two treatments have varying success in 
managing seizures. Resection of dysplastic brain areas either worsened or alleviated the seizures 
in some cases; same success rate was observed in VN interventions. No AEDs are universally 
effective in treating seizures and most AIC-related epilepsy are medically refractory (Table 1.5).  
 
Treatment4 Donnenfeld et al.,  
1989 
Menezes et al.,  
1994 
Rosser et al., 
2002 
Kasabeh et al.,  
2014 














Barbiturates 17 35 65 8/14 25 75      
ACTH 14 64 36 6/14 50 50      
Valproic acid 12 58 42    32/71     
Phenytoin 11 45 55         
Carbamazepine 9 44 56         
Clonazepam 8 25 75         
Diazepam 2 0 100         
Ethosuximide 2 100 0         
Mephobarbital 1 100 0         
Primidone 1 100 0         
Methsuximide 1 100 0         
Acetozolamide 1 100 0         
Benzodiazepines    10/14 60 40      
Topiramate       20/71     
Corpus Callosotomy       1/71 100 2/4 50 50 
Vagus Nerve Stimulation       5/71 40 3/4 25 75 
Ketogenic Diet       3/71 30    
Not specified    12/14 36 64      
Table 1.5: Anti-epileptic Treatments. This table summarises the anti-epileptic drugs or surgical 
interventions used to treat seizures in AIC patients Donnenfeld et al., 1989. 
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Early treatment of seizures is necessary to prevent further developmental delay and systemic 
effects; the latter include gastrointestinal disturbances and respiratory problems. To improve the 
development outcomes in AIC, a number of different therapeutic interventions are needed 
including: physical, occupational, speech and vision therapy (Sutton and Van den Veyver, 1993). 
In addition, monitoring of gastrointestinal and skeletal (scoliosis) complications is needed. A 
systematic plan for the management of AIC symptoms has yet to be established, partly due to the 
unknown aetiology of the disorder.   
 
1.5 Pathogenesis of Aicardi Syndrome 
1.5.1 Prenatal or Intrauterine Disturbances  
MCD can be caused by prenatal and intrauterine exposure to toxins, infections or other 
perturbations (Bertoni et al., 1979). However, infectious origins of AIC were not identified in 
serial studies or individual case reports, which tested for: toxoplasmosis, rubella, 
cytomegalovirus, syphilis and others (Donnenfeld et al., 1989, Yamagata et al., 1990, Constad et 
al., 1985). Furthermore, congenital infections can be differentially diagnosed based on the 
ophthalmologic and neurologic findings (Figure 1.3) (O’Driscoll et al., 2010). Maternal and 
paternal mean age at conception usually ranges from 26-28 and 30-32 respectively; which is not 
remarkable in the aetiology of AIC (Donnenfeld et al., 1989, Costa et al., 1997). The proposition 
of environmental factors and prenatal/intrauterine disturbances as a causative factor is further 
contradicted by the existence of twins discordant for AIC (Hattori et al., 1984, Taggard and 
Menezes, 2000, Grayton et al., 2012, Gilissen et al., 2014).  
 
                                                                                                                                                        
4The improvement and ineffectiveness of these treatments are not independent; two or more drugs were administered 
per individual. The number of each individual per study is given by ‘N’. Improvement (IP) and ineffectiveness (IE) 
of each treatment is given as a percentage. 
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1.5.2 Genetic Predisposition 
Genetic Findings 
In 1982, Ropers discovered a balanced translocation, 46,X,t(X;3)(p22;q12), in a female patient 
with an early diagnosis of AIC (Burch-Smith et al., 2012). A second female infant with an Xp22 
deletion and partial 3p trisomy was reported by Donnenfeld et al. (1989). Although the diagnosis 
of this case was disputable based on atypical appearances of the chorioretinal lacunae, early 
investigations still targeted Xp22.2, which was associated with syndromes listed in Table 1.6. 
These syndromes have various craniofacial, neurological and developmental defects overlapping 
with AIC (Van den Veyver, 2002). OFD1 and MLS (Table 1.6) are X-linked dominant and male 
lethal disorders as is suspected for AIC. Using southern blotting, Nielsen and Neidich used 
probes (5 and 8 DNA markers respectively) spanning the Xp22.3 locus to look for microdeletions 
in AIC patients, but no mutations were found (Neidich et al., 1990, Nielsen et al., 1991). 
Although recognised as the Aicardi locus, the Xp22 locus has yet to be confirmed, as no other 
mutations have been found in subsequent cases other than the two atypical cases reported by 
Ropers et al. (1982) and Donnenfeld et al. (1989).  
 
There are four target genes that have been investigated in AIC patients so far: CDKL5, FLNA, 
OCEL1 and TEAD1 (Anderson et al., 2009, Pai et al., 2013, Schrauwen et al., 2015). In a male 
patient, FLNA was sequenced due to its association with periventricular heterotopia and patent 
ductus arteriosus that was presented alongside the classical triad (Figure 1.1) (Anderson et al., 
2009, Clapham et al., 2012). In another unrelated female patient, CDKL5 was sequenced based 
on its association with infantile spasms and early epileptic seizures (Pai et al., 2013, Tao et al., 
2004). Targeted gene sequencing for mutations in CDKL5 and FLNA showed negative findings. 
In a recent WES study, de novo variants were found in TEAD1 and OCEL1 in two unrelated 
individuals (Schrauwen et al., 2015). However, subsequent WES studies in unrelated AIC cohorts 
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found no recurring mutations in either of these genes (Wong et al., 2017, Lund et al., 2015). To 
date, no recurring mutations have been discovered in any of the genes suspected to be involved in 
or implicated with AIC. This suggests that future sequencing studies involving AIC cohorts 
should utilise a disease gene discovery strategy with the expectation of genetic heterogeneity 











Dysmorphic features, neonatal hypotonia, myoclonic 
seizures, variable congenital anomalies involving central 
nervous system, cardiac and urinary systems, early infantile 
epileptic encephalopathy  
Opitz syndrome type 1 300000 MID1 Hypertelorism, hypospadias, cleft lip/palate, 
laryngotracheoesophageal abnormalities, imperforate anus, 









Choreoathetosis, hydrocephalus, Dandy-Walker 
malformation, seizures, iron or calcium deposition in the 
brain 
Orofaciodigital 






OFD1 Malformations of face, oral cavity and digits; thickened 
alveolar ridges, abnormal dentition, absent lateral incisors, 
polycystic kidney disease 
Microphthalmia with 




Unilateral or bilateral microphthalmia, linear skin defects 
limited to the face and neck, skin aplasia and 
hyperpigmentation 





Specific hindbrain formation, hypotonia, cerebellar ataxia, 




300424 RP23 Progressive retinal degeneration, dychromatopsia, decreased 
visual acuity, dark pigment clumps in midperiphery and 
perivenous areas, pigmented vitreous cells, mild hearing loss 
Table 1.6: Xp22.2 Syndromes. This table summarises the syndromes associated with the Xp22.2 
locus.   
                                               
5 Phenotype MIM number, associated genes on the Xp22 locus and clinical features related to each syndrome are 
given.  
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There are few published studies with reported genetic abnormalities in AIC patients (Table 1.7). 
A majority of the early studies reported large chromosomal abnormalities, which have yet to be 
defined as causative or incidental. Furthermore, the diagnosis of AIC in these females range from 
undisputed to disputed based on the revised diagnostic criteria (Aicardi, 2005). Nonetheless, it 
can be observed that genetic findings in AIC patients reported thus far are localized across 
multiple chromosomes. Despite the genetic and clinical heterogeneity seen in Table 1.8, the 
concept of AIC being a polygenic disorder has yet to be considered; particularly for early genetic 
studies with an ascertainment bias towards the X-linked male lethal hypothesis. 
 
Reference Genetic Abnormality Typical AIC traits Atypical AIC traits Diagnosis6 


















t(12;21)(q13.3;q11.2) Chorioretinal lacunae 
Coloboma 











Posterior hair whorl 
Teratoma/lipoma in optic chiasm 
Sharply demarcated chorioretinal 
defects 
 
No agenesis of the corpus callosum 
, costovertebral anomalies, infantile 




del(1)(p36.22) Infantile spasm 
Bilateral papillary 
coloboma 







Deep set eyes 















                                               
6 The diagnosis and genetic origins of these females are highly heterogenous. The diagnoses of these females are 
given: disputable cases have associated atypical features, undisputed cases have an accepted diagnosis for AIC.   
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Partial agenesis of the 
corpus callosum 
Ventricular dilatation 










45,X0/46,XX Ventricular dilatation 
Intraventricular cysts 
Muscular hypotonia 
Optic nerve coloboma 











Patent foramen ovale 
































Postfossa arachnoid cyst 
 Undisputed 












Table 1.7: Genetic Findings in Affected Females. This table summarises individuals who had a 
reported genetic abnormality in literature to date. SNV are described using HGVS nomenclature 
and SV are described using ISCN.  
 
Investigation Approaches 
Copy number variant (CNV) screening was performed in a cohort study of 18 and 38 girls across 
the whole chromosome X (ChrX) and genome respectively (Yilmaz et al., 2007, Wang et al., 
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2009). CNV screening across ChrX was completed using full coverage array comparative 
genomic hybridisation (aCGH) with an 82kb resolution and 1875 ChrX clones (Yilmaz et al., 
2007). CNV screening across the whole genome was conducted on Agilent 244K DNA 60-mer 
arrays (Wang et al., 2009). CNV contribute to the pathogenesis of multiple neurodevelopmental 
disorders including intellectual disability, epilepsy and other neuropsychiatric disorders 
(Spennato et al., 2013). However, no likely pathogenic CNV were identified in the cohorts of 
either Yilmaz et al. (2007) or Wang et al. (2009).  
 
The low diagnostic yield for CNV screening in AIC cohort was unexpected as genomic 
microarrays have contributed to the genetic diagnosis of at least 12% of patients with severe 
intellectual disability (n=1489), which is the most frequent comorbidity of AIC (Figure 1.3) 
(Gilissen et al. 2014). The low yield may be attributed to sample size: 38 girls in Wang et al. 
(2009) versus 1489 in Gilissen et al. (2014). Alternatively, it may be due to insufficient resolution 
of a-CGH used in Yilmaz et al. (2007) and Wang et al. (2009), which could miss the detection of 
smaller CNV. As shown in Figure 1.3, whole exome sequencing (WES) is able to improve the 
detection of mutations in patients with conclusive genetic diagnosis; among these are eight 
causative CNV that evaded detection by Sanger sequencing and genomic microarrays. It was 
further estimated by Gilissen et al. (2014) that whole genome sequencing (WGS) can achieve a 
conclusive diagnostic yield of 62, of which 21% will be represented by CNV, in a comparably 





Figure 1.3: Diagnostic Yield versus Technology. This figure obtained from Gilissen et al. 
(2014) shows the differences in resolution of different technologies in identifying genetic causes 
of intellectual disability in large patient cohorts. The pie chart represents the cohort; the total 
number of individuals included in the study is indicated below the pie chart.  
 
WES and WGS are becoming the first-line of approaches for investigating candidate genes in 
difficult to resolve Mendelian diseases (Majewski et al., 2012).  WES in particular has been 
highly effective at identifying causal mutations (mainly de novo) underlying epileptic 
encephalopathies (EE) (Epi4K Consortium et al., 2013, Veeramah et al., 2013). One of the 
advantages of WES and WGS is the ability to explore different inheritance models as outlined in 
Figure 1.4 (Gilissen et al., 2012).  Figure 1.4 further highlights the power of using parent-
proband trios for the identification of candidate disease genes. Only three studies have utilised 
WES and/or WGS to find candidate AIC genes (Schrauwen et al., 2015, Lund et al., 2016, Wong 
et al. 2017), however none has reported recurring variants in the same gene.   
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Figure 1.4: Gene Identification Strategies. This diagram extracted from Gilissen et al. (2012) 
shows different inheritance models that can be studied using whole exome sequencing. Circles 
and squares represent males and females respectively. Symbols enclosed with a dot represent 
carriers. Affected individuals are represented by filled symbols, while unaffected symbols 
represent unaffected individuals. Double lines represent consanguinity.   
 
There is the possibility that causal mutations underlying AIC are not obvious at the genomic level 
due to a lack of evidence for likely pathogenicity. The utility of matched transcriptome and/or 
methylome data may increase the resolution of these ambiguous casual mutations. For example, 
methylome matched with transcriptome data recently revealed the role of brain-specific 
methylation in the pathogenesis of schizophrenia and bipolar disorder (Xiao et al., 2014). In a 
different study, methylome and transcriptome data revealed sex differences in the human 
prefrontal cortex (Xu et al., 2014). The latter could be a contributing factor to the female-biased 
prevalence of AIC, which remains unexplored in literature. 
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There is an increasing role of somatic mutations in EE and other neurodevelopmental disorders 
(Insel et al., 2014, Jamuar et al., 2014). Somatic mutations in AKT1 and AKT3 were revealed to 
predispose the Proteus syndrome and hemi-megalencephaly respectively (Poduri et al., 2012, 
Yang et al., 2014). Somatic mutations in these genes were not present in peripheral blood; 
exclusive to affiliated tissues. These studies demonstrate that germinal tissues and whole-brain 
genomes are less suitable for the detection of somatic (causal) mutations that occur exclusively in 
the brain (Insel et al., 2014). Investigations into AIC were previously conducted using peripheral 
blood DNA (Eble et al., 2009, Yilmaz et al., 2007, Hoag et al., 1997, Neidich et al., 1990, Wang 
et al., 2009). The plausibility of somatic and brain-specific mutations underlying AIC has been 
postulated, but yet to be explored functionally (Sutton and Van den Veyver, 1993).   
 
Inheritance & Prevalence 
There is strong support for an underlying, X-linked, de novo dominant and male lethal mutation 
in AIC (Van den Veyver, 2002). The hypothesis is supported by the almost exclusive female 
prevalence of AIC and that the only affected males with an undisputed diagnosis of AIC 
coincidentally have Klinefelter Syndrome (Shetty et al., 2014, Zubairi et al., 2009). Furthermore, 
the diagnosis of AIC reported in normal 46,XY males have been disputed based on atypical 
findings (Table 1.8) (Chen et al., 2009, Curatolo et al., 1980). However, there are isolated reports 
of 46,XY males with typical AIC features and 47,XXY males with atypical AIC features (Chen 
et al., 2009, Chappelow et al., 2008). Despite these observations, there is preferential screening 
for X-linked pathogenic variants, which is evident from early investigations into the cause of AIC 
(Wieacker et al., 1985, Neidich et al., 1990, Nielsen et al. 1991, Hoag et al., 1997, Yilmaz et al., 




Reference Karyotype Classical Triad7 Typical AIC Features Atypical AIC Features 
Hopkins et al., 
1979 










Small right pupil 
Curatolo et al., 
1980 












Aggarwal et al., 
2002 















Saddichha et al., 
2007 




Right frontal dysplasia 




Chappelow et al., 
2008 
46 XY ACC 
CRL 
IS 





Low muscle tone 
Craniofacial anomalies 
Optic Nerve Hypoplasia  
 
Chen et al.,  
2009 
47 XXY ACC 
IS 






Cleft palate  
Salt and pepper 
pigmentations 
Lissencephaly 
Patent ductus arteriosus  






Zubairi et al., 
2009 






Lacked vertebral and 
rib anomalies 
Shetty et al.,  
2014 









No skeletal anomalies 
Table 1.8: Males with Aicardi Syndrome. This table summarises all the males in literature with 
suspected or confirmed Aicardi Syndrome.  
                                               
7 Abbreviations: agenesis of corpus callosum, ACC; chorioretinal lacunae, CRL; infantile spasm, IS; not available, 
NA.  
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There are also isolated cases that do not follow the classical X-linked dominant inheritance 
model, such as the six set of twins described by Chevrie and Aicardi (1986), where only one twin 
was affected with AIC from each pair. In a 1989 case study, the first familial case of AIC was 
reported in sisters born five years apart to non-consanguineous parents (Molina et al., 1989). X-
linked dominance was contested in these sisters as the parents were phenotypically normal. The 
twins may be the result of postzygotic mosaicism, while the sisters of germline mosaicism. 
Although an X-linked cause remains plausible in these isolated cases, the idea of cellular 
mosaicism has yet to be thoroughly investigated.  
 
The transmission of the disorder will remain ambiguous until the underlying genetic cause is 
discovered. Progenies from individuals with AIC have not been reported; there are no published 
reports of transmission from an affected parent to an affected child. It is unknown whether AIC 
patients have child-bearing potential, considering the mean age of death is estimated at 8.3 years 
and some girls experienced precocious puberty (Sutton and Van den Veyver, 1993).  There are 
however reports of females with milder forms of AIC, which may be capable of conceiving 
(Grosso et al., 2007). It is necessary to establish a registry for AIC or AIC-like patients to track 
for milder forms of the disorder and future offspring.   
 
Hypotheses Underlying Clinical Heterogeneity 
X-Inactivation (XIA) was also studied as a potential mechanism underlying the clinical 
heterogeneity of AIC. Skewed XIA has also been associated with various developmental 
disorders including Rett syndrome (MIM 312750; MECP2), alpha-thalassemia with mental 
retardation (MIM 301040; ATRX), incontinentia pigmenti (MIM 308300; IKBKG) and X-linked 
mental retardation with epilepsy (MIM 300419; ARX) (Fruhman et al., 2012). XIA studies in 
cohorts of AIC patients to date have yielded contradictory results; despite using the same 
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methodology (Androgen Receptor Assay) and source of DNA (peripheral blood). Hoag et al. 
(1997) reported XIA is random in affected females, correlating with XIA findings in a 47,XXY 
male described by Chen et al. (2009).  
 
These results can be interpreted as firstly, XIA is not a mechanism involved in AIC. Secondly, 
the gene responsible for AIC could be escaping XIA. Thirdly, low expression of the disease allele 
on chromosome X is sufficient in causing disease; therefore, skewing is not necessary to exert its 
full disease-potential. Fourthly, in the predicament that mutations underlying AIC occurred 
somatically, XIA may occur in clonal patterns.  
 
Conversely, Neidich and Eble reported non-random XIA in their cohort of seven and 33 patients 
respectively (Eble et al., 2009, Neidich et al., 1990).  Although these findings support the X-
linked hypothesis, it remains controversial whether XIA has a role in the pathogenesis of AIC 
based on these cohort studies alone. Furthermore, it is unknown whether XIA in lymphocytes is 
consistent with affiliated tissues in AIC; the brain and eye. Nonetheless, the role can be further 
elucidated in a large-scale cohort study or upon the identification of a candidate gene/locus. Other 
mechanisms that could contribute to clinical heterogeneity include pleiotropic genes and genetic 




1.6 Hypothesis & Aims 
The diagnosis for AIC thus far has been heavily reliant on accurate clinical diagnosis, which is 
complicated by the penetrance and expressivity of the major features included in the revised 
diagnostic criteria (Aicardi, 2005). The pathogenesis of AIC remains largely unknown due to the 
limited knowledge in the following areas. Firstly, the inheritance of AIC from phenotypically 
normal parents has been primarily focused on the X chromosome; although an X-linked cause 
has yet to be identified, other modes of inheritance has been less thoroughly investigated. 
Secondly, the genetic or molecular mechanisms that contribute to an almost female exclusive 
prevalence of AIC has yet to be explored. Thirdly, factors contributing to the phenotypic 
variability among AIC patients are not well understood; those presenting AIC and non-AIC 
characteristics. To address these disease aspects, we implemented a combined genetic and 
molecular approach to test the hypothesis with three research aims as outlined below. 
 
1.6.1 Hypothesis  
Based on the clinical heterogeneity of reported AIC patients and the chromosomal abnormalities 
reported thus far, we hypothesized that causes underlying Aicardi Syndrome are genetically 
heterogeneous.  
1.6.2 Research Aims 
The overall aim of the project is to identify genetic causes of AIC under the hypothesis 
previously stated. This will be conducted in the following systematic workflow:  
Aim 1: Develop a bioinformatics pipeline that will enrich for causal variants that underlie eye and 
cortical development. This pipeline will be developed for whole exomes and genomes of Aicardi 
proband-parent trios.  
 42 
Aim 2: Prioritise candidate genes by assessing the likely pathogenicity of causal variants using in 
silico and in vitro analyses.  
Aim 3: Investigate the biological role of causal variants in the pathogenesis of Aicardi Syndrome 
using in vivo models.  
 
The genetics pipeline from Aims 1 and 2 will be first tested on a pedigree that has three 
generations affected by abnormal eye and brain development (Chapter 3). This will test the 
efficacy of the pipeline as the precedent for assessing Aicardi exomes (Chapter 4).   
1.7 Expected Outcomes 
Based on larger sequencing projects involving cohort studies with neurodevelopmental disorders, 
the following outcomes were expected: 
1. Approximately 70% of the cohort will have a likely cause in a protein-coding sequence 
(Gilissen et al., 2014).  
○ This will be examined using whole exome and genome sequencing from all 
probands in our cohort.  
2. De novo mutations will account for 15% of yet to be resolved Aicardi cases (EpiK 
Consortium et al., 2013). 
○ This will be investigated using nine parent-proband trio from our cohort and 
whole exome/genome sequencing.  
3. A subset of de novo mutations will occur somatically (Jamuar et al., 2014).  
○ This will be explored using two paired blood-brain samples from our cohort and 




CHAPTER II: Materials & Methods 
2.1 Study Design  
This PhD Study has three components as represented in Figure 2.1, which was designed to 









Figure 2.1: Overview of PhD Study. This schematic diagram represents the 3 major 
components of this PhD study and the respective chapters describing the corresponding results. 
[1] Pathogenic variants identified from WES and WGS using either germline or somatic tissue. 
[2] Finding evidence to support the pathogenicity of variants identified from [1]; in accordance 
with the American College of Medical Genetics and Genomics, standards and guidelines for the 
interpretation of sequence variants (Richards et al., 2015). [3] Additional evidence that is needed 
to obtain a definitive genetic diagnosis for Aicardi syndrome is found in the surrounding ovals.  
2.1.1 Cohort of Study  
All probands recruited in this study had whole exome sequencing (WES). During our first parse, 
13 exomes were generated from Aicardi probands. Among the exomes, there were a total of: 9 
proband-parent trios, 2 mother-daughter pairs and 2 singletons. Of the 13 probands, 7 were 
selected for whole genome sequencing (WGS) on the following basis: (1) no candidate genes 
identified from WES or (2) only variants of unknown significance were identified from WES. 
Among the genomes, there were 5 proband-parent trios and 2 singletons. 
 
In addition to the Aicardi families, one epileptic encephalopathy family (Chapter 3) was 
included in our PhD study to test our list-based approach for WES analysis. Furthermore, the 
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family described in Chapter 3, who were affected by porencephaly, epilepsy and lens opacities, 
were the ideal test subjects to screen and enrich for variants involved in eye and brain 
development. In this family, four affected family members were sent for WES. DNA was 
available for all four individuals sequenced and one unaffected family member (maternal uncle).  
2.1.2 Inheritance-based Strategy 
COL4A2 Family 
Based on the pedigree of the COL4A2 family (Figure 3.1A), we assumed an autosomal dominant 
transmission of the disease allele. Using VCFTools ‘vcf-contrast’ module, we searched for 
heterozygous variants that were present in the exomes all affected family members and absent 
from 15 unrelated individuals. Next, we filtered and prioritised for variants that were: (1) 
harboured in genes within our eye-epilepsy-ID-MCD (EEIM) list and (2) had the highest 
concordance among multiple prediction algorithms (Table 3.6). This list-based approach leads to 
the discovery of the rare variant in COL4A2 (Chapter 3).  
 
Aicardi Cohort 
Based on the pedigree of the Aicardi families (Figure 4.2), we assumed three possible 
inheritance models for the transmission of the disease allele: (1) de novo dominant, (2) autosomal 
recessive or (3) compound heterozygous. We used proband-parent trio analysis (Figure 1.4) to 
filter for variants that complied with the assumed inheritance models. De novo variants had to be 
present as heterozygous (GT: 0/1) in the proband exome, but absent from both parent exomes. 
Autosomal recessive variants had to be present as homozygous (GT: 1/1) in the proband and 
present as heterozygous (GT: 0/1) in both unaffected parents. Compound heterozygous variants 
had to present as heterozygous (GT: 0/1) in the proband and present as heterozygous (GT: 0/1) in 
one of the unaffected parents, while absent in the other parent. Candidate variants from exomes 
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and genomes were prioritized by the same list-based and concordant-predictive approach 
described in the COL4A2 family (Chapter 3).  
 
The only difference for trio genomes were the additional investigation of non-coding variants. 
Non-coding variants were prioritized based on their genomic position in either: (i) evolutionary 
conserved sequences, (ii) regulatory motifs (iii) sequences absent from control genomes (n=125).  
2.1.3 Ethics for human and animals 
All sequencing and recruitment to this study was carried out under the Women’s and Children’s 
Hospital, Human Research Ethics number REC 2361/3/2014. All zebrafish work in this study 
was performed under the University of Adelaide, Office of Research Ethics, Compliance and 
Integrity Research Services approval number S-2017-073.  
 
2.2 Computational Methods 
Code and data files used to generate results for Chapter 4, 5 and 6 are stored in the following 
GitHub repository: https://github.com/ThuongHa/7.1-Appendix-Data-Code.git (Appendix 7.1).  
 
2.2.1 Pre-Processing Raw Reads 
Mapping to Reference 
WES was performed on a HiSeq2500 (Illumina) by the South Australian Cancer Council 
Genomics Facility and WGS on the HiSeqXTen (Illumina) by the Australian Genome Research 
Facility. Raw Illumina reads were processed under the Genome analysis toolkit (GATK) v3.5-0 
best practices guidelines (Van der Auwera et al., 2013). First, FASTQ files for WES and WGS 
generated by Illumina were mapped to the human genome (hg19) using BWA-MEM (Li et al., 
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2009). This step generates a SAM file (Table 2.1) containing Illumina reads aligned to hg19 
reference genome.  
Duplicate Marking 
Next, duplicate reads introduced by artefacts arising from PCR amplification is marked by Picard 
(https://broadinstitute.github.io/picard/). This step sorts the hg19-aligned SAM file by coordinate 
order and marks a duplicated BAM file.  
Base Recalibration 
Finally, base quality scores are recalibrated using the GATK ‘BQSR’ function to reduce errors 
introduced by the sequencing process or experimental preparation. This step generates a 
recalibrated BAM file with adjusted base quality scores for deletions, insertions and substitutions. 
 
Abbreviations Definitions Description 
FASTQ  Text-based format that stores biological sequences and 
its corresponding Phred qualities in a single file. 
SAM Sequence Alignment/Map Tab-delimited text format that stores biological 
sequences aligned to a reference sequence. 
BAM Binary Alignment Map Binary format that stores the same data as SAM files in 
a compressed binary representation. 
BED  Tab-delimited text file that defines a chromosome, start 
and end position. 
VCF Variant Call Format Text-based format that stores gene sequence variation 
and its position in the genome 
 
Table 2.1: Description of common file formats used in PhD study.  
 
2.2.2 Sequencing Coverage 
Whole Exome Sequencing 
We assessed the sequencing performance of the HiSeq2500 across the target capture plus 50bp 
flanking sites (SeqCap EZ Exome Enrichment v3.0) using CollectHsMetrics in Picard. We 
analysed the median target coverage, no base calls and fraction of target bases using the 
sequencing metrics summarized in Table 2.2. 
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Whole Genome Sequencing 
We assessed the sequencing performance of the HiSeqXTen across the whole genome using 
CollectWgsMetrics and CollectWgsMetricsWithNonZeroCoverage in Picard. Regions with 
minimum 1bp coverage or no coverage were analysed using the sequencing metrics outlined in 
Table 2.2.  
 
Whole Exome Sequencing 
Field Description 
Genome Size The number of bases in the reference genome used for alignment.  
Bait Territory The number of bases localized to one or more baits.  
Target Territory The unique number of target bases in the target sequence.  
On Target Bases The number of pass-filtered bases mapped to the target region.  
Mean Target Coverage The mean coverage of a target region.  
Median Target Coverage The median coverage of a target region. 
Zero CVG Targets PCT The fraction of targets that did not reach 1bp coverage. 
PCT Target Bases The fraction of all target bases achieved. 
Whole Genome Sequencing 
Field Description 
Genome Territory The number of non-N bases in the genome referencec 
Mean Coverage The mean coverage in bases of the genome. 
SD Coverage The standard deviation coverage of the genome. 
Median Coverage The median coverage in bases of the genome. 
PCT The fraction of bases attaining sequence coverage post filtering 
Table 2.2:  Summary of Picard HS metrics used for analysis of WES and WGS sequencing 
coverage. Descriptions were extracted from Picard HS metrics 
(https://broadinstitute.github.io/picard/). 
Coverage Plots 
Coverage data from Picard HS metrics were visualized using the ggplot2 package in a customised 




2.2.3 Variant Discovery 
Single Nucleotide Variants & Small Insertions and Deletions 
Small variants (<50bp) from WES, including single nucleotide variants (SNV) and small 
insertions and deletions (Indels), were called using GATK HaplotypeCaller, SAMtools Mpileup 
and DeNovoGear. HaplotypeCaller generated genomic VCF (gVCF) for all WES BAMs 
encompassing sites with and without variant calls (Van der Auwera et al., 2013). Joint 
genotyping was then applied to a combined VCF file containing all the WES gVCFs. SAMtools 
Mpileup was performed on the WES BAMs of just the AIC cohort (n=36) to compute the 
genotype likelihood across all samples into the VCF format (Li et al., 2009). BCFtools view was 
then applied to call variants and estimate allele frequencies; the called and genotype variants 
were then stored in both the VCF and BCF format. BCF files were used as input for DeNovoGear 
to estimate de novo variants in the Aicardi proband; not presents in either unaffected parents 
(Ramu et al., 2013). Based on the VCF files from HaplotypeCaller and Mpileup, each 
family/singleton from the AIC cohort was queried using vcf-contrast module in VCFtools. This 
module pre-filtered variants found in other unrelated individuals; allowing the analysis of 
recessive and de novo variants found in the proband (absent from parents).  
 
For WGS, small variants were called from single-samples using GATK HaplotypeCaller, 
FreeBayes and Strelka. Similar methods to WES were used to call variants from 
HaplotypeCaller, except single-sample gVCFs were generated for all WGS BAMs (Van der 
Auwera et al., 2013). Both FreeBayes and Strelka called variants from WGS BAM files based on 
a single diploid sample analysis; FreeBayes generated VCF files for SNV and Indels separately, 
while Strelka generated a single VCF file (Garrison and Marth, 2012, Saunders et al., 2012). A 
summary of all the SNV and indel callers for WES and WGS is summarized in Table 2.3.  
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 SAMtools GATK-HC DenovoGear Freebayes Strelka 
Language C Java C  C 
Model HMM & MAQ Bayesian Likelihood-based 
error 
Bayesian Empirical variant 
score 
Algorithm Extended BAQ Map Reduce Fragment-based 
phasing 
Haplotype-based Assembly & 
Alignment-based 
haplotyping 








Variants SNP & Indels SNP & Indels De novo SNP & 
Indels 
SNP & Indels SNP & Indels 
Features Sorting, 
indexing, 





   
Version  v3.5.0  v1.1.0 v2.7.1 
Reference Li et al.,  
2009 
Auwera et al., 
 2013  




Saunders et al., 
2012 
Table 2.3: Summary of SNP and Indels callers. This table was modified from Liu et al. (2013) 
and summarises the variants callers used to detect SNP and Indels from WES and WGS.  
 
Structural Variants 
Larger variants of 1kb or greater were called using Delly2, Lumpy, Manta and Retroseq. The 
classes of structural variants (SV) that were called included: deletions (DEL), tandem 
duplications (DUP), insertions (INS), balanced inversions (INV), reciprocal translocations (TRA) 
and mobile element insertions (MEI). Delly2 operates by using paired-end mapping analysis to 
calculate read-pair orientation and paired-end insert size; while split-read analysis was used to 
search for paired-ends where one pair is mapped, while the other is unmapped (Rausch et al., 
2012). Different SV classes were then identified based on paired-end evidence (supporting pairs 
and average mapping quality) and split-read evidence (number of split reads and consensus 
alignment against reference) (Figure 2.2). Delly2 utilised both paired-end and split-read analysis 
to increase sensitivity and specificity respectively across all SV classes (Rausch et al., 2012).  
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Figure 2.2: Delly2 SV detection based on joint paired-end and split-read analysis.  
Lumpy detects candidate breakpoints of genomic SV based on paired-end and split-read 
alignments; the logistics are similar to Delly2 as described previously (Layer et al., 2014). For 
DUP and DEL, Lumpy also analyses read-depth alignments, which are based on altered sequence 
coverage. By integrating all three types of alignment signals, Lumpy computes probability 
distributions that cover candidate breakpoint regions and then predict the SV subtype based on 
the multi-signal alignment signatures (Figure 2.3) (Layer et al., 2014).   
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Figure 2.3: Lumpy detection for SV breakpoints based on multiple alignment signals.  
Manta’s SV detection occurs in three multi-steps: graph construction, local assembly and then 
variant scoring (Chen et al., 2016). First, a global graph is constructed based on all the 
breakpoints identified within a genome. Graph edges are then analysed alongside paired-end and 
split-read evidence to predict candidate SV. Sequencing reads supporting each candidate SV were 
then assembled locally. Each SV was then scored, genotyped and quality filtered based on a 
germline diploid model.  
 
Although RetroSeq also utilizes paired-end and split-read analysis, it was solely designed for 
MEI discovery (Keane et al., 2013). Paired-end and split-read analysis were used to detect 
discordant paired-ends and single-anchored reads respectively, as described in Delly2. Candidate 
MEIs were then annotated with a known reference MEI or assigned a MEI class based on a 
transposable element sequence library. Candidate MEIs were then clustered based on their 
genomic position and read orientation. The density of the clusters was then used to refine the 
MEI breakpoints (Keane et al., 2013). 
 
Input files for all SV callers were WGS BAMs, while the output file was in VCF (Lumpy, Manta 
and Retroseq) or BCF (Delly) format. The sensitivity and specificity for different SV classes 
were analysed by: (i) running the all the algorithms on the NA12878 reference genome and (ii) 

























SNP within 50bp flanking 
regions considered 
‘complex variant regions’ 











small Indels, and 
homozygous reference 
calls 
Zook et al., 
2014 
NA12878.sorted.vcf.gz mtsinai_indel 43156 
Indels detected by three 
methods: PBHoney, 
custom script and Chaisson 








deletions from SVclassify 
Parikh et al., 
2015 
Spiral_Genetics_insertions.bed spiral_ins 68 
Preliminary benchmark 
insertion calls from 
SVclassify 





MEI (Alu, Line1,Sva), 
DEL, DUP, INS, INV, 
CNV of 2504 individuals 
from 26 populations  
1000 Genomes 




SV extracted from 1000g 
phase 3 project via vcf-
subset 
1000 Genomes 
Project Phase 3 
Table 2.4: Truth sets with benchmark structural variant calls from published NA12878 
datasets.  
 
2.2.4 Annotating Variants 
Annovar for SNVs and Indels 
SNV and Indels were annotated with five types of gene and function related information by 
ANNOVAR: (1) gene-based annotations to assign HGNC symbols to variants within or closest to 
a gene, (2) region-based annotations to identify highly conserved sequences or motifs predicted 
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to affect gene transcription, (3) filter-based annotations to mark variants previously reported in 
clinical databases or large sequencing projects, (4) mutation-based annotations to calculate 
variant effect on protein function or likely contribution to disease and (5) functional-based 
annotations to associate the candidate gene with known diseases or developmental pathways 
(Wang et al., 2010). Annotations that were applied to the VCF files of WES and WGS are 
detailed in Chapter 3 and briefly summarised in Table 2.5.  
 
Allele Frequency  Clinical Significance  Gene Annotations Predicted Pathogenicity 
● Unrelated genomes 
● Public exomes and 
genomes of healthy 
individuals 
 
● Gene list associated 
with: 
o Epilepsy 
o eye development 
o Intellectual disability 
and 
o malformations of 
cortical development 
●  Public dataset with 
reported pathogenic 
variants 
● Hg19 Locus 
● DNA and amino acid 
Change 
● Functional element 
● Protein function 
● Protein structure 
● Gene Tolerance 
● Amino Acid 
Conservation 
Table 2.5: Summary of variant annotations for SNV and Indels.  
 
Bedtools for SV and MEI 
Annotations for SV and MEI were more limited compared to SNV and Indels, particularly those 
flanking non-coding regions. Nonetheless, SV and MEI were annotated using the BEDtools 
‘annotate’ function (Table 2.6 & Appendix 7.1). The set of benign SV used for filtering were 
comprised of: the 1000 genomes project phase 3 findings (1000G), SV in healthy controls 
reported by Coe et al. (2014) (CnvDevDelay), SV from Genomes of the Netherlands consortium 
(GONL), ISCA curated benign SV (ISCA) and common variants detected from the Deciphering 
Developmental Delay study (DDD) (Genomes Project, 2015, Genome of the Netherlands, 2014, 
Riggs et al., 2012, Deciphering Developmental Disorders, 2014). The disease bed files used for 
annotation were compiled from: top 5% of predicted haploinsufficient genes, known genes 
causing inherited retinal diseases (Retnet), disease variants from the DDD study, known 
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Mendelian disease genes (GeneReviews) and SV submitted to ClinVar (Huang et al., 2010, Sun 
et al., 2015, Deciphering Developmental Disorders, 2015, Adam et al., 2018, Landrum et al., 
2016). UCSC Table browser was used to generate a bed file for the canonical transcripts of 
HGNC gene symbols. The regulatory bed is made of locus provided by the Open Regulatory 
Annotation database and the Encode project.  
 

















Variants found in healthy 
individuals or predicted 




Variants/genes found in 
individuals with NDD 
and eye disorders 
Description: 
Hg19 position of 
canonical transcripts with 
50 bp flanking 5’ and 3’ 
UTR. 
Description: 
Functional elements that 
act at protein or RNA 
levels and regulatory 
elements that control 
gene level activation 
Table 2.6: Summary of datasets used for filtering or annotating SV.  
 
2.2.5 Evaluating Variants 
Prioritising Likely Causative Variants 
Variants were assessed and prioritized in alignment with the standards and guidelines developed 
by the American College of Medical Genetics and Genomics (Richards et al., 2015). Briefly, 
evidence for likely pathogenicity was based on: (1) nonsense mutation in a gene associated with a 
loss of function disease (2) missense mutation predicted to be pathogenic via Polyphen2 and 
CADD, (3) inherited de novo or recessive in the proband, which is confirmed in both parents (4) 
in vitro and/or in vivo studies supporting the variants’ damaging effect on the gene or protein (5) 
the prevalence of the variant is rare among a phenotypically normal population.  
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For variants that lack pathogenic evidence, they were assessed based on the following criteria: (1) 
resides in known mutational hot spot or functional domain, (2) located in evolutionary conserved 
sequences, (3) variant alters protein expression or localization, 4) found in a mutation intolerant 
gene determined by RVIS and previous publications, (5) in a gene underlying eye or brain 
development but has yet been linked to disease and (6) strong in silico evidence for pathogenicity 
by multiple algorithms as listed in Table 3.6. The prediction algorithms listed in Table 3.6 were 
used to prioritise variants by: (1) calculating the number of concordant predictions supporting the 
pathogenicity and (2) ranking the variants from the number of highest to lowest concordant 
predictions. The rare variant identified in COL4A2 ranked the highest among the variants 
identified and listed in Chapter 3.   
Filtering Benign Variants 
Likely benign variants were pre-filtered using in-house dataset by generating a unique key for 
each called variant comprised of: starting coordinate, reference allele and alternate allele. Next, 
common variants were filtered out from each proband call set using variant allele frequency 
thresholds. For the in-house dataset, thresholds were set to consider two scenarios: (1) recurring 
de novo variants present in all Aicardi individuals and absent in unrelated individuals and (2) 
recurring recessive variants present in proband-parent trios with potentially one or two carriers in 
other unrelated individuals. For public databases or sequencing studies of phenotypically normal 
individuals, different thresholds were set based on the number of individuals per reference dataset 
(Table 2.7). Other lines of evidence that excluded likely benign variants included: (i) predicted to 
be benign by multiple in silico prediction programs and (ii) variants that did not segregate in a de 
novo or recessive manner.  
 
Dataset Source Number of individuals  Frequency threshold  
In-house exomes This study ~ 20 0.1 
In-house genomes This study ~ 120 0.01 
 57 
1000 Genomes 1000 Genomes Project 1096 0.001 
UK10K UK10K Consortium ~  4000 0.001 
ExAC Lek et al. 2016 ~ 65000 0.0001 
Wellderly Scripps Institute ~ 400 0.01 
CG69 Complete Genomics 69 0.1 
Table 2.7. Summary of variant allele frequency thresholds used to exclude likely benign 
variants.   
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2.3 Biological Methods 
2.3.1 Cell Culture 
Human Embryonic Kidney 293T Cells Maintenance & Freezing 
Human embryonic kidney 293T (HEK293T) cells were revived from pellets stored at -80oC by 
transferring frozen cells to a 10mL yellow cap tube and slowly added 5mL of fresh DMEM 
(Sigma Aldrich, Cat # D6546) growth media (DMEM, 10% foetal calf serum [FCS], 1% L-
glutamine [L-glut; 2mM] and no antibiotics). The tubes were spun at 1200rpm for 5 minutes, 
then supernatant was removed, and the pellet was resuspended with 5mL DMEM growth media. 
The resuspended pellet was transferred to a 250mL tissue flask with an additional 10mL DMEM 
growth media (total volume 15mL) and incubated at 37oC with 5% CO2. 
  
Once the culture reaches 90% confluency, the cells were split by removing all old growth media 
and the adhered cells were washed with 5mL 1X PBS (Sigma Aldrich, Cat # D8537). PBS was 
completely removed before adding 1mL of Trypsin EDTA (0.05%; Gibco, Cat # 25300054) and 
incubating the cells at room temperature for 1 minute to allow the cells to detach from the flask. 
10mL of DMEM growth media was added to the old flask and slowly pipetted 3-5 times to 
achieve single-cell suspension before transferring 0.5mL (1:20) or 0.75mL (1:15) of cell 
suspension to a new 250mL flask. The new flask is then topped up to 15mL with DMEM growth 
media and incubated at 37oC with 5% CO2. Cells from the old flask can be used for enumeration 
of viable cells by staining with Trypan blue (Invitrogen, Cat # 15250-061) and counting on a 
haemocytometer.  
 
HEK293T cell lysates were frozen down by transferring the cell culture into a 10mL yellow cap 
tube, then centrifuging at 1200rpm for 5 minutes. The supernatant is removed, and the cells are 
resuspended in PBS and transferred to screw-cap tubes; 1mL of resuspended cells per 1.5mL 
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screw-cap tube. The screw-cap tubes were then centrifuge at 2000rpm for 5 minutes followed by 
a quick suction and snap freeze (using either LN2 or dry ice). The pellets were then stored in the -
80oC freezer for later use.  
 
HEK 293T Cell Transfection for Protein Expression 
HEK293T cells were plated onto 12-well plates at a density of 0.5 x 106 cells/well with 2mL of 
growth media (DMEM, 10% FCS, 1% L-glut, no antibiotics) and incubated at room temperature 
for 2-4 hours. The plates are then incubated at 37oC overnight with 5% CO2. Prior to adding the 
transfection mix, 1mL of growth media is removed per well. Plasmids are transfected into 
HEK293T cells using Lipofectamine 2000 Transfection Reagent (Invitrogen, Cat # 11668027) 
and under the manufacturer’s recommendation with the following exceptions: final 
lipofectamine2000 reagent per well is reduced to 2μL per well, (2) Opti-MEM medium per well 
is increased to 250μL, (3) increasing concentration gradient for plasmid DNA (Table 2.7) and (4) 
cells are incubated with the transfection mix overnight at 37oC overnight with 5% CO2. Cells are 
then collected and stored at -80oC for further analysis. 
 
500ng empty vector 
control 
500ng empty vector 
control 
50ng plasmid 50ng plasmid 
200ng plasmid 200ng plasmid 500ng plasmid 500ng plasmid 
1μg plasmid 1μg plasmid 2μg plasmid 2μg plasmid 
Table 2.7: Transfection layout on 12-well plate for Plasmid expression.  
 
Lymphoblastoid Cell Line Transformation 
Lymphoblastoid cell lines (LCL) are set up from 1-2-day old blood, which was stored in EDTA 
tubes and kept at room temperature. Lymphocytes are isolated from blood using Ficoll Paque 
Plus (GE Healthcare, Cat # 17-1440-02) under the manufacturer’s protocol with the following 
adjustments: (1) blood is diluted 1:1 in neat RPMI 1640 (Sigma Aldrich, Cat # R5886) and (2) 
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after adding the ficoll to the diluted blood, centrifuge for only 20 minutes. After the wash steps, 
lymphocyte pellets were resuspended in 1mL Epstein-Barr Virus media; 1-part virus and 1-part 
RPMI growth media (RPMI, 20% FCS, 1% L-glut (2mM) and benzylpenicillin).   
 
To inhibit T-cell activation, 1mL of cyclosporine A (Sigma Aldrich, Cat # C1832) were added to 
new RPMI growth media per week for the first two weeks of transformation. Cells were 
incubated at 37oC with 5% CO2. After two weeks, healthy cultures were transferred to a 50mL 
tissue culture flask with 3mL of fresh RPMI growth media.  
LCL Maintenance & Freezing 
Once in flask, growth media was replaced every 3-4 days, gradually increasing the volume up to 
10mL. For freezing pellets, 5mL of healthy cell culture were transferred to a 10mL yellow cap 
tube, while the remaining culture was replaced with RPMI growth media reduced to 10% FCS; 
L-glut and antibiotics stayed the same. Cells in the yellow cap tube were spun at 1200rpm for 5 
minutes, then the supernatant was removed. Pellets were resuspended in storage media (RPMI 
1640, 20% FCS, 1% L-glut, 10% filtered DMSO); 1mL of resuspended pellet per cryogenic vial. 
After the first frozen vial, the cells were maintained with the RPMI growth media with the 10% 
FCS; media was changed every 3-4 days. Cells for -80oC storage were frozen down using the 
same method outlined in ‘Human embryonic kidney 293T cell Maintenance & Freezing’. The 
details of LCLs established for this study are summarised in Table 2.8.  
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DNA # PK # Sex Status Passage # Frozen Date 
T17262  F Affected 2 12 SEP 2016 
T25388 100234 F Unaffected parent 2 19 SEP 2016 
T25389 100234 M Unaffected parent 2 19 SEP 2016 
T22101  F Affected 2 21 OCT 2017 
T25483  104124 F Affected 3 21 OCT 2015 
T22420 104124 F Unaffected parent 3 28 OCT 2015 
T22419 104124 M Unaffected parent 3 28 OCT 2015 
Table 2.8 Summary of established LCL for Aicardi Cohort 
2.3.2 Genomic DNA Sequencing 
Primer Design & Storage 
For Sanger sequencing validation of variants, primers were designed using NCBI Primer Blast or 
Primer3Plus under the guidelines outlined in Dieffenbach et al. (1993). Briefly, oligonucleotides 
were designed to be: (1) between 18-24bp in length, (2) GC content approximately 50%, (4) 
annealing temperatures between 56-62oC, (5) amplicon length between 250-750bp and (6) 
avoided tandem repeats. Primer pairs were pre-checked using UCSC In-Silico PCR to exclude for 
non-specific amplification i.e. binds to sequences other than the target region. Primers were 
manufactured by GeneWorks or Sigma Aldrich; and re-suspended to a total concentration of 
100uM and stored at 4oC. All primers used in this study are listed in Table 2.9.  
Name Sequence Manufacturer Usage 










SZT2F44119 ACGTGCACTCGTTCAGCTAT Sigma sequencing 
SZT2R44120 CATGGGGACGTGGTATGTGT Sigma sequencing 
HCN1F244142 ACTGACATGCTGACATCTCCAA Sigma sequencing 
HCN1R344143 AGCATGTTTTTCTTCCAGATATGAT Sigma sequencing 
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DOCK7F44144 CTGAGCACTTTTGCATCAGC Sigma sequencing 
DOCK7R44145 AGTGGAGAATAGGAAAGGGAAT Sigma sequencing 
KCNAB1F44146 GCATACAAATTACAGCGAAGCC Sigma sequencing 
KCNAB1R44147 TCTCTGGAATGCATGGTTCTT Sigma sequencing 
C5orf42F44148 ACACACTCTGCTAATCTGCTTCA Sigma sequencing 
C5orf42R44149 TGGGAAAAGAATTGTGCTCAT Sigma sequencing 
ZNF462F44150 GGTGCTCCAATGTCTCCCAA Sigma sequencing 
ZNF462R44151 CTCAGAGCTGCTTCGGTTCA Sigma sequencing 
JMJD6F44152 ACTTTCTTCCAGTTCATCTATACCT Sigma sequencing 
JMJD6R44153 ATTCTGTAGGTGGTTTGTGATGG Sigma sequencing 
ELAVL4F44154 GGCTGTCATCTTGGTTGTGGA Sigma sequencing 







ANKRD32_1354F GTATGCGTTCTTCATGCCCTTCTAGAGA Sigma cloning 
ANKRD32_1630R CGTCAGGTGGAGCACCTTGGAGCCAATA Sigma cloning 
ANKRD32_1175F CTCAGGCTGTCAGATACAACTG Sigma cloning 
ANKRD32_1354R AAGGGCATGAAGAACGCATAC Sigma cloning 
SZT2_679F CTGGTCAGTATGATTCGTCAGGG Sigma cloning 
SZT2_915R AATTCCACATTGGGCACATGG Sigma cloning 
OPHN1_INT19F ACCTTCGCTTTCATCCAGGG Sigma sequencing 
OPHN1_EX20R TGTCCTACCCCCACCCATAG Sigma sequencing 
SP6_F ATTTAGGTGACACTATAG Sigma sequencing 
T3_F GCAATTAACCCTCACTAAAGG Sigma sequencing 
T7_F TAATACGACTCACTATAGGG Sigma sequencing 
ANKRD32_480R ATTTGCCTTTCCAGCCTCCA Sigma cloning 
TEAD1_298F CTTGCCAGAAGGAAATCTCG Sigma cloning 








TEAD1_893F ACTGCAATATTCAAGATGATGC Sigma cloning 
WNT4_354F AGGTGTGGCCTTTGCAGTGACG Sigma sequencing 
WNT4_806F ACCTGGTGTACTTGGAGCCTAG Sigma sequencing 
bactin1_F CGAGCAGGAGATGGGAACC Sigma qPCR 
bactin1_R CAACGGAAACGCTCATTGC Sigma qPCR 
elfa_F CTTCTCAGGCTGACTGTGC Sigma qPCR 

























KMT2B_F1 GAGGACCTGCCATCGGAAAT Sigma sequencing 
KMT2B_R1 AAGTGGACACCCTCTTGACG Sigma sequencing 
TCF4_534F CTATGACCACATGACCAGCAG Sigma cloning 
TCF4_698R ATGTCACCTCCAAGGAGACTCTGCTG Sigma cloning 
TCF4_1560F CATCCACAGCTATGCCTGGTGGTCAT Sigma cloning 
TCF4_1750R CAGACTGGACAGGAAGCTGTGGAA Sigma cloning 







TCF4_156XhoIF TGAGAACTGCTACTCGAGCTTCTCC Sigma cloning 
TCF4_830BstBIR TTTCGAACTTTCTTTGTCTGTACC Sigma cloning 
VANGL1_GA_FWD CTGCATGTTCACTGCCCTTT Sigma sequencing 
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VANGL1_GA_REV GAAACACAAACACCCGTGGC Sigma sequencing 
IFT122_CT_FWD CAAGGATGGAGTGCGGCTT Sigma sequencing 
IFT122_CT_REV TGTCCCTCTTCCCAAGGTCT Sigma sequencing 
CISD2_CT_FWD GTTGGGATTACAGGCGTAAACTAC Sigma sequencing 
CISD2_CT_REV AGTATTAGTGGACCCACATTATCTCC Sigma sequencing 
SCAF11_GA_FWD ACCATCATTTGCCCATCTTC Sigma sequencing 
SCAF11_GA_REV ATGCCGTCTTCTGATCTTGC Sigma sequencing 
LARGE_CT_FWD TGCTGCCAACTACCTGTGT Sigma sequencing 
LARGE_CT_REV TGGGATGAAAGGTTAGCAGGA Sigma sequencing 
ABCD1_TC_FWD CTGTCTCCAAATAAGGTCACACTG Sigma sequencing 
ABCD1_TC_REV TAGCAAGTGTGTGTGGTATTTCCT Sigma sequencing 
CLPB_GC_FWD AACTCTTAGGCAGGGCTGGT Sigma sequencing 
CLPB_GC_REV GGCCTTCCTAGCATGTTTCCT Sigma sequencing 
TTN_GA_FWD ATAGACTGCCGCATCCTCTG Sigma sequencing 
TTN_GA_REV TTAACTCGGCACTCTCAGCA Sigma sequencing 
CYP51A1_AC_FWD AGCTCCAAATGGCACATAGG Sigma sequencing 
CYP51A1_AC_REV GCTGGCTCACTGGAAATCAT Sigma sequencing 
CYB561_AG_FWD TTGGCACACTCAGAAAGCTG Sigma sequencing 
CYB561_AG_REV AAGGGCTACGCTGACCTGTA Sigma sequencing 
RNF34_GA_FWD TGGAGAGAACCAAAGTGCAG Sigma sequencing 
RNF34_GA_REV CTTTCCAGTCCCTTCTGTGC Sigma sequencing 
NAA25_CG_FWD CATGGTCAACCAGATGTTGC Sigma sequencing 
NAA25_CG_REV TGTGTTCTGATGGAGCTTGC Sigma sequencing 
CLEC18B_GA_FWD GAAGGATCAGACCCTCAAAGG Sigma sequencing 
CLEC18B_GA_REV AGTGACTTCGAGACCAGGAACTT Sigma sequencing 
WNT8B_ex3_fwd CTGGTGCCCAGAGTGGTATT Sigma qPCR 
WNT8B_ex4_rev CATGCACAAATGCTGTCTCC Sigma qPCR 
KMT2B_ex23_fwd GCCTCAGCAACTTCCACTTC Sigma qPCR 
KMT2B_ex24_rev ACAATTTCCTTGCCATCCAG Sigma qPCR 
SZT2_ex11_fwd TCAGTGCCTGAGCATTTCAC Sigma qPCR 
SZT2_ex12_rev GCTTCCAGTAGGCAGCAAAC Sigma qPCR 
SLF1_ex19_fwd GAAACAGCCCTGCATAGAGC Sigma qPCR 
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SLF1_ex20_rev GTCCAGCCAGCATTGTCTTT Sigma qPCR 
TEAD1_ex3_fwd AACTCAGGACAGGCAAGACG Sigma qPCR 
TEAD1_ex6_rev AGGGCCTTATCCTTTGCAGT Sigma qPCR 
TCF4_534F CTATGACCACATGACCAGCAG Sigma cloning 
TCF4_698R ATGTCACCTCCAAGGAGACTCTGCTG Sigma cloning 
TCF4_1560F CATCCACAGCTATGCCTGGTGGTCAT Sigma cloning 
TCF4_1750R CAGACTGGACAGGAAGCTGTGGAA Sigma cloning 







TCF4_156XhoIF TGAGAACTGCTACTCGAGCTTCTCC Sigma cloning 
TCF4_830BstBIR TTTCGAACTTTCTTTGTCTGTACC Sigma cloning 
RNF34F43657 GCCTTAGCTCTCTGTTGCCTT Geneworks sequencing 
RNF34R43658 CCCACACTCCAGTAGGACAC Geneworks sequencing 
PRDM16F43659 TTCCCAGCACTCATTCTTCC Geneworks sequencing 
PRDM16R43660 CCAGCTTCTTCTCCTGCATC Geneworks sequencing 
PCNXL3F43661 CGTGGACCAGGATTGGAAC Geneworks sequencing 
PCNXL3R43662 ACACCCGAGCACTCACCT Geneworks sequencing 
GIT1F43663 GAAGGTGCTTGACAATGGAGA Geneworks sequencing 
GIT1R43664 CTGACCCTTGCCCTCACC Geneworks sequencing 
PET117F43665 GTGGGGATGTCTAGGAG Geneworks sequencing 
PET117R43666 ACGTGACACCGACCTGCT Geneworks sequencing 
SLC2A4RGF43667 GCCTGAGCAGAGTGATGGT Geneworks sequencing 
SLC2A4RGR43668 GGGGACACTGGAGTCAGG Geneworks sequencing 
GAL3ST1F43669 TGATGAAGATGGCGTTGG Geneworks sequencing 
GAL3ST1R43670 GCCGCAATGACTTCGACTAC Geneworks sequencing 
HCN1F43671 ATCAGCTCGAACACTGG Geneworks sequencing 
HCN1R43672 ACTTGTTTTAAGTTGTGGGAAG Geneworks sequencing 
FAM20CF43673 CCAAGGAGGAGTACAAGCTGA Geneworks sequencing 
FAM20CR43674 TTCCTCTCCACGCAGTCCC Geneworks sequencing 
GPSM1F43675 GAGGTGCCAGGGTGGTG Geneworks sequencing 
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GPSM1R43676 TCAGCAGGTCCCAGGTCTC Geneworks sequencing 
CACNA1BF43677 TTCCCAAGCCTTCCTGTTTTCC Geneworks sequencing 
CACNA1BR43678 GCAGAGCAGGTGCCTTACC Geneworks sequencing 
FLNAF43691 CTGAGATGTTGATGGGGATG Geneworks sequencing 
FLNAR43692 CTGGACGCACACTGATGG Geneworks sequencing 
WNT8BF43693 CTGGTGCCCAGAGTGGTATT Geneworks sequencing 
WNT8BR43694 GCTGTGGCTGAGGTTTTTCT Geneworks sequencing 
G2E3F43695 TGTGACCCCTATTTTCACATACTCT Geneworks sequencing 
G2E3R43696 GAAGTCCACATGGGAAATGA Geneworks sequencing 
JMJD6F43697 GACAGTCTCTCCTGGTTTTTGTAAG Geneworks sequencing 
JMJD6R43698 GAGACGAAGGAGGGAACCAG Geneworks sequencing 
WNT8B2F43741 GCCCTGAGAGAGCCCCGCAGCTGTCCAGCCA Geneworks cloning 
WMT8B2R43742 TGGCTGGACAGCTGCGGGGCTCTCTCAGGGC Geneworks cloning 
USP40F43743 CTGGCATATTTACCTGCCTCTC Geneworks sequencing 
USP40R43744 GCTTGTTTTGCTGAGTCATTCTT Geneworks sequencing 
COL4A2F43745 CCCACCCATGTTTCCTTTT Geneworks sequencing 
COL4A2R43746 GATGGGGCACTCACCTCT Geneworks sequencing 
ANKRD32F43747 GAGGCAGAAAAATCGCTTGA Geneworks sequencing 
ANKRD32R43748 GGAGACTTCCAAGGAGGATG Geneworks sequencing 
WNT8B3F43810 AAGCAGAGCTCTCTGGCTAAC Geneworks cloning 















Table 2.9: Summary of primers used for Sanger sequencing, cloning and qPCR.  
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PCR Mix & Conditions 
We amplified genomic DNA using: (i) 50ng/μL of template DNA, (ii) in-house recombinant Taq 
DNA polymerase, (iii) 10X PCR buffer (100mM Tris-HCl, 500mM KCl, 15mM MgCl2, pH 8.3 
at 20oC, Roche Cat # 11699121001), (iv) 10mM dNTP (2.5mM dATP, dCTP, dGTP and dTTP), 
(v) 10uM primer (forward and reverse) and (vi) sterilized water up to the volume of 50μL. PCR 
reaction mixes were placed in 200μL PCR tubes and amplified in a thermal cycler (Eppendorf 
Mastercycler) with cycling conditions outlined in Table 2.10. For each primer pair, we optimised 
the annealing temperature using a gradient PCR on genomic DNA of an anonymous blood bank 
donor. For segregation analysis, we performed the PCR on water as a negative control, blood 
bank DNA as a positive control and LCL-derived DNA from the proband and their parents (if 
available). 
Step PCR with in-house Taq PCR with hi-fidelity Taq 




















1. Initial Denaturation 94 120 94  120 
2. Denaturation 94 30 94 15 
3. Annealing 60 30 55 30 
4. Elongation 72 30* 68 60 





Table 2.10: PCR cycling conditions.  
 
Gel Electrophoresis (GE) 
PCR amplicons were visualized on 1-1.5% agarose gel (agarose powder from Scientifix, Cat # 
9010B; 1X tris-borate-EDTA buffer, 0.5μg/mL of ethidium bromide). Samples were then 
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homogenized with 6x Orange DNA loading dye (Thermo Scientific, Cat # R0631) and loaded 
alongside 50ng/μL of 1 kb plus DNA ladder (Invitrogen, Cat # 10787026). Agarose GE was run 
at 110mV for 30 minutes per 500bp of DNA fragment. Gels were visualized in a UV 
transilluminator (INGENIUS Syngene Bio Imaging Capture System) and captured using the 
GeneSnap Image Acquisition Software (v7.05).  
PCR & Gel Purification 
For single bands on the agarose gel, PCR samples were purified using either the QIAquick PCR 
Purification Kit (Qiagen, Cat # 28104) or the GenElute PCR Clean-Up Kit (Sigma Aldrich, Cat # 
NA1020). PCR purification was performed following the respective manufacturer’s protocol with 
one adjustment to both kits: DNA was eluted in 30-50μL of sterilized water instead of the elution 
buffer described in both protocols. Final DNA concentrations per purified PCR sample was 
measured on a UV-Vis Spectrophotometer (NanoDrop ND-1000). 
 
For multiple bands on the agarose gel, PCR samples were purified using either the QIAquick Gel 
Extraction Kit (Qiagen, Cat #28704) or the GenElute Gel Extraction Kit (Sigma Aldrich, Cat # 
NA1111). Gel purification was performed following each of the manufacturer’s protocol with no 
modifications. Final DNA concentrations were measured using the NanoDrop.  
Sanger Sequencing & Purification 
For variant validation from WES, 30-50ng of purified PCR amplicons were sequenced using the 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Cat # 4337455) in a 10μL 
sequencing reaction (20-25ng PCR template, 2μL Sequencing buffer (5X), 1μL BigDye Reaction 
Mix, 1μL primer (3.2pmol) and sterilized water for final volume of 10μL). Sequencing reactions 




DNA from the sequencing mixes was precipitated using 75% isopropanol and washed with 70% 
ethanol. Residual ethanol was left to vapourise in a Speed Vac (10 minutes) or at room 
temperature (1 hour) in a dark place. The samples were then processed for Sanger sequencing by 
the DNA Analysis Facility (Department of Genetic Medicine, SA Pathology at the Women’s and 
Children’s Hospital) using the 370xl Sequencer (Applied Biosystems). The sequencer 
chromatogram files were viewed in the Seqman program (Lasergene DNAStar software package 
v.8.0.2).  
 
2.3.3 Plasmid cloning 
Plasmid Mini & Midi Purification  
Plasmids containing the full-length human ORF for WNT4 (Addgene, Cat # 35929), WNT8B 
(Addgene, Cat # 43819) and TEAD1 (Addgene, Cat # 33109) were purchased from Addgene, 
while SLF1 (Genscript, Cat # OHu04948D) was manufactured by GenScript (Figure 2.3). 
Addgene plasmids arrived in the form of transformed bacteria in a stab culture. Each stab culture 
was streaked onto LB agar plates with 100μg/mL of ampicillin and incubated at 37oC overnight. 
GenScript plasmids arrive in 10μg tubes of plasmid DNA, which was first transformed (Section 
2.2.3 ‘Ligation and Transformation’) into JM109 and then streaked the same as the addgene 
plasmids.  
 
For transformations where the negative control (water) contained no colonies or less than 1/1000 
of the experimental plate, six isolated colonies on the latter were inoculated separately in 5mL of 
LB with 5μL of ampicillin (100μg/mL). The mini cultures were incubated overnight on a 37oC 
shaker and 1mL of the culture was purified using the Wizard Plus SV Miniprep DNA 
Purification System (Promega, Cat #A1330) following the manufacturer’s protocol. 200ng of the 
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Miniprep DNA was used in a diagnostic digest to verify backbone and insert sizes; for those that 
aligned with predicted sizes, 300ng was used to verify the identity of the plasmids via Sanger 
sequencing (Section 2.2.3 ‘Plasmid Verification’). The mini cultures were stored at 4oC for 2-3 
weeks until validation was complete.  
  
Once the plasmids were sequence validated, 2mL from two of the validated mini cultures were 
inoculated separately in 200mL of LB with 200μL of ampicillin (100μg/mL). The midi cultures 
were incubated overnight on a 37oC shaker and the whole 200mL of culture was purified using 
the QIAGEN Plasmid Midi Kit (Qiagen, Cat # 12243). The midiprep followed the 
manufacturer’s protocol (January 2011) with the following adjustments: replaced step 12 and 13 
on page 2/2 with the DNA pellet resuspended in 1mL 100% ethanol, 0.25μL of sodium acetate 
and 0.5μL of glycogen. The tube was centrifuged, supernatant was removed, and the pellet 
washed with 70% ethanol. The previous step was repeated without more ethanol and then the 
pellet was air dried for 0.5-1 hour at room temperature. The DNA pellet was resuspended in 
100μL of sterilised water and the final yield was measured using a Nanodrop.  
Generation of Mutant Insert 
Primers (Geneworks) were designed to amplify candidate variants identified from our WES study 
using the donor plasmid sequences. The donor plasmid backbone and insert sequence was 
obtained from the manufacturers site and transferred onto the Seqbuilder program (Lasergene 
DNAStar software package v.8.0.2). Unique restriction sites in the multiple cloning site were 
incorporated into the primers flanking the ORF ends. Extra 6 adenine and thymidine pairs were 
added to the 5’ end of the primers to improve restriction digest efficiency. A second pair of 
primers were designed to amplify the sequence of interest containing the variants listed in Table 
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2.9; the primer sequence contains the variant and a synonymous restriction site for rapid 
diagnostic digest.  
 
Two successive rounds of PCR were performed: (i) amplification of the ORF ends with the 
sequence of interest and (ii) amplification of the full-length ORF containing the variant of 
interest. To amplify the fragments for the first cloning PCR we used Platinum Taq DNA 
polymerase (Invitrogen, Cat # 10966018) following the manufacturer's’ protocol. PCR products 
were purified using the gel extraction method described in Section 2.2.2 ‘PCR & Gel 
Purification’. For the second cloning PCR, we combined the purified PCR products to act as 
cDNA template to amplify the full-length sequence; also using the same amplification and 
purification methods as the first cloning PCR.   
Restriction digest 
Restriction enzymes (New England BioLabs) listed in Table 2.10 were used to digest the mutant 
insert and the donor plasmid in a 1.5mL eppendorf tube (1μg of DNA, 1.5μL of restriction 
enzyme, 3μL 10X NEB buffer and sterilized water to 30μL total volume). The tubes were 
incubated for 3 hours or overnight at their enzyme-specific temperature as recommended by the 
manufacturer’s (New England BioLabs) protocol. For the enzymes that needed to be heat 
inactivated, the digests were incubated at 65oC or 80oC for 20 minutes. After the digest, 2μL Calf 
intestinal alkaline phosphatase  (New England BioLabs, Cat # M0290S) is added to the digested 
vector along with 3μL 10X CutSmart Buffer; then incubated at 37oC for 1 hour.  
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Restriction Endonuclease Catalogue Number Reaction Temperature 
(oC) 
Target Gene 
SalI R0138S 37 SLF1 
NotI R0189S 37 SLF1 
KpnI R0142S 37 SLF1 
XhoI R0146S 37 SLF1, TCF4, WNT8B 
BstBI R0519S 65 TCF4 
HindIII R0104S 37 TEAD1 
EcoRII / BstNI R0168S 60 TCF4 
SacI R0156S 37 WNT8B 
ApaI R0114S 25 WNT8B 
BglII R0144S 37 TEAD1 
EcoRI R0101S 37 TEAD1 
Table 2.10: Restriction endonucleases used for cloning and diagnostic restriction digest.  
Insert & Vector Purification 
Both digested vector and insert were running on 1% agarose gel, then excised and gel purified 
using the methods outlined in Section 2.2.2 ‘PCR & Gel Purification’.  
Ligation & Transformation 
Ligation reactions were set up in parallel containing either: (1) cut vector alone, (2) cut vector 
and water, (3) cut vector and insert at a ratio of 1:3 and (4) cut vector and insert at a ratio of 1:10. 
Each ligation reaction also contains: 1μL of 10X ligation buffer (50mM Tris-HCl, 10mM MgCl2, 
1mM ATP, 10mM DTT, pH 7.5), 1μL of T4 DNA ligase (New England BioLabs, Cat # M0202S) 
and sterilized water to a total volume of 10μL. All ligation reactions were incubated overnight at 
4oC. To check for success of ligation, 2μL of each ligation reaction ran on 1% agarose gel 
(Section 2.2.2 ‘Gel electrophoresis’); reactions observing a ladder of bands on the gel were 
selected for transformation.  
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Ligation reactions were purified by adding 1mL of isopropanol (100%), 0.25μL of sodium 
acetate (3M) and 0.5μL of glycogen (50ng/μL); then incubated at -80oC for 15 minutes. The 
reactions were then centrifuged for 10 minutes at maximum speed, supernatant removed, and 
pellet rewashed in 100% ethanol; this step was then repeated with 70% ethanol. After a final 
centrifuge to remove residual ethanol, the pellet was resuspended in 10μL of sterilized water.  
 
Three 1.5mL Eppendorf tubes were set up for bacterial transformation: (1) negative water 
control, (2) positive pUC19 vector control and (3) purified vector and insert ligation mix. 1-5μL 
of these three components was added to separate vials of JM109 cells (40μL) cultured in-house. 
The cells were then electroporated using the Gene Pulser MXcell Electroporation System 
(BioRad) following the manufacturer’s protocol. Cells were then recovered in 1mL of SOC 
medium (Sigma Aldrich, Cat # S1797) in a 37oC shaking incubator for 0.5-1 hour. 50-100μL of 
the transformation mix was plated onto LB agar plates containing the antibiotic used for 
selection. The plates were then incubated at 37oC overnight. Mini cultures were prepared and 
purified following the methods outlined in Section 2.2.3 ‘Plasmid Mini & Midi Purification’.  
Plasmid Verification & Glycerol Stock  
Plasmids containing the vector and mutant insert are screened using a diagnostic restriction digest 
with the method and enzymes described in Section 2.2.3 ‘Restriction Digest’. To sequence verify 
the mutant insert and screen for non-synonymous variants in the ORF, Sanger sequencing was 
performed using 300ng of Mini prep DNA and the methods described in Section 2.2.2 ‘Sanger 
Sequencing & Purification’. 
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Glycerol stocks were prepared from mini cultures of plasmid DNA that were sequence validated. 
1.5mL of mini culture was transferred to a 1.5mL screw cap tube and centrifuged at low speed for 
2 minutes. Supernatant was aspirated, and the pellets were resuspended in 50% glycerol; then 
stored at -80oC for future use.  
2.3.4 RNA, whole exome & Whole Genome Sequencing 
RNA Extraction & Sequencing 
Two female control and three female Aicardi probands were selected for RNA sequencing based 
on the availability of LCLs established using the methods described in Section 2.2.1 ‘LCL 
Maintenance & Freezing’. RNA was first precipitated from LCL pellets using the Trizol Reagent 
(Invitrogen, Cat # 115596026) and followed the manufacturer’s (ThermoFisher Scientific) 
protocol. Total RNA was then purified using the RNeasy Mini Kit (Qiagen, Cat # 74104) starting 
from Step 5 on page 27 of the manufacturer’s handbook (RNeasy Mini Handbook 06/2012). 
Final RNA yield was measured using the nanodrop; while the quality was assessed based on 
visualising the 28S and 28S rRNA ratio on 1% agarose. 3μg of LCL-derived RNA was sent for 
RNA sequencing to the Australian Genome Research Facility. Preliminary RNA analysis was 
commenced, however was not comprehensively analysed and completed before the PhD 
expiration time.  
DNA Extraction & Whole Exome/Genome Sequencing 
For the main PhD study, 14 unrelated individuals suspected or diagnosed with Aicardi Syndrome 
(AIC) were selected for whole exome sequencing (WES). In total, there were: ten proband-parent 
trios, two proband-mother pairs and two singletons that were sent for WES. For 2/10 trios, there 
were DNA extracted from resected brain tissues; hence two blood-brain pairs were sent for WES. 
In a parallel study (Chapter 3), three affected individuals were also sent for WES. DNA was 
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extracted from blood using the QIAamp DNA Blood Maxi Kit (Qiagen, Cat # 51192) following 
the manufacturer’s protocol. WES analysis is detailed in Section 2.1.3 ‘Computational Methods’.  
 
1.5μg of genomic DNA were sent for WES to the South Australian Cancer Council Genomics 
Facility. From the original AIC cohort, five proband-parent trios and two singletons were 
selected for whole genome sequencing (WGS). 2.5μg of genomic DNA were sent for WGS to the 
Australian Genome Research Facility. WGS analysis is detailed in Section 2.1.3 ‘Computational 
Methods’. 
2.3.5 TOPFlash Assay 
HEK 293T Cell Transfection for TOPFlash Assay 
The method described in Section 2.2.1 ‘HEK293T cell transfection for protein expression’ was 
performed with the following exceptions: (1) maximum passage number of cells were 15 and (2) 
plasmid and final concentrations listed in Table 2.11 were added to each well along with 50ng of 
renilla and 500ng of M50 8X TOPFlash plasmid (Addgene, Cat # 12456). 
 
500ng pCDNA3.1 
empty vector control 
500ng pCDNA3.1  
empty vector control 
500ng WNT8B 
wildtype plasmid 




200ng WNT8B  
mutant plasmid 
500ng WNT8B mutant 
plasmid 
500ng WNT8B mutant 
plasmid 
500ng WNT8B wildtype 
plasmid 
200ng WNT8B mutant 
plasmid 
500ng WNT8B wildtype 
plasmid 
200ng WNT8B mutant 
plasmid 
500ng WNT8B wildtype 
plasmid 
500ng WNT8B mutant 
plasmid 
500ng WNT8B wildtype 
plasmid 
500ng WNT8B mutant 
plasmid 
Table 2.11: Transfection layout on 12-well plate for TOPFlash assay.   
 
Cell Harvest & Lysis 
Reagents from the Dual Luciferase Reporter Assay Kit (Promega, Cat # E1960) were prepared 
following the manufacturer’s recommendation for 12-well plates (Quick Protocol, 2009). Growth 
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media is removed from 12-well transfections plates and briefly rinsed with 500μL of 1X PBS. 
PBS is removed and 250μL of 1X Passive Lysis Buffer is added to each well; then gently rocked 
at room temperature for minimum 1 hour. Cell lysates were then transferred to a new 1.5mL 
screw cap tube.     
Luciferase Reporter Assay 
The luciferase reporter assay was then performed according to the manufacturer’s protocol 
(Promega). The luminescence of each cell lysate was measured using the GloMax 20/20 
Luminometer (Promega, Cat # E5311). The resulting data, containing the firefly:renilla ratio, was 
analysed by normalizing the relative luciferase activity (RLA) against the empty vector control 
measurement. The experiment was replicated three times and provided an indirect measure of 
canonical WNT signalling activation.  
2.3.6 Western Blot 
Protein Extraction 
Lysis buffer was prepared using 1X stock of Pagano buffer (50mM Tris (pH 7.5),  250mM NaCl, 
5mM EDTA and 0.1% Triton X-100 and sterilized water) or RIPA buffer (120mM NaCl, 0.5% 
Nonidet P-40 (NP-40), 50mM Tris-HCl (pH 8.0) and sterilized water) with 25X protease 
inhibitor cocktail (Sigma, Cat # P8340), 1mM NaF and 1mM NaVO4. HEK293T cell pellets 
stored at -80oC were resuspended in 300-500μL lysis buffer, then incubated on ice and after 
homogenized for 15 seconds (15 x 1 second pulses) via sonification. Samples were then spun at 
4oC; the supernatant was transferred to a new 1.5mL eppendorf tube for storage (-80oC) or 
protein quantification.   
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Protein Quantification 
Protein concentration of whole cell lysates was estimated using the Pierce BSA Protein Assay 
Kit. (ThermoFisher Scientific, Cat # 23209). From the original bovine serum albumin (BSA; 2 
mg/mL) stock, aliquots at the following concentration dilutions were prepared: 1mg/mL, 
0.5mg/mL, 0.25mg/mL and 0.10mg/mL. For each sample of unknown protein concentration, the 
original stock was diluted 1:10 in sterilized water. Unknowns and standards were prepared in 
triplicates on a 96 well plate following the manufacturer’s protocol. The plates were read at 
540nm using an automated plate reader (Dynatech MR5000). A concentration for each unknown 
was determined using the BSA standard curve and averaging the values of the triplicate samples.  
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis  
Protein samples were denatured in 1X Laemmli buffer (0.0625M Tris-HCl (pH 6.8), 2% sodium 
dodecyl sulfate, 10% glycerol, 5% beta-mercaptoethanol, 0.001% bromophenol blue and 
sterilized water) at 95oC for 10-15 minutes in a thermocycler or heating block.  20-30μL of each 
sample (10-20μg) was then loaded onto a 15-well homemade Bis-Tris gel (30% acrylamide, 0.8% 
bis-acryl, 0.375M Tris-HCl (pH 8.8), 0.1% SDS, 0.025% Temed and ammonium persulfate and 
sterilized water); the gel was made up of 7% separating gel (bottom) and 4% stacking gel (top). 
For molecular weight estimation of the target protein, we loaded the samples next to 2-3μL of the 
Precision Plus Dual Color Standard (BioRad, Cat #1610374). Proteins were separated on the gel 
in a Mini-Protean Tetra Cell (BioRad) at 100-140mV powered by the Power Pac 3000 (BioRad) 
for 1.5-2 hours depending on the target protein size.  
Membrane Transfer 
Separated proteins were then transferred from the gel to a nitrocellulose membrane (BioTrace 
NT, Cat # 66485) using the XCell II Blot Module Kit (Invitrogen, Cat # EI9051). Protein transfer 
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was conducted in a XCell SureLock Mini-Cell (Invitrogen, Cat # EI0002) filled with 1X 
NuPAGE Transfer Buffer (Invitrogen, Cat # NP0006) at 12mV overnight in a 4oC fridge.  Post 
transfer, the membranes were treated with Ponceau S solution (Sigma Aldrich, Cat # P7170) to 
check for even loading and then briefly washed with 1X Tris buffered saline with Tween20 
(TBS-T).  
Immunoblotting 
Transfer membranes were then blocked with 5% blocking milk (95% of 1X TBST and 5% skim 
milk powder) on an automatic shaker for either 1 hour at room temperature or overnight at 4oC. 
Primary antibodies were then diluted in 2.5% blocking milk and added to the membrane in a 
heat-sealed plastic sleeve for 4-24 hours on an automatic rotator (Table 2.12). The membrane 
was then washed to remove unbound antibodies using 1X TBS-T for 30 minutes (6 x 5 minutes) 
on the automatic shaker. HRP-conjugated secondary antibodies were then diluted and incubated 
the same way as primary antibodies except for only 1-2 hours.  
 
Detection   
Antibody-bound membranes were then treated with 0.5-1mL of Amersham ECL Western 
Blotting Detection Reagents (GE LifeSciences, Cat # RPN2109) following the Manufacturer’s 
protocol and exposed to the Amersham Hyperfilm ECL at time intervals of: 10 seconds, 30 





Primary Antibody Secondary Antibody 
Name (Supplier) Dilution Name (Supplier) Dilution 
B-actin 42 
Mouse Anti-B-Actin mAb  
(Sigma Aldrich,  
Cat # A3854) 
1:3000 
Goat pAb Anti-Mouse IgG 
HRP Conjugated 
(Dako, Cat # P026002-2) 
1:3000 
B-tubulin 50 
Rabbit Anti-beta Tubulin pAb 
(Abcam,  
Cat # ab21058) 
1:5000 
Goat anti-Rabbit IgG HRP 
Conjugated  
(Dako, Cat # P044801-2) 
1:3000 
HSP90 90 
Rabbit HSP90 [C45G5] mAb 
(Cell Signaling,  
Cat # 79641) 
1:2000 
Goat anti-Rabbit IgG HRP 
Conjugated  
(Dako, Cat # P044801-2) 
1:3000 
SLF1 116 
Rabbit Anti-BRCTD1  
[aa166-195) pAB 
(LifeSpan BioSci,  
1:1000 
Goat anti-Rabbit IgG HRP 
Conjugated  
(Dako, Cat # P044801-2) 
1:3000 
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Cat # LS-C319479) 
TEAD1 39 
Mouse c-Myc [9E10] mAb 
(Santa Cruz Biotech,  
Cat # sc-40)  
1:3000 
Goat pAb Anti-Mouse IgG 
HRP Conjugated 
(Dako, Cat # P026002-2) 
1:3000 
WNT8B 39 
Rabbit anti-V5 pAB  
(Bethyl Lab,  
Cat # A190-120P) 
1:2000 
Goat anti-Rabbit IgG HRP 
Conjugated 
(Dako, Cat # P044801-2) 
1:3000 
wnt8b 39 
Rabbit anti-WNT8B pAB 
(Aviva Systems Biology, 
Cat # ARP33491_T100) 
1:1000 
Goat anti-Rabbit IgG HRP 
Conjugated 
(Dako, Cat # P044801-2) 
1:3000 
wnt8b 39 
Rabbit anti-WNT8B pAB 
(Aviva Systems Biology, 
Cat # OAAB22283) 
1:2000 
Goat anti-Rabbit IgG HRP 
Conjugated 
(Dako, Cat # P044801-2) 
1:3000 
Table 2.12: Detailed summary of primary and secondary antibodies used for 
immunoblotting. 
  
2.3.7 Morpholino Knockdown in Zebrafish 
Breeding & Maintaining Zebrafish Embryo 
Tubingen zebrafish was bred and maintained by the Alzheimer’s Disease Genetics Laboratory 
(The University of Adelaide). Briefly, adult zebrafish was kept in filtered and oxygenated fresh 
water with temperatures maintained at 28.5oC. There were two feeds daily with dry trout pellets 
in the morning and live adult brine shrimp in the evening. Breeding was controlled by an 
automated 12-hour light and 12-hour dark cycle; embryos were collected via the marbling 
technique described in Westerfeld et al. (1995). 
Morpholino Antisense Oligonucleotides & Microinjection 
Morpholino antisense oligonucleotides (MO) were designed and synthesized by GeneTools 
(http://www.gene-tools.com). All experimental MO were designed to block translation by 
targeting sequences upstream of the ATG start codon of genes listed in Table 2.13. A control 
morpholino that shares the same morpholino backbone as the experimental MO, but has no target 
and minimal biological activity is also included in the experiment as a negative control (Table 
2.13). Embryos at one or two-cell stage were injected with MO as described by Westerfield et al. 
(1995); at a concentration gradient of 0.25mM, 0.5mM, 0.75mM and 1mM. The dose of MO that 
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resulted in less than 50% of early embryonic death were selected for phenotype analysis. We 
performed double-blinded injections of six different groups: uninjected, control-MO and four 
experimental-MO. A total of 240 embryos were injected per group for the final analysis.     
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Target Morpholino sequences  Reference 
control 5'-CCT CTT ACC TCA GTT ACA ATT TAT A 3' GeneTools 
tead1b 5’ - GAGTCGCTCATCCTCTCGATGTC - 3’ N/A 
ankrd32/slf1 5’ - GTATTGTCCACCATCCTGAAACCGA - 3’ N/A 
hcn1 5’ - TGCCGCTGCATAAACCCGTATTGCC - 3’ N/A 
szt2 5’ - TGCCATGCCGTGCTTCTCATTAC - 3’ N/A 
wnt8b 5’ - AGGGAGACTTTTCTTCACCTTTCAC - 3’ Hofmeister et al., 2013 
Russek et al., 2008 
Lee et al., 2006 
Table 2.13: Morpholinos used for gene knockdown in zebrafish embryos.  
 
Imaging & Morphant Phenotype Analysis 
Embryos were viewed and scored under a dissection microscope (Paul Thomas lab) at 48 and 72 
hours post fertilization (hpf). All embryos were classified into four morphological classes 
(Figure 2.4) based on their alignment with or deviation from normal embryonic development 
(Kimmel et al., 1995). There were three independent scorers for the morphological assessment 
based on images taken at 72hpf.  
 
 
Figure 2.4: Morphant Phenotype Classes. Zebrafish embryos were scored according to eye 
classifications by Miesfeld et al. (2015). Class I: normal phenotype; Class II: normal eye 
pigmentation with mild body defects; Class III: reduced eye pigmentation with normal to mild 
body defects; Class IV; reduced eye pigmentation and severe body defects.   
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Protein Analysis 
For wnt8b morphants, 10 72hpf whole embryos were dechorionated, deyolked and lysed in 15μL 
sample buffer (2% sodium dodecyl sulfate, 5% B-mercaptoethanol, 25% glycerol, 0.0625 M Tris-
HCl [pH 6.8] and bromophenol blue). Sample buffer containing the embryos were immediately 
incubated at 95oC for 20 minutes and stored at -80oC. Protein from the embryo lysates were then 
separated, transferred, probed and visualized based on methods described in Section 2.2.6 
‘Western Blotting’. Unfortunately, none of the purchased antibodies were specific for the wnt8b 




CHAPTER III: A mutation in COL4A2 causes autosomal dominant 
porencephaly with cataracts. 
3.1 Introduction 
The central nervous system is mostly recognised for its neural and glial network, however 10-
20% of the mammalian adult brain is comprised of the extracellular matrix (ECM) (Lau et al., 
2013). There are ECM glycoproteins involved in every facet of early brain development from 
maintenance and modulation of neural stem cells, to cell differentiation and migration (Barros et 
al., 2011). Among these glycoproteins, collagens have been shown to facilitate cortical 
lamination, orchestrate neuronal migration and provide axonal guidance during brain 
development (Luo et al., 2011, Caglayan et al., 2014, Shinwari et al., 2015, Ackley et al., 2001). 
Mutations in various collagen subtypes have been linked to cortical malformations such as 
polymicrogyria (Caglayan et al. 2014).  
 
The ECM is comprised of three compartments: the basal lamina, perineuronal nets and neural 
interstitial matrix, which dynamically reassembles during different stages of brain development 
(Lau et al., 2013). Collagen IV (COL IV) is an important component of the basal lamina, which 
is comprised of six α-polypeptide chains encoded by six differentially expressed genes (Schmidt 
et al., 1993). These genes are arranged in pairs on chromosomes: 2, 13 and X (Khoshnoodi et al., 
2008). Each pair produces two paralogous α-peptides through a bidirectional promoter (Haniel et 
al., 1995, Khoshnoodi et al., 2008). The COL IV α-peptides assemble into heterotrimers with the 
following stoichiometry: α1α1α2, α3α4α5 and α5α5α6 (Khoshnoodi et al., 2008).  
 
Aberrations to COL IV heterotrimers can lead to genetic and acquired diseases (Table 3.1) 
(Haniel et al., 1995). For example, autosomal dominant and recessive mutations in COL IV α3 
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and α4 chains can lead to Alport Syndrome (MIM 104200; MIM 203780) and hematuria (MIM 
301050) (Lemmink et al., 1996, Vahedi and Alamowitch, 2011). Meanwhile, X-linked mutations 
in COL IV α-5 and α-6 can lead to Alport Syndrome (MIM 301050) and deafness (MIM 300914) 
respectively (Rost et al., 2014, Lemmink et al., 1997, Vahedi and Alamowitch, 2011).  COL4A1 
and COL4A2 are the most abundantly and ubiquitously expressed COL IV peptides (Favor et al., 
2007). Mutations in the corresponding genes can affect multiple organs resulting in various 
cerebral, ocular, renal and muscular pathologies (Favor et al., 2007, Kuo et al., 2014).  
 
Mutations in COL4A1 result in well-recognised phenotypes (Table 3.1) including: porencephaly 
(MIM 175780), brain small vessel disease (MIM 607595), cerebral haemorrhages (MIM 614519) 
and angiopathy with other systemic defects (MIM 607595) (Vahedi and Alamowitch, 2011). The 
current clinical picture of COL4A2 is limited to porencephaly type II (MIM 614483) and 
intracerebral haemorrhage (MIM 614519). While systemic and eye findings have been reported 
in isolated cases (Table 3.2), these clinical features are less well recognised as part of the 
COL4A2 spectrum (Gunda et al., 2014, Verbeek et al., 2012). 
 
Cerebral defects are prominent in all individuals with pathogenic COL4A2 mutations and there is 
in vivo evidence from mice models, that missense mutations in Col4a2 can also induce ocular, 
myopathic and systemic defects (Favor et al., 2007, Kuo et al., 2014). Here, we expand the 
current clinical spectrum of COL4A2 by identifying a novel missense mutation in a family with 






 OMIM DISORDERS REFERENCE 
COL4A1 18000 Tortuosity of retinal arteries 
(Gekeler et al., 2006, Plaisier et al., 2010, 
Zenteno et al., 2015) 
 61773 
Angiopathy with nephropathy, aneurysms 
and muscle cramp 
(Plaisier et al., 2007) 
 607595 Brain small vessel disease 
(Gould et al., 2006, Sibon et al., 2007, 
Lemmens et al., 2013, Coupry et al., 2010, 
Rodahl et al., 2013, Deml et al., 2014) 
 175780 Porencephaly 1 
(Gould et al., 2005, Aguglia et al., 2004, 
Breedveld et al., 2006, Smit et al., 1984, de 
Vries et al., 2009) 
 614519 Susceptibility to intracerebral haemorrhage (Weng et al., 2012, Shah et al., 2012) 
COL4A3 104200 Alport Syndrome (dominant) 
(Heidet et al., 2001, van der Loop et al., 
2000, Jefferson et al., 1997) 
 203780 Alport Syndrome (recessive) 
(Mochizuki et al., 1994, Lemmink et al., 
1997, Knebelmann et al., 1995, Finielz et al., 
1998, Webb et al., 2014) 
 141200 Benign hematuria (Badenas et al., 2002) 
COL4A4 203780 Alport Syndrome (recessive) 
(Lemmink et al., 1997, Mochizuki et al., 
1994, Boye et al., 1998) 
 141200 Benign hematuria (Badenas et al., 2002, Lemmink et al., 1996) 
COL4A5 301050 Alport Syndrome 
(Turco et al., 1995, Guo et al., 1995, Smeets 
et al., 1992, Knebelmann et al., 1992, Renieri 
et al., 1992, Boye et al., 1991, Barker et al., 
1990) 
COL4A6 300914 X-linked Deafness (Rost et al., 2014a) 
 
Table 3.1: Collagen IV related disorders. This table summarises the disorders associated with 
mutations in Collagen IV genes.   
                                               
8 Genes are represented by their HUGO Gene Nomenclature Committee (HGNC) symbol The OMIM phenotype 
number is provided along with the corresponding studies. 
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9Mutations in the corresponding genes are divided into two groups: one that displaces a glycine in the triple helical 
region (THR-G), while the other displaces a non-glycine residue (NGM).  
10 Total genotypes refer to the total number of genotypes observed per mutation group. The values in the table 
represent the sum of observed phenotypes per mutation group. Abbreviations: ADHD, Attention Deficit Hyperactive 
Disorder; BCA, Bowman’s capsule abnormality; CK, creatine kinase; IOP, internuclear ophthalmoplegia; MCD, 
malformation of cortical development; NGM, non-glycine mutation; SEB, subependymal bleeding; THR-G, triple 
helical region-glycine. 
11 The values in the table represent the sum of observed phenotypes per mutation group.  
 
Abbreviations: ADHD, Attention Deficit Hyperactive Disorder; BCA, Bowman’s capsule abnormality; CK, creatine 
kinase; IOP, internuclear ophthalmoplegia; MCD, malformation of cortical development; NGM, non-glycine 
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Table 3.2: Phenotypes of COL4A1 and COL4A2 variants in humans and mice. This table is 
modified after Kuo and Meuwissen (Kuo et al., 2012, Meuwissen et al., 2015).  
3.2 Materials & Methods 
Informed written consent was obtained from all subjects or their parents or legal guardians in the 
case of minors. The study was approved by the New Zealand Health and Disability Ethics 
Committee and the Adelaide Women's and Children's Health Network Human Research Ethics 
Committee. 
3.2.1 Exome Sequencing 
Whole exome sequencing (Roche Nimblegen SeqCap v3) was performed on a HiSeq2500 
(Illumina) by the South Australian Cancer Council Genomics Facility on three affected 
individuals (I-2, II-2, III-1; Figure 3.1A). Reads were mapped to the human genome (hg19) 
using BWA-MEM (Li and Durbin, 2009) and mapping refined using Genome Analysis Toolkit 
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(GATK) version 3.2-2 (DePristo et al., 2011). Mapping achieved a minimum median target 
coverage depth of 46 reads/sample and covered 95% of intended targets with at least 10 reads 
(Supplementary Fig. S1). Single nucleotide variants and small insertions and deletions were 
called by the GATK haplotype caller version 3.2-2 (DePristo et al., 2011). Larger copy number 
and structural variants were analysed by CoNIFER (Krumm et al., 2012); however, no 
segregating, rare copy number variants were detected. All variants were annotated for allele 
frequency, clinical significance, locus identity, and likely pathogenicity using ANNOVAR 
(Wang et al., 2010). Novel genotypes shared between affected individuals, but absent from a 
control set of 15 exomes, were separated using the vcf-contrast module from VCFtools (Danecek 
et al., 2011). 
3.3 Results 
3.3.1 Clinical Findings 
The proband (Figure 3.1A, III-1) of this family was a 15-year-old male. He was born at term by 
emergency caesarean section at 41 weeks due to failure to progress. First developmental concerns 
occurred at 11 weeks due to a lack of head control. By 5 months it was clear he was globally 
delayed and was developing hydrocephalus.  Twelve hours after a VP shunt insertion at 2 years 
of age, he had his first seizure.  Subsequently he has had intractable multifocal seizures including 
episodes of convulsive status epilepticus.  At three years of age he was noted to have bilateral 
small posterior lens opacities which have not been progressive.  He now has spastic quadriplegia 
and profound Intellectual disability. EEGs show marked asymmetry of the background with 
suppression of amplitude, increased slowing in the left hemisphere and epileptic activity in the 
right parietal region. MRI at 3 months shows a large right frontal region of porencephaly that 
communicates with a very dilated right lateral ventricle and moderate left lateral ventricular 
dilatation (Figure 3.1B, i).  Prior intraventricular haemorrhage has resulted in hemosiderin 
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staining of the ventricular walls with residual blood products evident in the posterior horns.  The 
right caudate nucleus, lentiform nucleus, internal capsule, thalamus and right hippocampus are 
destroyed. The corpus callosum is extremely thinned (Figure 3.1B, ii). 
 
The proband’s 11-year-old brother (Figure 3.1A, III-2) presented at 3 years of age with focal 
dyscognitive seizures.  He was born at 39 weeks following an uneventful pregnancy by 
emergency caesarean section due to cord prolapse. His early development was slightly delayed in 
that he didn’t walk until 18 months and had no words until 2 years of age. At 5 years of age he 
was diagnosed with pervasive developmental disorder with associated mild to moderate 
intellectual impairment.  His focal seizures continue and are all of similar semiology. At 14 
months of age he was noted to have bilateral posterior subscapular lens opacities, which were not 
progressive, but his neurological examination was otherwise in keeping with his developmental 
level. His MRI revealed a right frontal porencephalic cyst communicating with the right lateral 
ventricle (Figure 3.1B, iii).  There is partial destruction of the periventricular white matter and 
caudate body.  A smaller cyst is was present in the right external capsule.  The corpus callosum 
has had a very unusual appearance (Figure 3.1B, iv).  COL4A1 sequencing was normal and at the 
time COL4A2 was not considered as a candidate gene. 
 
The 42-year-old mother (Figure 3.1A, II-2) of the two boys was asymptomatic with no seizures 
or neurological symptoms and had a normal IQ.  Her neurological examination was normal apart 
from a mild left internuclear ophthalmoplegia. MRI showed a cluster of small cysts in the right 
frontal periventricular white matter and bilateral anterior caudate nuclei (Figure 3.1B, v). There 
are numerous scattered T2/FLAIR hyperintense lesions in keeping with foci of gliosis, scattered 
throughout the white matter, more prominent frontally (Figure 3.1B, vii). 
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The 67-year-old maternal grandmother (Figure 3.1A, I-2) was noted to have a mild right 
hemiplegia in the first year of life. At the time, this was felt to be due to a difficult delivery at 
term, which required high forceps. She was left handed early and delayed in walking. She had 
learning difficulties at school and although is in the normal range cognitively has never felt her 
memory was very good. She developed focal dyscognitive seizures in childhood, which were 
treated with phenobarbital. She did not develop convulsive seizures until the age of 47 years. 
These continue occurring 4 times per year and she has had episodes of convulsive status. 
Following the convulsive seizures, she has a right-sided Todd’s paresis. Her focal seizures have 
failed to respond to carbamazepine, valproate, vigabatrin and clobazam. On examination her right 
limbs are smaller than the left and she has an obvious right hemiplegia. She has refused 
neuroimaging and has never had an EEG. She developed bilateral cataracts at the age of 65 years. 
 




Figure 3.1: Familial porencephaly caused by a COL4A2 mutation. A: Pedigree. Affected 
individuals shown in black boxes (males) and circles (females). B: MRI brain scans. (i) Proband 
 92 
III-1: Axial T2 demonstrates right frontal porencephalic cyst (star) and hydrocephalus. 
Hemosiderin staining (T2 hypointensity) of the ependymal lining of the posterior horns of the 
lateral ventricles (arrows). (ii) Sagittal T1 weighted image demonstrates thinning of the corpus 
callosum (long arrow) and loss of visualisation of the aqueduct of Silvius (arrowhead). (iii) III-2: 
Coronal T1 IR sequence shows multiple right frontal porencephalic cysts (arrows), the largest 
extends into the superior frontal lobe. (iv) Sagittal T1 weighted image demonstrates a dysmorphic 
corpus callosum the thick rostrum (short arrow) and splenium (long arrow) missing the callosal 
body (double arrowheads). (v) II-2: Coronal T2 weighted image of the frontal lobes demonstrate 
multiple small cysts in the right frontal periventricular white matter (long arrow). Numerous 
scattered foci of T2 hyperintensity are in keeping with gliosis related to small vessel disease 
(short arrows). (vi) Axial FLAIR demonstrates two small cysts in the right frontal periventricular 
white matter with surrounding hyperintense gliosis (arrow). Foci of gliosis in the left frontal lobe 
and right posterior temporal periventricular white matter (arrowheads). C: Chromatogram 
showing the heterozygous c.2339G>A change (arrows), which is present in the affected 
grandmother (I-2), mother (II-2), proband (III-1) and brother (III-2); and absent in the father (II-
1) and maternal uncle (II-3).  D: Predicted pathogenicity of COL4A2 c.2399G>A, p.G800E 
determined by four prediction algorithms. E: Ideogram of chromosome 13 and the COL4A2 
locus (arrow) at 13q34. The mutated amino acid G800 is highly conserved across different 
orthologs (boxed). F: Domain structure and mutations of COL4A2. COL4A2 p.G800E (grey) is 
located within the triple helical region (THR). Published COL4A2 mutations predisposing to 
porencephaly (squares) and intracerebral haemorrhage (triangles) are shown. 
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3.3.2 Overview of filtered variants 
Whole exome sequencing (Roche Nimblegen SeqCap v3) was performed on a HiSeq2500 
(Illumina) by the South Australian Cancer Council Genomics Facility on three affected 
individuals (Figure 3.1A, I-2, II-2, III-1). Reads were mapped to the human genome (hg19) 
using BWA-MEM (Li and Durbin, 2009) followed by local realignment around Indels using 
Genome Analysis Toolkit (GATK) version 3.2-2 (DePristo et al., 2011). Mapping achieved a 
minimum median target coverage depth of 46 reads per sample and covered 95% of intended 
targets with at least 10 reads (Figure 3.2). Single nucleotide and small insertions and deletions 
were called by the GATK haplotype caller version 3.2-2 (DePristo et al., 2011). Larger copy 
number and structural variants were analysed by CoNIFER (Krumm et al., 2012) however, no 
segregating, rare copy number variants were detected. All variants were annotated for allele 
frequency, clinical significance, locus identity and likely pathogenicity using ANNOVAR (Wang 
et al., 2010). Novel genotypes shared between affected individuals, but absent from a control set 




Figure 3.2: Median read depth coverage across capture targets and open reading frames 
(ORF). A: The median coverage depth across the Roche Nimblegen SeqCap v3 target capture 
(blue) and ORF within the target capture (pink). B: The percentage of base pairs with zero 
coverage across the target capture and ORF within the target capture. 
3.2.3 Predicted pathogenicity of COL4A2 p.G800E 
There were 8388 variants that were shared between the three affected individuals (Table 3.3). Of 
these, 1049 variants were below the frequency thresholds of 0.01 (EVS, 1000genomes, CG69, 
Wellderly) and 0.001 (ExAC, UK10K). Then there were 409 variants with a minimum read depth 
of 10 X that passed GATK variant quality score recalibration. Finally, 69 of these were exonic 
variants, which were assessed for further likely pathogenicity (Table 3.3). Only one variant was 
 95 
found that passed our filtering criteria and also best fit the clinical description of the patients: 
CCDS41907.1(COL4A2):c.2399G>A, p.(G800E) (Table 3.4). Sanger sequencing confirmed the 
segregation of the variant in the grandmother, mother and grandsons (Figure 3.1C). The 
COL4A2 p.G800E variant was predicted as likely disease causing by multiple variant predictors 
(Table 3.5). The COL4A2 p.G800 is highly conserved across multiple species; primates through 




Table 3.3: Summary of filtered variants. This table lists the criteria used for filtering common 
(likely benign) variants from rare (potentially pathogenic) variants. 12 
                                               
12  The number of variants that passes each filtering stage is shown on the right.  
aThe frequency thresholds were set at 0.01 in CG69 (n=69), 0.001 in Wellderly (n=454), 0.0001 in UK10K (n=3781) 
and 1000 genomes (n=1092); and 0.00001 in ExAC (n>60,000).  
bVariants flagged as PASS following variant quality score recalibration using GATK. cVariants were considered to 
affect protein function as determined by SIFT and PolyPhen. Abbreviations: GATK-HC, genome analysis toolkit 




Table 3.4: Summary of potentially pathogenic variants. The likely pathogenicity of variants was determined by: low allele count in normal 
population, expressed in the brain, gene intolerant to mutations, predicted to affect protein function and related phenotype to our family. 13  
                                               
13 The ExAC frequency provides the observed allele count (AC) among the called genotypes (GT) of individuals without neurodevelopmental disorders. Genes expressed in the 
brain were determined via Allen Brain Atlas (http://www.brain-map.org/). Six variant prediction tools (SIFT, PolyPhen, LRT, MutationTaster, MutationAssessor and 
FATHMM) were used to predict the effect on protein function. Related phenotypes were obtained via OMIM (http://www.omim.org/) and PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed).  
Green boxes support causality, red boxes indicate insufficient evidence for causality and yellow boxes provide inconclusive support for causality.  
 
Abbreviations: gDNA, genomic DNA; HGNC, HUGO gene nomenclature committee; LRT, Likelihood Ratio Test. 
 
 
Table 3.5: Predicted pathogenicity of COL4A2 c.G2399A. This table summarises the different 
algorithms and tools used to assess the likely pathogenicity of variants.14    
                                               
14 The predicted pathogenicity of COL4A2 c.G2399A (blue panel) is given as the raw score, as well as the 
interpretation of that score in context with the protein or disease likelihood.  
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3.4 Discussion 
3.4.1 Phenotypes in human COL4A2-related disorders 
We describe a family that was originally thought to best fit phenotypes associated with COL4A1 
mutations (Table 3.2) (Vahedi and Alamowitch, 2011). Lens opacities were observed in the 
proband and brother (Table 3.2). Lens opacities have not been recorded in any previous COL4A2 
cases (Table 3.2) but are a well-recognized feature, among other ocular defects, associated with 
COL4A1-related disorders (Coupry et al., 2010). To date, only one COL4A2 mutation was 
associated with ocular defects that included myopia, amblyopia and abnormal optic discs (Table 
3.2) (Verbeek et al., 2012). This suggests that COL4A2 mutations can manifest dysgenesis of the 
retina (Verbeek et al., 2012) and lens (present case) in humans. 
3.4.2 Phenotypes of COL4A2 and COL4A1 mutations in human and mice 
The phenotypes observed in COL4A2-related disorders in humans, including the case we present 
here, have been replicated in and in some cases predicted by mice carrying Col4a2 mutations 
(Favor et al., 2007, Kuo et al., 2014). Mice, identified from ethylnitrosurea (ENU) mutagenesis 
screens that were heterozygous for Col4a2 mutations showed defects to the eye, including 
microphthalmia, buphthalmos and lens opacities; brain, such as porencephaly, intracerebral 
haemorrhage and abnormal neuronal migration; kidney function, indicated by increased urea in 
blood; vessel system, resulting from reduced vascular development (Favor et al., 2007) and; 
reduced muscle fibres suggestive of myopathy (Kuo et al., 2014). The renal and myopathic 
defects observed in mice correlate with the patient phenotype described by Gunda et al.  (Gunda 
et al., 2014), which included: hematuria, muscle cramps and elevated creatine levels but these 
were not observed in the present case (Table 3.2). The severity and penetrance of eye, brain and 
muscular defects varied greatly among a single allele group of 18 mutant Col4a2 mice on the 
inbred C57Bl/6J background strain (Kuo et al., 2014). In humans, dominant COL4A2 mutations 
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also exhibit incomplete penetrance (Table 3.6) (Verbeek et al., 2012, Yoneda et al., 2012). The 
similarities observed between mice models and patients with COL4A2 mutations support the 
notion that the effects of COL4A2 mutations extend beyond the brain. 
 
3.4.3 Prognosis of THR glycine mutations versus NGMs 
A majority of COL4A1/A2 mutations occur at highly conserved glycine residues within the triple 
helical region (THR), (Figure 3.1E & 3.1F) (Favor et al., 2007). It is proposed that glycine 
substitutions in the THR destabilise COL IV heterotrimer formation leading to accumulation of 
misfolded protein and subsequent chronic stress on the endoplasmic reticulum (ER) (Kuo et al., 
2014, Yoneda et al., 2012). Similar to COL4A1, missense glycine mutations in the THR of 
COL4A2 are likely to predispose severe cerebral pathologies with early onset (Table 3.2). While 
severe, COL4A2 THR glycine mutations usually lead to milder phenotypes and better prognosis 
compared to equivalent mutations in COL4A1, in both mice and humans (Favor et al., 2007). It 
has been hypothesised that the difference in phenotypic severity of COL4A1 versus COL4A2 
mutations is due to the stoichiometry of α1: α1: α2 per heterotrimer (Favor et al., 2007, Jeanne et 
al., 2012, Khoshnoodi et al., 2008). Assuming that heterotrimer formation proceeds as usual, a 
heterozygous COL4A2 mutation will lead to 50% of COL4A1/A2 trimers with a mutant peptide, 
whereas a heterozygous COL4A1 mutation will lead to 75% of COL4A1/A2 trimers having a 
mutant peptide (Favor et al., 2007, Jeanne et al., 2012). Location of the pathogenic variant 
relative to different functional domains of the COL4A1/A2 peptides also influences phenotype 
(Des Parkin et al., 2011). 
 
 
Table 3.6: Phenotypes associated with COL4A2 variants in humans. This table provides a summary of human cases with COL4A2 variants. 15
                                               
15 The variant is described by the predicted protein change identified in the corresponding studies. The age of onset (clinical presentation) and gender of the proband per study 
is noted. For familial cases, the clinical findings of extended family members are included.  
 
Abbreviations: AO, amblyopia; CB, caudate body; CC, corpus callosum; CK, creatine kinase; CN, caudate nucleus; CP, cerebral peduncle;; DD, developmental disorder; HC, 
hydrocephalus; HH, hemihypesthesia; HP, hypothyroidism, IC, internal capsule; ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage; LD, learning difficulties; 
LE, leukoencephalopathy; LN, lentiform nucleus; Mat, maternal; MC, Microcephaly; MF, multifocal; MO, myopia; MP, monoparesis; OD, optic disks; OP, ophthalmoplegia 
PC, porencephaly; PV, periventricular; SCHIZ, schizencephaly; QP, quadriplegia; VM, ventriculomegaly; WMC, white matter change. 
 
Non-glycine mutations NGMs within the THR and also the non-collagenous domain are likely 
low penetrance, risk alleles for late onset ICH with good survivability (Table 3.1) (Jeanne et al., 
2012). Our review of, all COL4A2 mutations showed NGMs are present in the ExAC database 
quite frequently while pathogenic THR glycine mutations are absent (Table 3.7) (Gunda et al., 
2014, Verbeek et al., 2012, Yoneda et al., 2012). Nonetheless, these NGMs were shown to 
decrease the ratio of extracellular to intracellular COL4A2 relative to wild-type and also two of 
three variants induced stress in the ER in a similar way to THR glycine mutations, which 
supports their potential to be causal (Jeanne et al., 2012). It is interesting to note in hindsight that 
based on their population frequencies, all three NGMs would have been excluded in their original 
study (Jeanne et al., 2012). This acts as a cautionary tale that filtering of variants using public 
databases must be tailored to the disease, especially those disorders with late onset. 
 
3.4.4 Concluding remarks 
In conclusion, we identified a novel CCDS41907.1(COL4A2):c.2399G>A, p.(G800E) mutation 
that is predicted to be highly pathogenic based on the substitution of a highly conserved, critical 
THR-glycine residue that segregated with the phenotype in affected individuals. Our findings are 
supported by the existing genotype to phenotype correlation between previous COL4A2 THR 
glycine mutations and porencephaly with focal structural epilepsy due to ischaemic damage. We 
also extend the COL4A2 phenotype spectrum, with the observation of lens opacities in some 
affected individuals; reducing the distinction between COL4A1 and COL4A2 mutations. This 
highlights the importance of simultaneous screening both COL4A1/A2 genes for accurate 
diagnosis of severe, early onset porencephaly. 
 
 
Table 3.7: Allele frequency of COL4A2 mutations in ExAC. This table summarises the variant allele frequency of reported COL4A2 
Mutations.16  
                                               
16 Two allele frequencies (right hand panel) are provided. The first frequency is the observed allele among all participants in the corresponding study (multiple observations are 
usually from related individuals). The second frequency is the observed allele count among ~60,000 individuals in the ExAC browser.  
**COL4A2 c.3448C>A was identified in a male with two affected sisters with intracerebral haemorrhage. The related members were not available for segregation analysis, thus 
inheritance is unconfirmed but predicted as likely autosomal dominant.  
 
Abbreviations: AA, amino acid; ExAC, Exome Aggregation Consortium; VAF, Variant Allele Frequency. 
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CHAPTER IV: Genetical heterogeneity and complexity of Aicardi Syndrome 
revealed through whole exome and whole genome sequencing. 
4.1 Introduction 
Genetic testing for Aicardi Syndrome is currently unavailable as the underlying cause(s) have yet 
to be identified. Early investigations into the genetics of AIC were predominantly focused on 
chromosome X for two reasons (Neidich et al., 1990, Nielsen et al., 1991, Hoag et al., 1997, 
Yilmaz et al., 2007, Eble et al., 2009, Pai et al., 2013). Firstly, the first chromosomal aberration 
reported in a suspected AIC female was an X/3 translocation (Ropers et al., 1982). Secondly, an 
X-linked male-lethal cause would best explain the predominance of the disease in females, which 
are represented in more than 99% of cases reported in literature. Despite 70 years of genetic and 
genomic investigations, an X-linked cause has yet to be established. By reviewing the genetic 
loci of variants reported in AIC thus far, we have yet to observe a recurring gene hit or sub-
chromosomal overlap (Table 1.7).  
 
Genetic investigations into AIC has yet to be thoroughly explored outside of the X chromosome; 
except for the study by Schrauwen et al. (2015). In this study, two autosomal variants in TEAD1 
and OCEL1 were identified in two unrelated individuals respectively. Both of these affected 
individuals had intact corpus callosum accompanied with chorioretinal lacunae and infantile 
spasms. Therefore, did not display the classical triad (Figure 1.1), but the presence of other 
MCDs sufficed the AIC diagnosis recommended by Aicardi (2005). No functional validation was 
performed to assess the molecular consequence of the predicted deleterious variants in TEAD1 or 
OCEL1; thus, the genotype to phenotype correlation is not proven. In an independent study of a 
cohort of 38 girls who displayed the hallmark classical triad (Figure 1.1), additional variants 
were not identified in these genes (Wong et al., 2016). Similarly, no further variants were 
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identified in TEAD1 or OCEL1 from two parent-proband trio who were analysed for overlapping 
autosomal-pathogenic variants (Lund et al., 2016).   
 
In this study, we used a similar sequencing strategy to Schrauwen et al. (2015) by incorporating 
both WES and WGS for variant discovery. In contrast to previous genetic studies, we searched 
for small variants (SNP and Indels) using multiple variant callers (Figure 4.1). We also explored 
three potential inheritance models: de novo, homozygous recessive and compound heterozygous. 
Our cohort was comprised of individuals displaying the classical triad (strong diagnosis; Figure 
1.1), major and minor features (supported diagnosis) and overlapping features with AIC 
(suspected diagnosis). The clinical heterogeneity of our cohort enabled us to query whether there 
are: (1) different genetic causes underlying different clinical subsets of AIC or (2) mutations in a 
recurring gene that is pleiotropic and with variable penetrance or expressivity. We also  
investigated the molecular consequences of potential candidate genes using protein-specific in 
vitro assays and/or the phenotypic consequences of morpholino-mediated knockdown in 
zebrafish embryos. Our study aimed to provide insight into the genetic and molecular factors that 
may contribute to the pathology of AIC.  
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Figure 4.1 Schematic Overview of SNP and Indels processing pipeline. This diagram was 
adapted from GATK best practice guideline for SNP and Indels discovery. It summarises the 
processes involved in converting raw sequencing reads to a list of candidate variants, which were 
then manually assessed for their likely pathogenicity.   
 
4.2 Results 
4.2.1 Clinical summary of Aicardi cohort  
A majority of the probands were identified and clinically assessed by Professor Ingrid Scheffer of 
The University of Melbourne and Florey Institute. Other clinicians that recruited single patients 
for our cohort included: Dr. Nick Smith (WCH Paediatric Neurology), Dr. Chirag Patel (Genetic 
Health Queensland) and Dr. Vandana Shashi (Duke University Medical Centre). Consent was 
obtained for all patients enrolled in this study by the ethics committees affiliated with each 
respective clinician. The clinical characteristics for all probands in our AIC cohort are 
summarised in Table 4.1, while the full phenotypic spectrum is described in Table 4.2. 
Serological tests for congenital viruses and metabolic levels, performed antenatally were negative 
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for all probands. 9/12 probands had no family history of neurodevelopmental disorders (Figure 
4.2), while 10/12 had unremarkable pregnancy and delivery.  No genomic or genetic 
abnormalities were detected through prior clinical genetic testing for some of the patients that 














































































Major Features              
Infantile spasms* 1 1 1   1  1 1 1 1 1 8 
Chorioretinal lacunae 1 1 1   1  1  1  1 8 
Coloboma of the optic disc     1 1     1  3 
Agenesis of the corpus callosum   1 1 1   1 1 1  1 7 
Cortical malformations (mostly 
microgyria) 
 1 1 1 1 1 1  1 1 1 1 10 
Periventricular (and subcortical) 
heterotopia 
 1 1         1 3 
Intracranial cysts   1         1 2 
Papilloma of choroid plexuses 1     1     1  3 
Supporting Features              
Vertebral and costal 
abnormalities 
1 1 1  1     1   5 
Microphthalmia and/or other eye 
abnormalities 
  1       1 1  3 
‘Split brain’ EEG  1 1  1 1 1      5 
Gross hemispheric asymmetry         1   1 2 
Other Features              
Developmental delay 1 1  1 1 1   1    6 
Intellectual disability (severe or 
profound) 
 1        1   2 
Hemiplegia (or 
diplegia/quadriplegia) 
 1 1    1      3 
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Secondary microcephaly             0 
Strength of Diagnosis              
Strong   1   1  1  1  1 5 
Supported 1 1   1      1  4 
Suspected    1   1  1    3 
Table 4.1: Clinical summary of patients in study cohort.  
 







































































HP:0001263 Developmental Delay 1 1 1  1 1 1 1 1 1   9 
HP:0007858 Chorioretinal Lacunae 1 1 1   1  1  1  1 7 
HP:0001274 Agenesis of the Corpus Callosum   1  1   1  1  1 5 
HP:0012469 Infantile Spasm 1 1 1     1  1  1 6 
HP:0002126 Polymicrogyria  1 1  1  1     1 5 
HP:0002119 Ventriculomegaly 1  1   1    1  1 5 
HP:0002282 Heterotopia  1 1         1 3 
HP:0200022 Choroid Plexus Papilloma 1     1     1  3 
HP:0002521 Hypsarrhythmia  1   1  1      3 
HP:0000588 Optic Disc Coloboma     1 1     1  3 
HP:0001338 
Partial Agenesis of the Corpus 
Callosum 
     1   1  1  3 
HP:0000729 Autism Spectrum Disorder         1    1 
HP:0002539 Cortical dysplasia  1    1       2 
HP:0011182 Epileptiform Discharges     1  1      2 
HP:0011968 Feeding Problems      1   1    2 
HP:0010841 Multifocal Epileptiform Discharges   1   1       2 
HP:0002650 Scoliosis   1       1   2 
HP:0002069 Tonic Clonic Seizure 1       1     2 
HP:0010818 Tonic Seizure      1   1    2 
HP:0010576 Intracranial Cystic Lesions            1 1 
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HP:0005263 Gastritis      1      1 2 
HP:0001249 Intellectual Disability  1        1   2 
HP:0000610 Abnormality of Choroid           1  1 
HP:0002269 Abnormality of Neuronal Migration       1      1 
HP:0000493 Abnormality of the Fovea          1   1 
HP:0000932 Abnormality of the Posterior Fossa          1   1 
HP:0001965 Abnormality of the Scalp            1 1 
HP:0002335 Agenesis of Cerebellar Vermis          1   1 
HP:0003355 Aminoaciduria            1 1 
HP:0100702 Arachnoid Cyst   1          1 
HP:0002099 Asthma        1     1 
HP:0000483 Astigmatism   1          1 
HP:0001272 Cerebellar Atrophy   1          1 
HP:0030048 Colpocephaly            1 1 
HP:0001305 Dandy Walker Malformation          1   1 
HP:0000670 Dental Caries        1     1 
HP:0002376 Developmental Regression            1 1 
HP:0002307 Drooling         1    1 
HP:0001999 Dysmorphic Facial Features          1   1 
HP:0000577 Exotropia          1   1 
HP:0012427 Femoral Anteversion   1          1 
HP:0010734 Fibrous Dysplasia of the Bones   1          1 
HP:0007359 Focal Seizures        1     1 
HP:0010821 Gelastic Seizures         1    1 
HP:0001269 Hemiparesis       1      1 
HP:0002937 Hemivertebrae     1        1 
HP:0000238 Hydrocephalus           1  1 
HP:0000540 Hypermetropia          1   1 
HP:0001252 Hypotonia  1           1 
HP:0002123 Myoclonic Seizures        1     1 
HP:0000121 Nephrocalcinosis       1      1 
 107 
HP:0001052 Nevus Flammeus            1 1 
HP:0001845 Overlapping Toes            1 1 
HP:0002445 Quadriplegia   1          1 
HP:0010636 Schizencephaly      1       1 
HP:0004322 Short Stature          1   1 
HP:0010535 Sleep Apnoea          1   1 
HP:0000473 Torticollis     1        1 
HP:0002948 Vertebral Fusion          1   1 
HP:0003422 Vertebral Segmentation Defect          1   1 
Table 4.2: Summary of human phenotype ontology (HPO) terms for probands in study 
cohort.  
 
Figure 4.2: Pedigree map of Aicardi cohort study. A-C: The family history of 
neurodevelopmental disorders in probands T2846, T22842 and T22352. D: Proband T22842 is 
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the offspring of a consanguineous relationship. E: Unremarkable family history for Proband 
T17262. F: Schematic diagram representing the remaining probands in the cohort with 
unremarkable family history. Abbreviations: B, blood; S, saliva; Mod ID, moderate intellectual 
disability; GTCS, generalised tonic-clonic seizure; FS, febrile seizure. 
    
4.2.2 Coverage analysis across whole exome sequencing and whole genome sequencing. 
Prior to investigating the variants called using the SNP and indel discovery pipeline (Figure 4.1), 
we assessed SNP and Indels that may have been missed due to inadequate sequencing coverage. 
The average number of reads aligned to a reference genome, sequencing depth, was assessed 
across all Aicardi exomes and genomes using Picard (http://broadinstitute.github.io/picard/). 
Whole exome sequencing (WES) and whole genome sequencing (WGS) achieved a median 
sequencing depth of 30X and 40X respectively (Table 4.3). WGS had greater sequencing 
coverage and depth across protein-coding regions compared to WES (Figure 4.3). This can be 
observed from 30X sequencing depth, where WES covered 30-70% of target protein-coding 
sequences, while WES covered 75-95%. Overall, the observed sequencing depth of the Illumina 
exomes and genomes were comparable to other genetic studies that were successful at identifying 














T22842 50 3.5 FR07959033 34 0.26 
T25217 28 0.77 - - - 
T22101 30 1.36 - - - 
T2846 38 2.73 FR07959023 42 0.26 
T25752 23 0.78 FR07958909 48 0.21 
43774 30 0.75 FR07958917 35 0.31 
T22352 35 3.86 - - - 
T17262 30 3.76 - - - 
T22418 - - FR07959030 42 0.26 
49265 - - FR07958956 - - 
SQC0025F8 30 4.89 - - - 
T25387 22 7.89 FR07958885 38 0.26 
T25820 35 0.65 - - - 
 WES Median 30 2.73 WGS Median 40 0.26 
Table 4.3: Median target depth and coverage. This table summarises the sequencing coverage 
across the open reading frame (ORF) of the SeqCap EZ Exome v3 capture targets (WES) or 
Hg19 canonical transcripts with 50bp flanking sequences (WGS).17 
  
                                               
17 dash (-), samples were not sent for sequencing or failed quality control; ID, identification; WES, whole exome 





Figure 4.3: Aicardi Cohort WES and WGS coverage and depth across target bases. These 
line graphs for WES (top) and WGS (bottom) show the percentage of target bases covered (Y-
axis) over different coverage depths (X-axis). Hg19, human genome build 19; ID, identification; 




We further examined the regions with any base of zero sequencing coverage across exome and 
genome targets. Approximately 3% (n = ~6.3Mb) of sequence bases were not covered by WES, 
while less than 0.3% (n = ~73kb) were not covered by WGS (Table 4.3). Among the regions with 
zero sequencing coverage, approximately 74% (n = ~54kb) of WGS and 98% (n = ~6.2Mb) of 
WES were observed in both Aicardi and unrelated (phenotypically normal) individuals (Figure 
4.4). The majority of no coverage regions contained interspersed repeats or low complexity DNA 
sequences; approximately 75% for both WES and WGS (Figure 4.4) consistent with  the known  
limitations of Illumina sequencing across repetitive and non-complex DNA sequences (Treangen 
et al., 2011, Aird et al., 2011).  
 
A majority of the no coverage regions (NCR) resided outside of the open reading frame (ORF). 
After removing those found in unaffected individuals and flanking repeated sequences, there 
were less than 0.5% of NCR flanking ORF in WGS (n = ~2700) and WES (n = 37). The higher 
number of NCR in ORF of WGS is likely due to its increased sequence coverage and depth 
across ORF compared to WES (Figure 4.3). Next, we looked at NCR that flanked putative genes 
associated with eye, epilepsy, intellectual disability or malformations of cortical development 
(EEIM). Approximately 14% (WES) and 26% (WGS) of NCR that flanked ORF were in EEIM 
genes (Figure 4.4). Irrespective of being autosomal or X-linked, most of these NCR resided in 
sequences that were not well conserved, distant from splice junctions or did not overlap with a 
known regulatory element.   
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Figure 4.4: WES and WGS with zero sequencing coverage. Faceted boxplot of the different 
sequencing regions not covered by WES or WGS. UNAFF is the number of no coverage regions 
(NCR) from Aicardi exome or genome that is also present in unaffected individuals. RMSK is the 
number of NCR from Aicardi exome or genome that is flanking interspersed repeats and low 
complexity DNA sequences (Jurka et al., 2000). ORF is the number of NCR remaining after 
filtering out NCR that overlap with UNAFF and RMSK; and overlaps with human genome build 
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19 canonical transcripts from UCSC. EEIM are NCR that overlap with ORF and candidate gene 
list. EEIM, gene list text-mined with eye, epilepsy, intellectual disability and malformation of 
cortical development; ORF, open reading frame of Hg19 canonical transcripts; WES, whole 
exome sequencing; WGS, whole genome sequencing; XL, X-linked.    
4.2.3 Detecting likely pathogenic SNP and Indels across exomes and genomes.  
From our cohort (n=13), we performed whole exome sequencing (WES) on 12 probands and 
parents (if available) using peripheral blood DNA and the Agilent SureSelect EZ human exome 
version v3 capture kit (Agilent). We also performed WES using DNA extracted from resected 
focal cortical dysplasia (Proband T25217) or choroid plexus papilloma (Proband T25387). WES 
was conducted on the HiSeq2500 (Illumina) platform and the fastq files were processed as 
described in Figure 4.1. There were approximately 58,000 variants (SNP and Indels) called by 
GATK Haplotype Caller 3.2-2 per exome and pre-filtered using a control set of 15 exomes using 
VCFtools ‘contrast’ module (Table 4.4). Four percent of the called variants resided in protein-
coding sequences of which ~83% were present in public datasets above a minimum allele 
frequency threshold for rare variants (Table 2.5 & 4.4). Approximately 30 variants per exome 
were predicted as likely deleterious by CADD20 (=>15) and PolyPhen2 (damaging or possibly 
damaging). Variants were then viewed on the Integrative Genome Viewer (IGV) using the 
probands’ BAM files and parents (if available) to confirm for likely de novo and recessive 
variants. We applied the same variant filtering and candidate prioritising criteria to the paired 
blood-brain exomes from probands T25217 and T25387 (Table 4.1), but no somatic variants that 




All variants that validated in silico (via IGV) were then manually evaluated and prioritised for 
sequencing if: (1) there were more than 5 remaining candidate genes and (2) associated with 
EEIM genes. For individuals with variants in less than 5 genes, all of the variants were 
sequenced. After manual evaluation and Sanger sequencing, only four variants were confirmed as 
truly de novo (Table 4.6 & Figure 4.5). This number of variants that validated is as expected, 












De novo or 
Recessive Validated Variant 
T22842 4304618 1885 310 38 9  
T25217 24642 2397 530 29 2 
De novo SZT2 
(c.9103C>T; NM_015284; p.His3035Tyr) 
T22101 86948 2819 406 66 9 
De novo WNT8B  
(c.209T>C; NM_003393; p.Leu70Pro) 
T2846 64862 2052 476 28 1  
T25752 47480 1671 178 1 0  
43774 69695 2648 207 1 0  
T22352 34009 1894 471 36 14 
De novo HCN1  
(c.1625G>T, NM_021072, p.Cys542Phe) 
T17262 137573 2262 543 41 2 
De novo SLF1 
(c.1409T>C, NM_032290, p.Leu470Ser) 
SQC25F8 49698 6921 873 61 1 
 
T25387 19014 1627 423 31 4 
 
T25820 58509 1645 188 0 0 
 
WES 
Average 57771 2529 419 30 4 
 
 
Table 4.4: Summary of filtered SNP and Indels from Whole Exome Sequencing (WES).   
                                               
18 This table shows the remaining number of variants per proband following each filtering parameter (first row). 
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For the remaining cohort with ambiguous or no variant hits, we proceeded with whole genome 
sequencing (WGS) using the HiSeqXTen (Illumina) platform. Sequence reads were processed 
and variants called by the Australian Genome Research Facility, using Genome analysis toolkit 
(GATK) v3.5-0 best practices guidelines (Van den Auwera et al. 2013). Variants within protein-
coding regions were annotated and analysed equivalently to WES. On average, approximately 5 
million SNP and Indels were called per genome. For our first parse, we analysed variants in 
protein-coding regions that may have been missed from WES. Here, an average of 42,000 exonic 
variants remained per proband and a further 82 fulfilled our disease-variant filtering criteria 
(Table 4.5). From our parent-proband trios (n = 5), after we applied inheritance-based filtering 
and variant prioritisation (Section 2.1.5), only one de novo variant in KMT2B validated via 
Sanger sequencing (Table 4.6 & Figure 4.5). For the remaining two singletons, we compiled a 















De novo or 
Recessive Validated Variant 
FR07959033 4937261 41055 4475 56 41 3 
De novo KMT2B (c.6418C>G;  
NM_014727; p.Pro214Ala) 
FR07959030 5026012 41880 4757 65 43 8 
 
FR07959023 5029242 41939 4965 58 40 5 
 
FR07958909 5071754 42832 5551 91 69 36 
 
FR07958917 5544399 46746 5532 115 102 N/A 
 
FR07958885 5000206 41386 4731 68 42 1 
 
FR07958956 5002490 42007 4502 49 40 N/A 
 
WGS Average 5087338 42549 4930 72 54 11 
 
 
Table 4.5: Summary of SNP and Indels filtered from Whole Genome Sequencing. 19 
                                               






                                                                                                                                                        
 
 
Figure 4.5: Sanger validation of de novo variants. Sequence chromatogram of each proband-
parent trio (top line) with the locus harbouring the variant indicated by grey arrows (parent 
sequence) or pink arrows for confirmed de novo mutation (proband sequence). Two peaks can be 
seen in all of the probands, corresponding to the heterozygous variant (bottom row).  
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 T25217 T22101 T17262 T22352 T22842 
HGNC Symbol SZT2 WNT8B SLF1 HCN1 KMT2B 
Hg19 Position chr1:43912827 chr10:102239737 chr5:94001606 chr5:45267349 chr19:36223868 
cDNA Variant c.9103C>T c.209 T>C c.1409T>C c.1625G>T c.6418C>G 
Transcript ID NM_015284 NM_003393 NM_032290 NM_021072 NM_014727 
AA Change p.His303Tyr p.Leu70Pro p.Leu470Ser p.Cys542Phe p.Pro214Ala 
PolyPhen2 0.997 (D) 0.962 (D) 0.946 (D) 0.994 (D) 0.677 (P) 
CADD 18.2 21.2 21.1 27.2 15.1 
GERP+ 5.43 5.7 5.41 5.82 3.99 
ExAC 0 0 0 0 0 
Zygosity Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous 
Inheritance De novo De novo De novo De novo De novo 
Eye no no no no yes 
Epilepsy yes yes no yes yes 
ID yes no no yes yes 
MCD no no no no yes 
Table 4.6: Summary of potentially pathogenic variants. This table provides locus information 
and predicted pathogenic scores for each de novo variant found in the respective proband. 20  
                                               
20 Abbreviations: AA, amino acid; D, damaging; ExAC, gDNA, genomic DNA; GERP, genome evolutionary rate 
profiling; Het, heterozygous; ID, intellectual disability; MCD, malformation of cortical development; P, probably 
damaging; WGS, whole genome sequencing. 
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4.2.4 Assessing the HCN1 (p.Cys542Phe) variant via Voltage clamp assay. 
Among our implicated genes, only HCN1 and WNT8B had pre-existing in vitro assays that can 
assess the functional consequence of the variants identified in proband T22352 and T22101 
respectively. Our collaborators (Dr Melody Li and Dr Christopher Reid) assessed the biophysical 
properties of the HCN1 (c.1625G>T, NM_021072, p.Cys542Phe) variant by performing a two-
electrode voltage-clamp assay on frog (Xenopus laevis) oocytes expressing the wildtype HCN1 or 
mutant Cys542Phe channel. The mutant Cys542Phe channel displayed a slower activating inward 
current and a left-shift in the voltage-dependent activation relative to the wildtype channel 
(Figure 4.6 A-C). Oocytes expressing the Cys542Phe channel had a; hyperpolarising shift in the 
voltage of half activation (mutant = -73.98 ± 0.23 mV vs. wildtype = -6.16 ± 0.25mV, n = 13-17, 
P = 0.0001), a reduced slope of the activation curves (mutant = 6.35 ± 0.21 vs. wildtype = 7.66 ± 
0.23, n = 13-17, P < 0.05) and significantly slower activation kinetics (Figure 4.6 D-F). The 
biophysical changes of the mutant Cys542Phe channel compared to the wildtype HCN1 channel 




Figure 4.6: Electrophysiological characterisation of HCN1 variant. A: Series of current 
responses from a single oocyte expressing WT (black) or Cys542Phe (red) plasmids. B: Raw 
current-voltage relationship of WT (n=20) and Cys542Phe (n=14) mutant. Raw current was 
measured at the end of pre-pulse. C: Activation curve from average normalised tail current of WT 
(n=17) and Cys542Phe (n=13) mutant with Botlzmann fit. D: Average half activation voltage 
(V1/2). E: Slope factor derived from Boltzmann fit. F: Time to half maximal activation of WT 
(n=20) and Cys542Phe (n=14). Asterisks represent Student’s t-test P-values (* P < 0.05, **** P 
= 0.0001). Error bars represent standard deviations across replicate experiments 
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4.2.5 Assessing the WNT8B (p.Leu70Pro) variant via TOPFlash assay.  
We assessed the effect of the WNT8B (c.209T>C; p.Leu70Pro; NM_003393) variant on β-catenin 
mediated WNT signalling using the TOPFlash assay in human embryonic kidney 293T (HEK 
293T) cells (Appendix 7.2.2). In HEK 293T cells transfected with either the wildtype WNT8B or 
mutant Leu70Pro ligand, the relative firefly luciferase activity was 4.13 and 2.04-fold higher (P < 
0.001), respectively, than the pcDNA 3.1 empty vector control (Figure 4.7A). The gene reporter 
activity was not dose-dependent as increasing plasmid concentrations did not significantly alter 
the luciferase activity (Figure 4.7B). In HEK 293T cells co-expressing the wildtype and 
Leu70Pro mutant ligand, the gene reporter activity was 2.17-fold higher than the control vector 
(Figure 4.7A), which was comparable to cells expressing the Leu70Pro ligand alone (Figure 
4.7C). The luciferase activity was not a result of altered protein expression as wildtype, mutant 
and coexpressed plasmids were stably and equivalently expressed in HEK 293T cells (Figure 
4.7D). The luciferase activity, resulting from the independent and co-expression of both the 
wildtype and mutant ligand, suggests that the Leu70Pro ligand has a dominant negative effect on 




B    C  
D     E  
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Figure 4.7: WNT8B Activation of Canonical Wnt Signalling. A: Schematic diagram showing 
the plasmid maps of the Wnt ligands (left) and reporter constructs (right). B: Pilot study showing 
the fold activation of the luciferase activity from HEK 293T cells expressing the TOPFlash or 
FOPFlash vector. C: Gene reporter activity of the WNT8B wildtype or mutant L70P expressed in 
HEK 293T cells across a concentration gradient. D: Independent and co-transfected luciferase 
activity of the wildtype and mutant WNT8B ligand in HEK 293T cells across three replicate 
experiments. E: Immunoblot showing stable expression of plasmids across different 
concentrations. Proteins were extracted from cell lysates from experiment (D) of which 20μg 
were used for western blotting. β-tubulin antibody (Abcam, Cat # ab21058) was used as loading 
control, while anti-V5 antibody (Bethyl Lab, Cat # A190-120P) was used to probe for WNT8B-
tagged (C-terminal V5) protein. No other bands were observed on the blot other than those 
shown. Asterisks represent Student’s t-test P-values (* P < 0.05, ** P < 0.01, *** P < 0.001). 




4.2.6 Morpholino-mediated knockdown of Aicardi candidate genes in zebrafish embryos. 
For the remaining genes that did not have established molecular or biochemical assays and are 
yet to be implicated in both eye and brain development, we used morpholino knockdown in 
zebrafish (Danio rerio) embryos to screen for phenotypes that were reminiscent of AIC. We 
included tead1, which is the only other previously identified gene implicated AIC that is 
conserved in zebrafish. We designed a study in which the translation-blocking morpholino 
injections and data analysis were carried out under blinded conditions and morphant 
classification counts were verified by three independent researchers. More than 90% of 
uninjected and scrambled morpholino control group displayed normal embryonic development 
with or without minor body abnormalities such as bent tail (Figure 4.8).  
 
In contrast, our experimental morphants displayed a spectrum of developmental abnormalities 
including: lack of eye pigmentation, body curvatures, pericardial oedema, tail defects and head 
malformations (Figure 4.8B). The most consistent phenotype among the slf1, tead1 and wnt8b 
morphants was the lack of eye pigmentation, which was patchy in appearance and often unilateral 
(Figure 4.8A). A lack of eye pigmentation was also observed in szt2 morphants, however as 72 
hours post fertilization (hpf) szt2 morphants often resembled 48 hpf morphants, this may be 
attributed to developmental delay. The eye phenotype is similar to the absence of mature 
melanosomes observed from 48hpf slc24a5 and tyrp1a/b morphants (Lamason et al., 2005, 
Takamiya et al., 2016). The only exception to the experimental group were hcn1 morphants, 
whom displayed normal phenotype similar to the uninjected and control group (results not 
shown). There are known limitations to disease modelling in zebrafish (Kok et al., 2015) and the 
morpholino knockdown approach models a loss of function whereas our de novo variants are 
likely to be dominant negative. Nonetheless, we showed a unifying morphant phenotype of AIC-




Figure 4.8: Phenotype analysis of morpholino mediated knockdown in zebrafish embryos. 
A: Ocular morphology of zebrafish embryos at 72hpf either uninjected or injected with a control 
morpholino or gene-targeted morpholino. B: Zebrafish embryos were scored according to eye 
classifications by Miesfeld et al. (2015). Class I: normal phenotype; Class II: normal eye 
pigmentation with mild body defects; Class III: reduced eye pigmentation with normal to mild 
body defects; Class IV; reduced eye pigmentation and severe body defects. C: Observed 
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morphant phenotypes after blinded injections of 240 zebrafish embryos per group. The number of 
viable embryos remaining after 72 hpf are denoted by (n). The amount of morpholino injected per 
group is indicated by (+). 
 
4.3 Discussion 
4.3.1 Lack of X-linked pathogenic variants 
We identified likely pathogenic variants in different autosomal genes from five unrelated 
individuals. There are possible X-linked causes that were not discovered from other and our 
genetic studies due to: (1) the paired-end sequencing (PES) approach, (2) 40X sequencing 
coverage, (3) peripheral blood as DNA source and (4) interpretation of variants in non-coding 
sequences. PES has limited resolution for variants in repetitive DNA sequences, regions with 
high or low GC bias and non-random DNA fragmentation bias (Treangen et al. 2011; Aird et al. 
2011). Terminal, tandem and interspersed repeats have yet to be investigated as a cause of AIC. 
Our 38X average sequencing coverage was also inadequate for detecting somatic variants with 
low levels of mosaicism (less than 5% of allelic fraction); which could be disguised as false 
positives. Furthermore, a majority of our sequencing was based on peripheral blood DNA, thus 
we were unable to comprehensively screen for brain-specific variants. Finally, due to the lack of 
paired WGS and RNA sequencing data, we were unable to prioritise and interpret the 
significance of some non-coding variants; especially in regions lacking functional annotations. 
For the remaining unresolved individuals in our cohort, an X-linked cause may still be possible, 




4.3.2 Variants identified in known neurodevelopmental disorder genes 
Six de novo mutations in HCN1, encoding the hyperpolarization-activated cyclic nucleotide-gated 
channel 1, that cause early onset epileptic encephalopathy (EIEE; MIM 615871) were described 
previously by Nava et al. (2014). Proband T22352, in whom we identified the NM_021072.3 
(HCN1);c1625G>T; p.Cys542Phe variant, has partial agenesis of the corpus callosum, absence of 
the anterior body, genu and rostrum, hypoplasia of splenium, Lennox Gastaut syndrome and 
bilateral paroxysmal fast activity. Her MRI brain findings and EEG abnormalities are not present 
in other individuals with HCN1 variants. Nonetheless, there were also similar clinical features in 
proband T22352 to other individuals reported such as autism spectrum disorder and seizures 
beginning during the first year of life.  
 
Functional differences between HCN1 p.Cys542Phe and previously reported mutations are likely 
due to the location of the affected amino acid. Mutations reported by Nava et al. were located in 
the transmembrane domain or the intracellular domain closer to the N-terminus (Nava et al., 
2014).  Patch clamp recordings in CHO-K1 cells revealed a majority of these human HCN1 
mutations lead to a gain of function or dominant negative effects. Meanwhile, the HCN1 
p.Cys542Phe we identified is located in the cyclic nucleotide binding domain, which is 
responsible for the direct regulation of the channel function (Figure 4.9) (Wainger et al., 2001). 
We conducted voltage clamp recordings in Xenopus oocytes to measure the gating function of 
the HCN1 p.Cys542Phe mutant channel. We found that the oocytes expressing HCN1 
p.Cys542Phe left-shifted the voltage dependence of activation resulting in a loss of function 
(Figure 4.5). In light of our findings and other published cases, the diagnosis for proband T22352 
was revised from Aicardi-like syndrome to a HCN1-EIEE.  
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Figure 4.9: HCN1 variants in affected individuals with epileptic encephalopathy. Lollipop 
plot showing published HCN1 variants from Nava et al. (2014) in red and the Cys542Phe variant 
from Proband T22352 in yellow.  
 
Mutations in SZT2, encoding seizure threshold 2, are associated with autosomal recessive EIEE 
and non-syndromic intellectual disability (Nakamura et al., 2018, Tsuchida et al., 2018, 
Venkatesan et al., 2016, Falcone et al., 2013, Basel-Vanagaite et al., 2013) (Figure 4.10). We 
discovered a de novo NM_015284 (SZT2); c.9103C>T; p.His3035Tyr variant in proband T25217 
who displayed: focal cortical dysplasia, polymicrogyria, subcortical heterotopia, modified 
hypsarrhythmia, developmental delay, ID and hypotonia. The brain MRI findings and 
neurological anomalies present in proband T25217 share some overlap with the phenotypes 
described in patients with SZT2. Although the disease mechanism underlying pathologies 
associated with mutations in SZT2 has yet to be elucidated, it was recently discovered that SZT2 
has a role in GATOR-dependent nutrient sensing and MTORC1 regulation (Peng et al., 2017). 
SZT2 is part of the KICSTOR complex, which is a negative regulator of MTORC1 signalling. 
Coincidentally, the knockout of SZT2 in mice had led to an increase in MTORC1 signalling in 
tissues such as neurons in the brain (Wolfson et al., 2017). Hyperactivity of MTORC1 signalling 
has many physiological impacts including: neuronal death, axon regeneration, abnormal cell 
differentiation and morphogenesis (Bockaert and Marin, 2015). These physiological changes are 
involved in a number of MTORC1-associated brain pathologies listed in Table 4.5.   
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The SZT2 protein is highly conserved across multiple species and has two predicted functional 
domains: superoxide dismutase and peroxisomal targeting signal (Toutzaris et al., 2010). It is 
ubiquitously expressed with its highest expression in the CNS (Frankel et al., 2009 & Toutzaris et 
al., 2010). From an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in mice, a majority of Szt2 
homozygotes died embryonically (Frankel et al., 2009). Those that survived were more 
susceptible to induced seizures and potentially epileptogenic compared to wildtype mice. Single 
Szt2 heterozygotes had less seizures compared to compound Szt2 heterozygotes, but more 
compared to wildtype mice; which supports allelism and dominant effects respectively (Frankel 
et al., 2009). The clinical spectrum associated with SZT2 mutations are phenotypically 
heterogeneous, but mostly bi-alleic in cases reported so far. Given that a second variant was not 
identified in SZT2 from patient T25217, the likely pathogenicity of the p.His3035Tyr variant 
remains unknown until further functional validation. The latter may involve measuring the effect 
of the p.His3035Tyr variants on MTORC1 signalling.   
 
 
Figure 4.10: SZT2 variants in affected individuals with various neurodevelopmental 
disorders. Lollipop plot showing the biallelic SZT2 variants reported thus far (red) and the 
His3035Tyr variant from proband T25217 (yellow). Image was adapted from Figure 1 of the 




Brain Disease21  Mutated Gene  Phenotype 
Tuberous sclerosis TSC ● SEGA cells 
● Benign tumours 
● Epilepsies 
● Intellectual disability 
● ASD 
Polyhydramnios-megalencephaly 
symptomatic epilepsy syndrome 
STRADα ● Cranio-facial dysmorphism 
● Large brain 
● Intractable epilepsy 
Familial focal epilepsies with 
variable foci 
DEPDC5 ● Intractable epilepsy 
Hemimegaloencephaly AKT3, PI3K and MTOR ● Cerebral asymmetry, 
laminar cortical 
abnormalities 
● Intractable epilepsy 
Ganglioglioma BRAF ● Giant atypical ganglion 
cells 
● Intractable epilepsy 
Cowden syndrome PTEN ● Multiple haematomas 
● Uncontrolled neurogenesis 
● Cortical dysplasia 
Lhermitte-Duclos disease PTEN ● Dysplastic gangliocytoma 
of the cerebellum 
Lafora disease EPM2A ● Accumulation of 
polyglucosan inclusions 
● Myoclonus epilepsy 
Brain tumours PTEN and TSC  ● Glial cell proliferation 
ASD, Down syndrome, 
neurofibromatosis 
TSC, NF1 ● Cognitive deficits 
● Decreased autophagy 
 
Table 4.5: Mutations linked to hyperactivation of MTOR signalling in brain pathologies.   
                                               
21 Table was modified from Table 2 of the Bockaert and Marin (2015) study. 
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From patient T22842, a de novo (c.6418C>G; p.Pro214Ala; NM_014727) variant was identified 
in KMT2B, encoding the lysine specific methyltransferase 2B (Table 4.5 & Figure 4.11) (Zech 
et al., 2016). In a cohort of 31 patients with dystonia, four missense variants were identified in 
KMT2B in four unrelated probands; three were de novo and one was inherited (Zech et al., 2016). 
In addition to generalized dystonia, other phenotypes observed from these four probands 
included: microcephaly, short stature, delayed speech, normal to mild cognitive impairment. 
None of the four probands displayed neurological abnormalities or brain MRI findings. However, 
the phenotype spectrum of KMT2B-related disorders was later expanded by Meyer et al. (2017) 
to include for developmental delay, intellectual disability, dysmorphic features and other isolated 
systemic manifestations. These clinical features were based on 17 unrelated patients with 
previously unreported missense and nonsense variants in KMT2B. Some of the clinical features in 
patient T22842 were not commonly observed in patients with KMT2B-related disorders, such as: 
chorioretinal lacunae (Figure 1.1), infantile spasm, tonic-clonic seizures and choroid plexus 
papilloma (Table 4.2).   
 
From some of the unrelated probands with nonsense variants in KMT2B, there were reduced 
expression of KMT2B in patient fibroblasts, which supports haploinsufficiency as a disease 
mechanism (Zech et al., 2016, Meyer et al., 2017). However, for the remaining intragenic 
missense variants in KMT2B, including our Pro214Ala variant, the molecular mechanism 
underlying the pathogenesis of KMT2B-related disorders remains unknown. In the Meyer et al. 
(2017) study, there were no differences in histone H3K4 methylation between patient and control 
cell lines. However, in three unrelated probands, there were reduced expression of THAP1 and 
TOR1A, which suggests some KMT2B variants may alter the expression profiles of other known 
dystonia genes. Given the lack of candidate genes, it is currently unknown whether our 
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Pro214Ala variant can alter the expression profiles of genes involved in AIC or AIC-related 
disorders.       
 
Figure 4.11: KMT2B variants in affected individuals with dystonia. Lollipop plot showing 
published KMT2B variants from Meyer et al. (2017) and Zech et al. (2016) in red and the 
Pro214Ala variant from proband T22842 (yellow).   
 
4.3.3 Variants identified in novel disease genes 
 
In WNT8B, encoding the wingless-type MMTV integration site family member 8B, we 
discovered a de novo (c.209T>C; p.Leu70Pro; NM_003393) variant in patient T22101 (Table 4.1 
& 4.2). There are 19 Wnt ligands that can stimulate Wnt signalling pathways including: the 
canonical β-catenin dependent pathway, the planar cell polarity pathway and the Wnt/Ca2+ 
pathway (Komiya and Habas, 2008).  The Wnt signalling pathways play a major role in 
embryonic development. Disruptions to the Wnt signalling can result in lethal and severe 
consequences such as cancers, skeletal defects and congenital disorders (Logan and Nusse, 2004). 
To date, no human pathologies have been associated with WNT8B mutations (Figure 4.12).  
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The expression of WNT8B appears to be restricted to the developing forebrain, particularly the 
hippocampus and hypothalamus (Lako et al., 1998). Knockout mouse studies in other Wnt genes 
show phenotypes ranging from embryonic lethality to complete absence of brain structures (van 
Amerogen and Berns, 2006). The Wnt8b knockout mouse showed no gross morphological 
differences from the wildtype mouse; but did alter the expression levels of other Wnt genes 
present in the developing forebrain (Fotaki et al., 2010). There is an overlap between the 
expression domain of Wnt8b and the other Wnt genes, which may provide compensatory 
functions; thus diminishing the gross effects of Wnt8b deficiency (Fischer et al., 2007). 
Morpholino knockdown of wnt8b in the zebrafish showed commissural defects in structures of 
the zebrafish brain akin to the corpus callosum and demonstrate the role of Wnt8b in regulating 
axon guidance (Hofmeister and Key, 2013). In zebrafish and mice, Wnt8b has been shown to be a 
negative regulator of eye development, particularly the specification of retinal progenitor cells 
(Cavodeassi et al. 2005 & Liu et al. 2010). Although mutations in WNT8B have yet to be 
implicated in epileptic encephalopathy, its role in eye and forebrain development makes it a 
potential candidate gene for AIC. 
 
 
Figure 4.12: WNT8B and SLF1 variants in human disorders. Lollipop plot showing the 
WNT8B (top) and SLF1 (bottom) variants reported in Lemay et al. (2015) and Sifrim et al. (2016) 
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respectively (red). For each respective gene, the variants reported in patient T17262 and T22101 
are shown in yellow.  
 
In SLF1, encoding the SMC5-SMC6 complex localization factor protein 1, we found a 
(c.1409T>C, p.Leu470Ser; NM_032290) variant in patient T17262 (Table 4.1 & 4.2). SLF1 has 
primarily been investigated for its potential role in cancer (Liu et al., 2012 & Adams et al., 2005). 
The SLF1 gene contains a breast cancer gene 1 carboxyl-terminal (BRCT) domain. There are 23 
human genes with a BRCT domain and the knockout of these genes have resulted in embryonic 
lethality, tumor formation, infertility and growth abnormalities (Liu et al., 2012, Adams et al., 
2005, Sharan et al., 1997).   However, the Slf1 knockout mouse showed no histopathological 
differences from the wildtype mouse (Adams et al., 2005). From a yeast two hybrid screen, SLF1 
was shown to interact and co-localise with RAD18, an E3 ligase that is involved in DNA damage 
signalling pathways. The Slf1 knockout mouse did not display any DNA repair impairment, 
genomic instability or DNA growth defects. In a corresponding study, SLF1 and RAD18 
interaction was revealed to be important in UV-induced DNA damage repair (Liu et al., 2012). 
However, SLF1 alone and its role in tumorigenesis has yet to be determined.  The SLF1 
p.Leu470Ser variant identified in proband T17262 lies outside of the BRCT domain, thus its 
functional significance has yet to be determined (Figure 4.12). 
4.3.4 Identifying additional carriers of variants in putative Aicardi genes  
To provide additional evidence to support our implicated AIC genes as true disease drivers rather 
than incidental findings, we sought additional carriers in these genes using: biomedical literature 
(Pubmed), disease cohorts (Epi4K and DDD) and genotype-to-phenotype matching platforms 
(Denovo-db, Geno2mp and GeneMatcher) (Table 4.6). Variants in HCN1 and SZT2 has been 
reported in individuals with early infantile epileptic encephalopathy (MIM 615871 & MIM 
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614576). Meanwhile KMT2B variants have been implicated in childhood onset dystonia (MIM 
617284). While the inheritance mode (de novo) of published HCN1 and KMT2B variants overlap 
with probands T22352 and T22842 respectively, the congenital disorders described in the 
reported affected individuals share minimal to no phenotypic overlap with our cohort. 
Conversely, there are some overlap in the neurodevelopmental phenotype of reported individuals 
with SZT2 variants and proband T25217, but a majority of reported cases are autosomal recessive 
versus de novo in ours. Variants in SLF1 and WNT8B have only been identified in two different 
individuals, who both display different clinical characteristics to proband T17262 and T22101 
respectively. Finding a second variant in our implicated Aicardi genes from disease cohorts and 
online patient archives was also unsuccessful; either the inheritance or phenotype was unmatched 
with individuals in our cohort.   
4.3.4 Protein subcellular localisation and interaction of candidate genes 
From published immunohistochemistry (IHC) data, we observed that 4/5 protein products of the 
candidate AIC genes (excluding WNT8B) were localized to the nucleus or nucleoplasm (Figure 
4.13) (Uhlen et al. 2010). Despite similar subcellular localisation, none of the implicated genes 
have been predicted to interact on a genetic or protein level (Szklarczyk & Jensen 2015; Chatr-
Aryamontri 2016). This may be a reflection of the diverse molecular function and biological 
processes of the genes harbouring the DNV (Table 4.7).  
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HCN1 KMT2B SLF1 SZT2 WNT8B 
EpiK Consortium et al., 
2013 EE WES 264 pros - - - - - 
Yang et al., 2013 Mendelian Disorders WES 250 pros  - - - - 
Falcone et al,. 2013 SZT2 WES 3 sibs - - - 1 - 
Basel-Vanagaite et al., 
2013 SZT2 WES 2 pros - - - 3 - 
EuroEpinomics et al., 
2014 EE WES 356 trios - 1 - - - 
Wright et al., 2015 Developmental Delay 
Array & 
WES 1133 pros  - - - - 
Schrauwen et al., 2015 Aicardi Syndrome 
WES & 
WGS 10 trios - - - - - 
Lemay et al., 2015 Neural Tube Defects WES 43 trios  - 1 - - 
Sifrim et al., 2016 Congenital Heart Defects WES 1891 pros - - - - 1 
Lelieveld et al., 2016 Intellectual Disability WES 2104 trios - 1 - - - 
Venkatesan et al., 2016 SZT2 WES 1 pros - - - 1 - 
Zech et al., 2016 KMT2B WES 30 pros - 4 - - - 
Lund et al., 2016 Aicardi Syndrome XES 10 trios - - - - - 
DDD et al., 2017 Developmental Delay WES 4293 trios - - - 2  
Posey et al., 2017 Multilocus Diseases WES 7374 pros - - - - - 
Meyer et al., 2017 KMT2B 
Array, WES 
& WGS 27 pros - 27 - - - 
Wong et al., 2017 Aicardi Syndrome WES 38 pros - - - - - 
Tsuchida et al., 2018 EE WES 3 pros - -  6 - 
Table 4.6: Additional carriers of variants in putative Aicardi genes reported in affected 
individuals. 22   
                                               
22 EE, epileptic encephalopathy; pros, probands; sibs, siblings; trios, parent-proband trios; WES, whole exome 




Figure 4.13: Subcellular localisation of Implicated Aicardi genes. This figure shows the 
localisation of the target genes (bold) derived from database annotations. The confidence of each 
association is signified by stars, where five stars is the highest confidence and one star is the 
lowest. Images were obtained from the Jensen Lab ‘Compartments’ site 
(https://compartments.jensenlab.org/Search).   
 137 
 
A. GO - Molecular Function HCN1 KMT2B SLF1 SZT2 TEAD1 WNT8B 
cAMP binding yes      
core promoter proximal region DNA binding     yes  
DNA binding  yes   yes  
frizzled binding      yes 
histone-lysine N-methyltransferase activity  yes     
histone methyltransferase activity (H3-K4 specific)  yes     
identical protein binding yes      
potassium channel activity yes      
protein complex binding   yes    
protein heterodimerisation activity     yes  
receptor ligand activity      yes 
RNA polymerase II transcription factor binding     yes  
sequence-specific DNA binding     yes  
transcription coactivator binding     yes  
transcription factor activity, RNA polymerase II core promoter 
proximal region     yes  
transcription factor activity, sequence-specific DNA binding  yes   yes  
transcription factor activity, transcription factor recruiting     yes  
ubiquitin protein ligase binding   yes    
voltage-gated cation channel activity yes      
voltage-gated potassium channel activity yes      
voltage-gated sodium channel activity yes      
zinc ion binding  yes     
 
B. GO - Molecular Function HCN1 KMT2B SLF1 SZT2 TEAD1 WNT8B 
apical protein localisation yes      
beta-catenin destruction complex disassembly      yes 
canonical Wnt signalling pathway      yes 
cell fate commitment      yes 
cellular response to amino acid starvation    yes   
cellular response to cAMP yes      
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cellular response to DNA damage stimulus   yes    
cellular response to glucose starvation    yes   
cellular response to retinoic acid      yes 
central nervous system development    yes   
chromatin-mediated maintenance of transcription  yes     
corpus callosum morphogenesis    yes   
determination of dorsal identity      yes 
DNA repair   yes    
embryonic organ development     yes  
gastrulation      yes 
gene silencing  yes     
hippo signalling     yes  
histone H3-K4 methylation  yes     
histone H3-K4 trimethylation  yes     
memory  yes     
negative regulation of TORC1 signalling    yes   
nervous system development      yes 
neuron differentiation      yes 
oocyte differentiation  yes     
ovarian follicle development  yes     
ovulation  yes     
pigmentation    yes   
positive regulation of double strand break repair   yes    
positive regulation of maintenance of mitotic sister chromatid 
cohesion   yes    
positive regulation of pri-miRNA transcription from RNA 
polymerase II promoter     yes  
positive regulation of protein complex assembly   yes    
positive regulation of transcription, DNA-templated     yes  
post embryonic development    yes   
potassium ion transmembrane transport yes      
protein complex assembly     yes  
protein homotetramerisation yes      
protein localisation to lysosome    yes   
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protein localisation to site of double-strand break   yes    
regulation of histone H3-K4 methylation  yes     
regulation of megakaryocyte differentiation  yes     
regulation of membrane potential yes      
regulation of superoxide dismutase activity yes   yes   
response to estradiol      yes 
response to retinoic acid      yes 
retinal cone cell development yes      
signal transduction      yes 
sodium ion transmembrane transport yes      
transcription, DNA-templated  yes     
transcription, initiation from RNA polymerase II promoter     yes  
Wnt signalling pathway      yes 
Table 4.7: Gene ontology for implicated Aicardi genes. This table summarises the predicted 
molecular function (A) and biological role (B) for each gene of interest 
(http://www.geneontology.org/).  
 
4.3.5 Early developmental expression of candidate genes 
Next, we explored whether the implicated genes converge on developmental processes (temporal 
or spatial) that can contribute to AIC phenotypes. This was observed for  nine recognised autism 
spectrum disorder genes, harbouring DNM identified from WES and WGS studies that 
converged in the same time point, brain region (mid-foetal layer) and neuronal cell type (cortical 
projection neurons) Willsey et al. (2013). From human RNA-Seq data across multiple somatic 
tissues, the expression of SLF1 and WNT8B are sparse; while KMT2B, SZT2 and TEAD1 are 
ubiquitously expressed (Figure 4.14). In the developing human brain, there is restricted and low 
expression of WNT8B across different regions; while the remaining genes are consistently 
expressed, but at different magnitudes depending on the tissue type. From the current publicly 
available transcriptome data, our implicated AIC genes do not appear to converge at a particular 
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region at whole brain resolution. However, given the heterogeneity and complexity of brain 
development, our target genes may need to be investigated at single-cell resolution across 
different tissues and stages to identify potential molecular signatures.  
 
Only some of the target genes have been studied during similar embryonic stages, thus we turned 
to murine embryonic data to scan for overlapping developmental profiles. We observed that 
Kmt2b and Tead1 are ubiquitously expressed throughout murine embryonic development; while 
Slf1, Szt2 and Wnt8b expression is restricted to the brain (Smith et al., 2007). At embryonic day 
14.5, the Slf1 and Wnt8b mouse display similar expression in the developing forebrain (Figure 
4.15 & 4.16) (Diez-Roux et al., 2011, Visel et al., 2004). Both Wnt8b and Tead1 are expressed 
during early eye development, while Kmt2b is expressed later during retinal development (Ang et 
al., 2004, Blackshaw et al., 2004, Visel et al., 2004). Although the role and expression of Slf1 and 
Szt2 during eye development has yet to be documented, our zebrafish data indicates a potential 
role of slf1 in early eye development (Figure 4.7). We observed that all genes except for Szt2 are 
expressed in the murine brain during 10.5 to 15.5 days of embryonic development (ED) and 
approximates to the 4th to 7th week of human gestation. This gestational stage coincides with the 
predicted emergence of eye, brain and skeletal abnormalities observed in AIC; and the 




Figure 4.14: RNA-Seq of target Aicardi genes from published datasets. This figure shows the 
expression level of each target gene (left side, blue writing) across different tissue types. A: The 
expression level of coding RNA across different prenatal human brain regions (source: Human 
Developmental Biology Resource). B: The expression level of the target genes across individual 
and mixtures of 16 human tissues (source: Illumina Body Map). C: The strand-specific 
expression of the target genes across 16 different human tissue sources: Michael Snyder’s lab for 




Figure 4.15: RNA in situ hybridisation in mouse embryo at day 14.5 post conception.  This 
figure shows the RNA localisation of Kmt2b, Slf1, Tead1 and Wnt8b across whole mount in situ 
hybridisation of E14.5 mouse embryos. The images were derived from Visel et al. (2004) and 
Diez-Rouz et al. (2011).   
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Figure 4.16: Expression of implicated Aicardi genes across different forebrain cell types. 
This figure shows expression of target genes based on data obtained from Affymetrix GeneChip 
Mouse Genome 430 2.0 Array (NCBI Geo DataSets platform ID: GPL1261). Each dot graph 
represents a different target gene and its expression across four different forebrain cell types. 
Among the six implicated AIC genes, Wnt8b and Slf1 have similar gene expression profiles in 
the forebrain. Images from NeuroExpresso (https://pavlab.shinyapps.io/neuroexpresso2/).   
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4.3.6 Concluding Remarks 
Our study provided a comprehensive review of existing literature and new genetic findings to 
shed light on the clinical and genetic heterogeneity of AIC, which for more than 70 years was 
perceived as a monogenic and likely X-linked disorder. We highlight the importance of utilising 
genetic studies to guide differential diagnosis of syndromes like AIC that involve multiple 
complex traits. From our cohort, we identified five likely pathogenic variants in three known 
disease genes (HCN1, KMT2B and SZT2) and two potentially novel developmental genes (SLF1 
and WNT8B). For five of these families, we provided some insight into the potential contributing 
genetic factors, which were not identified from previous clinical genetic testing. Meanwhile for 
the remaining unresolved families, we may have missed variants that were: in less annotated 
regions (non-coding and repeated sequences), transmitted in a non-Mendelian manner (somatic 
and epigenetic) or undetectable by paired-end sequencing (complex SV, short tandem repeat 
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CHAPTER V: Contribution of copy number and submicroscopic structural 
variants to Aicardi Syndrome. 
5.1 Introduction 
Whole genome sequencing (WGS) has recently emerged as an alternative to array-based 
platforms, for the detection of structural variants (SV) including: CNV, balanced rearrangements 
and mobile element insertions (MEI). Paired-end sequencing (PES) has the ability to detect 5000 
to 10,000 SV per human genome using the following methods (Figure 5.1): read-depth, split-
read and sequence assembly (Chiang et al., 2017, Alkan et al., 2011). The advantage of using 
short PES over older SV discovery methods is the ability to detect multiple SV subtypes across 
different range of size alterations (Figure 5.2) and finding nucleotide resolution breakpoints 
(Baker et al., 2012, Alkan et al., 2011). The discovery and genotyping of SV in 2504 human 
genomes, using WGS, revealed that a median of 18.4 megabases of SV are present per diploid 
human genome (Sudmant et al., 2015). There are molecular models that can explain the 
formation of SV (Figure 5.3), however the challenge remains in interpreting the functional and 
phenotypic consequences of these SV (Weischenfeldt et al., 2013). 
 
The contribution of SV to human diseases can be monogenic and display positional effect, or 
multigenic thus relaying gene dosage effects (Weischenfeldt et al., 2013). Large cohort studies 
have facilitated the discovery of common SV associated with complex traits and autoimmune 
diseases; as well as rare SV underlying neurodevelopmental and neurocognitive disorders 
(Girirajan et al., 2011, Conrad et al., 2010, Pinto et al., 2010, Fanciulli et al., 2007). In a cohort 
study comprised of more than 15,000 children with intellectual disability and other congenital 
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abnormalities, 14.2% of cases were predicted to have a likely causative CNV that was larger than 
400kb (Cooper et al., 2011). In other independent studies, it is estimated that rare CNV contribute 
to 3-5% of epileptic encephalopathies and an overall 5-10% of all childhood epilepsies (Mefford 
et al., 2011). More recently, using the WGS platform, putative pathogenic SV were identified in 
cohorts that share overlapping neurodevelopmental and retinal phenotypes with Aicardi 
Syndrome (AIC) (Carss et al., 2017, Monlong et al., 2018, Gilissen et al., 2014).  
 
 
Figure 5.1 Mapping signatures of structural variants. This diagram was extracted from Alkan 
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et al. (2011) to illustrate the strategies used to identify different classes of structural variants by 
mapping sequence reads to a reference genome. 
 
 
Figure 5.2: Variant size distribution and discovery methods. This graph was extracted from 
Alkan et al. (2011) to show the differences in variant length detected by four different 
technologies: BAC arrays, fosmid mapping, array platform and next-generation sequencing.  
 
The genetic causes underlying Aicardi Syndrome have recently been investigated at the single 
nucleotide level (Lund et al., 2016, Schrauwen et al., 2015). However, earlier studies were 
focused on finding chromosomal aberrations and submicroscopic abnormalities; using 
cytogenetic techniques followed by array-based tools that were available at the time. The 
resolution of these techniques enabled early researchers to detect variants at sizes ranging from 
hundreds of kilobases to whole chromosomes. Thus, the earliest finding in Aicardi patients were 
large interchromosomal translocations, deletions and aneuploidies (Ropers et al. 1982, 
Donnenfeld et al. 1990) (Figure 5.4). Although these findings occurred in patients whose AIC 
diagnosis is disputable, it instigated two decades of further investigations into the X chromosome 
in hopes of finding an X-linked candidate locus (Figure 5.5).  
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Figure 5.3: Molecular mechanisms underlying structural variant formation. This diagram 
was extracted from Weischenfeldt et al. (2013) to represent the different mechanisms that lead to 




Figure 5.4: Schematic overview of genetic findings. This diagram shows a timeline of the 
chromosomal abnormalities and aneuploidies reported in Aicardi patients thus far. The 
chromosomal location and variant type is positioned on top of a reference to the original study. 
 
In 2007, Yilmaz et al. conducted an array based comparative genomic hybridisation (array-CGH) 
study on a cohort of 18 Aicardi patients; which had a resolution of 82kb and superseded previous 
X-linked studies. Using BAC clones with a full coverage of the X chromosome, they screened for 
microdeletions and microduplications, however no deleterious CNV were detected. In a 
subsequent study, Wang et al. (2009) performed genome-wide screening using a higher 
resolution array-CGH, which detected 110 SV from a cohort of 38 Aicardi girls. 105 of these SV 
were either polymorphic or observed in unrelated healthy individuals; four were inherited from 
an unaffected parent and one de novo X-linked CNV was in a region absent of genes. Although 
the 244k DNA 60-mer array had the spatial resolution of approximately 9kb, the smallest 
detected CNV was approximately 30Kb; thus CNV smaller than the resolution may potentially be 
missed or masked by a larger CNV. Although no detectable SV were found in either cohort 
studies, this does not exclude the potential role of SV to AIC.   
 
Figure 5.5: Schematic overview of Genetic Investigations. This diagram shows a timeline of 
the genetic studies conducted on Aicardi patients or cohorts. The molecular technique used for 
variant discovery is positioned on top of a reference to the original study. 
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In order to complement our SNP and Indels analysis (Chapter 4), we designed an SV discovery 
pipeline that incorporated multiple SV calling algorithms (Figure 5.6). These callers differ in the 
strategy used to detect different SV signatures (Chapter 2) and by combining them, it allowed us 
to increase the sensitivity and specificity for different SV types from different genomic regions 
(non-coding and coding) and of different lengths; overall improving breakpoint precision (Tattini 
et al., 2015). In contrast to the previous array-based CNV studies, we used whole genomes to 
screen for potential X-linked and autosomal SV at a resolution of 50 base pairs to tens of 
kilobases (Chiang et al., 2017). This enabled us to search for smaller SV (50bp to 5kb) and 
submicroscopic SV (10kb to 1mb) that may have been missed by previous methods. 
 
 
Figure 5.6: Schematic overview of SV detection and filtering pipeline. This flowchart was 
modified from the SNP and Indels discovery pipeline in Chapter 5 to show the changes made for 




5.2.1 SV Discovery Pipeline versus NA12878 genome 
Our structural variant (SV) pipeline was tested on the GIAB pilot genome (NA12878) that was 
sequenced on the Illumina HiSeq 2500 v4 platform (Zook et al., 2016). Among the SV callers we 
selected for our pipeline, Delly called the greatest number of variants (122890) while Manta 
called the least (9820). In a comparison of the different types of SV, single-anchored breakpoints 
(BND) represented more than half of the SV called across all SV callers; followed by deletions, 
duplications, inversions and then insertions (Figure 5.7). BND often represent a single 
breakpoint of an insertion or translocation; the paired-end is either unmapped or located on 
another chromosome. The low number of insertions called were as expected due to the short-read 
length (2x125bp) of the WGS platform; the median length (bp) for insertions with resolved break 
ends were 82 and 24, called by Manta and Delly respectively. In contrast, all SV callers were 




5.7: NA12878 structural variants with predicted breakpoints detected by different calling 
algorithms. The bar plot on the left shows the total number of SV types detected across different 
SV callers. The box plot on the right shows the log10 difference in SV length (base pair) for each 
SV type across different SV callers. Abbreviations: BND, single break ends; DEL, deletion; 
DUP, duplication; INS, insertion; INV, inversion; SV, structural variant. 
 
The precision and sensitivity of each SV caller was assessed by comparing each call set with the 
truth sets from the 1000 Genomes Project phase 3 (1000G) and SVClassify study (Parikh et al., 
2016). For the 1000 Genomes Project, different SV types were extracted using a custom script. 
Overlaps between the call sets and truth sets were obtained via the ‘BEDtools intersect’ module. 
For each call set and truth set comparison, three values were calculated: true positive, false 
positive and false negative (Figure 5.8). Based on these values, the precision and sensitivity of 
each SV caller in detecting each SV subtype was calculated as shown in Figure 5.9.  
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Delly had greater sensitivity but less precision at calling deletions and duplications compared to 
Lumpy and Manta (Figure 5.9). Inversions called by Delly and Manta had similar sensitivity and 
precision, which were both higher than Lumpy. For insertions, we compared either predicted 
resolved breakpoints (two-ends) or BND (single-end) (Figure 5.9). Lumpy BND detected more 
insertions that overlap with the 1000G truth set, but less with the SVClassify truth set. Manta’s 
resolved breakpoints had approximately 50% concordance with both insertion truth sets; while its 
BND had no to minimal overlap. Unsurprisingly, Retroseq superseded all of the other SV callers 
in detecting true mobile element insertions (Figure 5.9).  
  
 
Figure 5.8: Formulas for calculating concordance. This figure shows all of the formulas used 
to calculate the overlap between different callsets (SV callers) and truthsets (1000 Genomes or 
SVClassify). Abbreviation: N, number.  
 
When we combined all of the call sets by their SVtype, we observe a higher concordance 
between the combined call sets and truth sets (Figure 5.10). Based on the NA12878 genome, it 
can be assumed that almost 100% of putative deletions and inversions will be detected by our SV 
discovery pipeline; and over 90% for duplications. Combining the BND and resolved INS calls 
from all the callers increased the detection rate of insertions in the 1000G truth set to 75% and 
50% respectively. Taking into account the 75% of the detectable MEI by Retroseq (Figure 5.9), 
we expect our SV discovery pipeline to detect over 75% of any SV subtypes present in a sample 
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genome that is similar to the NA12878; in terms of read length (2x150bp) and sequence coverage 
(20-30X).    
 
Figure 5.9: Comparing sensitivity and precision of SV callers across NA12878 truthsets. 
Each bar plot represents an NA12878 truth set for different SV types. Different SV types were 
extracted from the 1000 Genomes Project Phase 3 to generate “1000G” truth sets. Benchmark SV 
calls from SVclassify (Parikh et al., 2016) were also used as truth sets for deletions 
(Person_DEL) and insertions (Spiral_INS). The call sets were based on bed files generated from 
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the vcf files of each SV caller. Call sets with resolved breakpoints are designated with a SV type 
suffix; while single break ends are labelled as BND. Abbreviations: BND, single break ends; 
DEL, deletion; DUP, duplication; INS, insertion; INV, inversion; MEI, mobile element 
insertions; SV, structural variant. 
 
Figure 5.10: Combined SV call sets versus NA12878 truth sets. This faceted boxplot shows 
the number of real (true positive) and potentially missing (false negative) SV that overlap with 
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the truth sets, once all of the call sets from the different callers are combined. Abbreviations: 
BND, single break ends; DEL, deletion; DUP, duplication; INS, insertion; INV, inversion; MEI, 
mobile element insertions; SV, structural variant. 
5.2.2 Unfiltered structural variants in Aicardi cohort and In-house genomes 
We ran our SV discovery pipeline across all of the AIC genomes, five proband-parent trios and 
two singletons. For genomes that were unrelated and unaffected by AIC, we ran the pipeline 
across the following number of individuals per SV caller: 108 (Delly), 99 (Lumpy), 94 (Manta) 
and 104 (Retroseq) (Table 5.1). We observed a similar trend to NA12878, where BND 
represented a majority of the SV subtypes called, while INS were the least. Unexpectedly, we 
observed a 4-fold reduction in the number of MEI present in our set of genomes compared to the 
NA12878. Correspondingly, there were also slightly less deletions and BND called in our 
genomes. For the remaining SV subtypes, we observed a slight increase in the median number of 
called SV. These variations are likely due to different program versions used for pre-processing 
(Figure 5.1) of the Illumina reads; our genomes were sequenced in 2016 while the NA12878 was 






BND23 DEL DUP INS INV MEI 
Delly 125 66980 18472 7172 3793 5972 - 
Lumpy 116 10254 5044 1291 - 2984 - 
Manta 111 1708 5248 534 2272 435 - 




473 78942 28764 8997 6065 9391 7506 
NA12878 1 98746 29164 8737 5328 7029 26846 
                                               
23 Abbreviations: BND, single break ends; DEL, deletion; DUP, duplication; INS, insertion; INV, inversion; MEI, 
mobile element insertions; SV, structural variant. 
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Table 5.1: Summary of structural variants called by Delly, Lumpy, Manta and Retroseq.  
5.2.3 Automated Filtering of Structural Variants in Aicardi Probands 
SV in Aicardi genomes were prefiltered to reduce the number of: false positive calls due to 
sequencing-induced errors and poorly mapped reads; and potentially benign SV that were 
frequently observed in the control population. From the original number of SV in Aicardi 
genomes (Table 5.2, Unfiltered SV), we were able to filter out approximately 79% of variants 
using a combined set of SV from unrelated genomes (Table 5.2, Absent In-house). Another 6% 
of original SV were filtered out based on quality parameters recommended by the original 
authors of each SV caller (Table 5.2, Passed Quality) (Chen et al., 2016, Layer et al., 2014, 
Keane et al., 2013, Rausch et al., 2012). Retroseq calls were filtered based on the number of 
supporting reads and confident calls that meet breakpoint criteria (GQ tag => 20; FL tag => 5). 
Lumpy calls were filtered based on the Phred quality that the site is non-reference in any sample 
in the VCF (QUAL => 90). Manta and Delly calls were filtered based on those that passed all 
sample filters in the VCF filter fields such as MinQUAL, MinGQ and others (FT = PASS). After 
filtering variants that were present in a set of published SV that were discovered in an unaffected 
control population (Chapter 2; Table 5.2, Known Benign), we were left with approximately 


















FR07959033 65169 1820 987 844 177 20 7 0 
FR07959030 76860 3400 1121 924 371 38 16 0 
FR07959023 76177 3555 962 783 291 34 13 0 
FR07958956 142471 13798 1584 1393 1393 146 60 N/A 
FR07958917 70610 4738 3212 2403 2403 244 115 N/A 
FR07958909 69862 4020 1648 1426 332 31 13 0 
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FR07958885 72297 3503 1086 908 207 16 5 0 
Average 81921 4976 1514 1240 739 76 33 0 
Table 5.2: Summary of filtered structural variants from whole genome sequencing. 
 
Next, we filtered for heterozygous SV that were absent from both parents to enrich for de novo 
variants or homozygous SV that were present in both parents for homozygous recessive variants. 
We also included SV that were heterozygous but present in only one parent for the manual 
filtering of compound heterozygous variants. The advantage of having a complete proband-parent 
trio for SV analysis is shown in Table 5.2, where inheritance-based filtering reduced the number 
of filtered SV to a few hundred (177-371); compared to a few thousand (1393-2403) as seen in 
the singletons FR07958956 and FR07958917. For a first parse analysis, we filtered for variants 
that flanked the Hg19 canonical transcript of genes; as well as variants that are present in known 
genes associated with neurodevelopmental or retinal disorders (Chapter 2). This left us with 
approximately 30 SV per genome to manually evaluate (Table 5.2).  
 
5.2.4 Manual evaluation of Structural variants in Aicardi probands 
Putative SV were manually evaluated by visualising the proband SV alongside the parents’ 
genome (if available) and two unrelated control genomes to assess: (i) the mapping quality of the 
genomic interval and (ii) heritability of the variant. From manual viewing using IGV and 
Structural Variant Prediction Viewer (https://github.com/VCCRI/SVPV): 3/35 variants appear to 
be false positives; 13/35 variants were present in both parents and the remainder were present in 
one of the parents (Table 5.3). The high number of inherited variants that remained after 
automated filtering is likely due to the break end resolution of the called variants in the proband. 
For each SV, we buffered the breakpoints by adding 50bp to the left and right outer coordinates, 
which allows us to eliminate neighbouring and overlapping SV. Furthermore, a minimum 10% of 
 160 
reciprocal overlap of two SV is needed to be considered overlapping; this is to prevent smaller 
sized SV from being excluded due to its co-localisation with a larger sized SV. For variants 
outside of the ORF and flanking regions that lack functional annotations, we were unable to 
prioritise for potential regulatory variants as RNA sequencing data was unavailable for these 
probands.  
 
Sequencing ID Chr Start End SV Type SV Caller SV Length Gene Symbol Inherited 
FR07959033 chr10 101104236 101104286 MEI Retro 50 CNNM1 mother 
FR07959033 chr11 108051282 108051332 MEI Retro 50 NPAT father 
FR07959033 chr2 118862803 118862823 INS Delly 20 INSIG2 father 
FR07959033 chrX 74728497 74728547 MEI Retro 50 ZDHHC15 father 
FR07959030 chr1 165304109 165304125 INS Delly 16 LMX1A mother 
FR07959030 chr15 41040027 41040077 MEI Retro 50 RMDN3 father 
FR07959030 chr17 71421936 71421986 MEI Retro 50 SDK2 mother 
FR07959030 chr19 5936661 5936711 MEI Retro 50 RANBP3 father 
FR07959030 chr2 189162673 189162723 MEI Retro 50 GULP1 father 
FR07959030 chr2 189162677 189162727 MEI Retro 50 GULP1 father 
FR07959030 chr3 33225062 33225112 MEI Retro 50 SUSD5 father 
FR07959030 chr4 170658925 170658975 MEI Retro 50 C4orf27 mother 
FR07959030 chr5 168145422 168145472 MEI Retro 50 SLIT3 father 
FR07959030 chr6 136367281 136367331 MEI Retro 50 PDE7B father 
FR07959030 chr6 136367281 136367331 MEI Retro 50 AJ606316 father 
FR07959030 chr6 155111866 155111916 MEI Retro 50 SCAF8 father 
FR07959030 chr9 111949405 111949455 MEI Retro 50 EPB41L4B father 
FR07959030 chrX 100357481 100357499 INS Delly 18 CENPI father 
FR07959023 chr1 172306980 172307030 BND Manta 50 DNM3 mother 
FR07959023 chr1 175920598 175920619 INS Delly 21 RFWD2 father 
FR07959023 chr10 125592193 125592343 DEL Delly 150 CPXM2 father 
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FR07959023 chr11 10363248 10363298 MEI Retro 50 EF537580 mother 
FR07959023 chr14 24682592 24682625 INS Delly 33 TM9SF1 father 
FR07959023 chr14 24682592 24682625 INS Delly 33 NEDD8-MDP1 father 
FR07959023 chr2 233857820 233857915 DUP Manta 95 NGEF mother 
FR07959023 chr5 168244780 168244830 MEI Retro 50 SLIT3 mother 
FR07959023 chr8 99754722 99754772 MEI Retro 50 STK3 mother 
FR07958909 chr1 32584633 32584652 INS Delly 19 KPNA6 father 
FR07958909 chr1 62234144 62234164 INS Delly 20 INADL father 
FR07958909 chr1 67774469 67774519 MEI Retro 50 IL12RB2 father 
FR07958909 chr15 50592346 50592396 MEI Retro 50 GABPB1 mother 
FR07958909 chr17 73961732 73961782 MEI Retro 50 ACOX1 mother 
FR07958909 chr2 207045494 207045512 INS Delly 18 GPR1 mother 
FR07958909 chr20 37527454 37527469 INS Delly 15 PPP1R16B mother 
FR07958909 chr8 96697243 96697261 INS Delly 18 LOC100616530 mother 
FR07958885 chr10 61412821 61412871 MEI Retro 50 SLC16A9 father 
Table 5.3: Summary of inherited SV flanking open reading frames and regulatory elements. 
 
5.3 Discussion 
We developed a bioinformatics pipeline that was able to detect from 75% to 100% of SV from 
the benchmark NA12878 genome (Figure 5.9). It is known that different SV types have different 
functional consequences (Figure 5.11), thus for the filtering steps we divided SV by their class 
and length for comparison with unrelated in-house genomes and published datasets 
(Weischenfeldt et al., 2013). We also ensured that comparisons were made with exact 
breakpoints (if provided) or a buffered breakpoint of 50 base pair from single break ends. For SV 
prioritisation, we used multiple published datasets containing putative benign and pathogenic SV, 
which allowed us to enrich for known SV involved in human NDD and retinal disorders. 
Although we were able to detect more SV from our cohort of 13 girls compared to the findings in 
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Yilmaz et al. (2007) and Wang et al. (2009), we did not identify any putative causal SV in our 
Aicardi trios.  
 
Figure 5.11: Functional consequences of structural variants. This diagram was extracted from 
Weischenfeldt et al. (2013) to show the different functional impacts of different structural variant 
subtypes on coding sequences or regulatory elements.  
 
During our first parse analysis, we looked for variants that overlapped protein-coding and 
disease-associated regions. A majority of these variants were found in either deep intronic 
sequences free of known expression quantitative trait loci (eQTLs) or regions that were poorly 
conserved across multiple species. There was insufficient evidence to suggest these SV cis-
regulated the expression of the harboured or nearby genes. In a recent deep whole genome 
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sequencing study, approximately 88% of putative causal SV were non-coding and resided in 
eQTLs that are predicted to directly alter gene expression; which coincidentally has also been 
associated with phenotypic traits as inferred by GWAS (Chiang et al., 2017). From our coverage 
analysis (Chapter 4), a majority of the regions not covered by WGS were outside of protein-
coding regions or flanking complex (repetitive) sequences. Thus, our SV pipeline may have 
missed putative causal SV in these non-coding eQTLs.  
 
In contrast our SNP and Indels discovery pipeline, where we incorporated multiple prediction 
tools to assess the consequences on gene expression and protein function (Chapter 3 & 4), our 
SV pipeline relied on known disease-associated loci or regulatory elements. The lack of in silico 
tools to predict SV impact hindered our ability to prioritise novel-disease SV, especially for our 
two singleton cases whose parent genomes were unavailable for trio-analysis. There are limited 
numbers of sequencing-based tools available to assess SV impact due to the fact that different SV 
types spanning the same genomic region may have: (i) different functional consequences on the 
sequences they induce or rearrange, (ii) exact SV breakpoints that are difficult to resolve and 
often non-reciprocal across multiple SV callers and (iii) emphasis on positional effects rather than 
the potential cis or trans regulatory effects (Weischenfeldt et al., 2013).       
 
For a future second parse analysis, we can incorporate the in silico tools (though limited) that are 
available for SV such as VEP and SVScore. Using Ensembl provided information, VEP 
(https://github.com/Ensembl/ensembl-vep) can annotate SV that overlap with: (a) transcripts or 
regulatory regions, (b) known allele frequencies and (c) disease or phenotype association 
(McLaren et al., 2016). The limitation of VEP is that its predictions can only be applied to 
balanced SV such as insertions, deletions and duplications. Meanwhile, SVScore 
(https://github.com/lganel/SVScore) has the ability to aggregate SNP scores across the genomic 
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region harbouring a putative SV, which generates an SV pathogenic score that predicts the likely 
deleterious effect (Ganel et al., 2017). However, SVscore is unable to assess the impact of gain of 
function mutations or cis-regulatory elements. Many of these variant prediction tools are based 
on a training set of known variants. Thus with the emergence of putative causal SV detected in 
human disease cohorts and functional datasets with synthetic genetic variants, we can expect 
better methods for quantitative assessments of SV in the near future (Mahmood et al., 2017).  
5.4 Concluding Remarks 
In summary, we performed genome-wide screening of submicroscopic SV and CNV in seven 
Aicardi probands; five proband-parent trio and two singletons. Similar to previous studies, we did 
not identify any X-linked SV with sufficient evidence to support its pathogenicity (Yilmaz et al., 
2007, Wang et al., 2009). Furthermore, we did not detect any recessively inherited variants 
(homozygous or compound) that were absent from unrelated in-house or public genomes. Our SV 
analysis also did not reveal likely pathogenic variants in protein-coding or known regulatory 
regions. Overall our findings reveal that Aicardi Syndrome is unlikely to be caused by SV that 
were detectable using the WGS platform in our seven-patient cohort.   
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CHAPTER VI: Final Discussion & Future Directions 
6.1 Significance of Study 
Our study is the first to incorporate both computational and molecular approaches to identify 
candidate genes that may contribute to the pathogenesis of Aicardi Syndrome. To date, TEAD1 
and OCEL1 are the only genes that have harboured likely pathogenic variants discovered in the 
exomes of Aicardi probands (Schrauwen et al., 2015). Findings from our WES and WGS study 
(Chapter 4 & Chapter 5), revealed five more genes that are likely to contribute to the clinical 
manifestations in five of our unrelated probands. Based on the locus heterogeneity of ours and 
previous findings, we support the hypothesis that causes underlying Aicardi syndrome are 
genetically heterogeneous. These findings broaden the investigative window for future genetic 
studies involving individuals diagnosed with Aicardi or Aicardi-like syndromes.  
 
Achieving Aim 1: Develop a bioinformatics pipeline that will enrich for causal variants that 
underlay eye and cortical development.  
We compiled four gene lists to enrich for variants involved in eye and brain development; as well 
as genes associated with epilepsy and MCDs. For a clinically heterogeneous syndrome like AIC, 
we screened for variants that can explain for both the pathognomonic CRL and characteristic 
spectrum of MCDs. This differs from genetic studies like Schrauwen et al. (2015), where the 
variant identified in the Aicardi proband is likely associated with the eye phenotype, but the 
connection to the brain MRI findings are not well understood. Chapter 3 highlighted the 
effectiveness of our bioinformatics pipeline and variant prioritisation in achieving a genetic 
diagnosis for a previously unresolved case, wherein the segregating phenotype included both eye 
and brain abnormalities.   
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Achieving Aim 2: Prioritise candidate genes by assessing the likely pathogenicity of causal 
variants using in silico and in vitro assays.  
The power of segregation to support a genetic diagnosis in the case of our Aicardi cohort was 
insufficient due to: (1) lack of additional carriers with overlapping clinical phenotype as our 
proband and (2) distinguishing the variant as a true disease driver rather than incidental finding. 
To counteract this issue, we investigated de novo variants in HCN1 and WNT8B that were 
identified from our cohort and had pre-existing in vitro assays; tailored to either the gene or its 
protein family (Chapter 4.2.4 & 4.2.5). The HCN1 variant showed a loss of function in 
membrane conductivity of the mutant protein compared to its wildtype counterpart; meanwhile 
the WNT8B mutant protein displayed a dominant negative effect on the intracellular signalling of 
the wildtype protein. Our in vitro findings provided the differential diagnosis for proband 
T22352, while added further functional evidence to support the pathogenicity of the Leu70Pro 
variant in proband T22101. 
 
Achieving Aim 3: Investigate the biological role of causal variants in the pathogenesis of 
Aicardi Syndrome using in vivo models.  
To avoid multiple gene testing using independent protein-specific assays, which for a larger 
cohort study was not practical, we explored the use of zebrafish modelling as a pre-screening 
method to assess potential candidate genes. Based on the cost and time effectiveness of the 
morpholino-mediated knockdown approach, we examined four potential Aicardi genes: three 
from our study and one from Schrauwen et al. (2015). Using the zebrafish assay, we investigated 
whether the knock down of the implicated genes could lead to an eye pigmentation phenotype; 
equivalent to the pathognomonic chorioretinal lacunae of AIC (Chapter 4.2.6). In all four genes 
we tested, we saw either a uniform reduction in eye pigmentation (szt2) or sparse areas of eye 
pigmentation often occurring unilaterally (slf1, tead1 and wnt8b). For our implicated Aicardi 
 168 
genes, we also observed other developmental defects such as skeletal, cerebral and muscular; 
which correlates with the clinical features observed in the Aicardi patients with likely pathogenic 
variants in these genes. Although the knockdown in the zebrafish does not model the de novo 
(likely dominant negative) variant observed in the patients, it showed unifying morphant 
phenotypes in biologically distinct genes; which justifies further functional testing on these genes 
and their potential role in AIC.  
6.2 Limitations  
6.2.1 X-linked variants 
The most enigmatic aspect of AIC pathology is the excess of affected females compared to males 
that have been reported in literature thus far. Historical efforts towards answering this enigma 
were largely focused on finding X-linked candidate genes or loci using investigative tools such 
as: Southern blotting, skewed X-inactivation studies, X-linked CNV screening and whole X 
exome sequencing (Chapter 1.5.2). Although no X-linked candidates were identified from 
previous studies, this may be attributed to the resolution of the techniques restricted to either 
large chromosomal abnormalities or protein-coding regions. In our independent study based on 
WES and WGS, we extended our window of investigation to include protein-coding and non-
coding sequences; as well as regions with no sequencing coverage. Furthermore, our 
bioinformatics pipeline is able to detect variants at a resolution of single nucleotides to tens of 
kilobases (Chapter 4.2.2 & Chapter 5.2.1). We also investigated regions that may have been 
missed by sequencing, albeit potentially harbouring pathogenic variants on the X chromosome. 
Despite all of our considerations, we did not identify any X-linked candidate genes or locus that 
were enriched in our Aicardi cohort compared to our in-house genomes or public genomes.  
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The lack of X-linked candidates identified from others and our genetic studies may be attributed 
to variants residing in sequences inaccessible to the molecular tools utilised thus far. From our 
coverage analysis (Chapter 4.2.1), we show that the X-chromosome was adequately covered 
across all Aicardi genomes. Combined with segregation analysis in silico, we did not find any X-
linked denovo or inherited variants. Based on the coverage and segregation analysis, we suggest 
that X-linked protein-coding variants are unlikely to contribute to the AIC pathology in our 
cohort. However, for the unresolved individuals, there are potentially X-linked non-coding 
variants that lie in complex sequence regions that may have been missed by our sequencing 
approach.  For both WES and WGS, we selected paired-end sequencing (PES) for the detection 
of SNP and genomic rearrangements, which is widely used for large-scale disease studies such as 
the DDD and Epi4K (Deciphering Developmental Disorders et al., 2015; Epi4K Consortium et 
al., 2013). Despite its success in disease gene discovery, PES has limited or no coverage across: 
repetitive DNA sequences, regions with high or low GC bias and regions with non-random DNA 
fragmentation bias (Treangen et al., 2011, Aird et al., 2011).   
 
6.2.2 Non-coding variants 
A number of mutations residing in non-coding sequences have been recently implicated in 
neurodevelopmental disorders (Kumar et al., 2016, Huang et al., 2012). Approximately 98.5% of 
the human genome is comprised of non-coding sequences, which were historically considered as 
‘junk DNA’ as they were not functionally transcribed (Estellar et al., 2011).  However, the 
functional importance of non-coding sequences was proposed based on: (1) conserved non-
coding sequences were 10x more abundant compared to conserved coding sequences and (2) 
evolutionary studies have shown that all genomic regions are equally subjective to selective 
constraints (Attanasio et al., 2008, Thomas et al., 2003, Dermitzakis et al., 2003). In addition, 
multiple large-scale GWAS studies have presented statistical evidence that show disease-
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associated SNP usually reside in non-coding sequences (Herman et al., 2015, Bush et al., 2012). 
Although the disease-relevance of non-coding sequences have finally been recognised, there are 
comparatively less resources and tools available to assess the functional effect of non-coding 
sequences compared to protein-coding sequences (PCS).  
 
One of the limitations of our bioinformatics pipeline is the reliance on existing functional 
annotations for variant prioritisation outside of (PCS). Our search for likely pathogenic variants 
flanking exon-intron boundaries, untranslated regions (5’ and 3’) and known regulatory 
sequences was unsuccessful. A majority of non-coding variants that passed quality assessment 
and segregation analysis had: poorly conserved flanking sequences, no prior association to 
disease trait or unknown regulatory significance. Furthermore, algorithms used to assess protein-
coding mutations were not effective at assessing the potential regulatory and structural effects of 
non-coding sequences (Mather et al., 2016). In addition, we were unable to assess potential trans-
regulatory elements as matching RNA sequencing data was unavailable for most of our Aicardi 
WES and WGS.  
6.2.3 Structural variants 
The genomic instability of microsatellite and minisatellite repeats, more specifically short tandem 
repeat (STR) expansions, have been associated with several neurodevelopmental disorders such 
as Fragile X Syndrome, Myotonic dystrophy and Spinocerebellar ataxia (La Spada et al., 2010). 
Tandem and dispersed repeats may localise in both coding and non-coding regions; leading to 
disturbances to DNA processes like replication and recombination or protein consequences such 
as cellular toxicity (Usdin et al., 2000). Based on the short read-length (2x125bp) of the Illumina 
platform, our variant discovery pipeline is unable to detect STR that extend into complex 
sequence regions; especially in non-coding sequences. Fortunately, the systematic biases and 
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assembly problems presented by PES can be overcome with long-read sequencing (LRS) by 
Pacific Bioscience or Oxford Nanopore, which provides uniform coverage and de novo assembly 
from average read lengths of 10-15kb (Schatz et al., 2010). Repeated sequences constitute 
approximately 50% of the human genome (De Koning et al., 2011). Thus utilising LRS 
technology can expand our investigative window to include potentially pathogenic and 
previously missed STR on the X chromosome and autosomes. 
 
6.2.4 Somatic variants 
A majority of our findings were de novo germline variants, as the primary source for our genetic 
study was peripheral blood, which favours the detection of underlying germline mutations. 
However, somatic mutations have recently emerged as a genetic driver of various MCD and EE 
pathologies (Iffland et al., 2016, Moller et al., 2016, Jamuar et al., 2015, Lim et al., 2015). The 
allelic frequencies of brain-specific somatic mutations can be as high as 6.9-12.6% as reported by 
Lim et al. (2015) to extremely low mosaic levels of 0.1-3% as detected by Moller et al. (2016). 
From our cohort, 2/13 proband had paired blood-brain samples available for sequencing; the 
brain samples were derived from resected focal cortical dysplasia and choroid plexus papilloma. 
We were unable to detect somatic mutations present in the brain that was also absent from the 
blood. This could partly be due to our low sequencing coverage of 40x, which would only allow 
the detection of somatic variants above the allelic fraction of 5%. Variants that are below this 
frequency threshold were harder to prioritise as germline variants below this proportion were 
often false positives; thus did not validate with Sanger sequencing.  
6.2.5 Non-Mendelian inheritance  
Based on the observation of Aicardi individuals born to phenotypically normal parents, we 
filtered for variants under three potential modes of inheritance: de novo, compound heterozygous 
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and homozygous recessive. However, there are non-Mendelian transmission mechanisms that 
could also explain the phenotypic variability and lack of heritability of AIC such as: incomplete 
penetrance, epigenetic factors (including imprinting), repeat expansions and polygenic traits with 
continuous spectrum. We excluded variants that were present in only one parent and the proband 
assuming that autosomal dominance was unlikely as family history for a majority of our probands 
was unremarkable. However, gonadal mosaicism can occur in the parents resulting in affected 
progenies, which would resemble sporadic cases similar to those observed in bowel and breast 
cancer (Delon et al., 2013, Hes et al., 2008). This could also potentially explain the underlying 
cause of monozygotic twins discordant for AIC (Pons et al., 2008, Costa et al., 1997).  
6.3 Future Directions 
6.3.1 Improving variant screening 
X-linked Variants 
Other X-linked causes that we may have missed could include genes that escape from X-
inactivation, thus protecting females from the dosage effect of losing a functional single allele 
(Dunford et al, 2017). Alternatively, there could be an X-linked gene that requires the male 
patient to have a mosaic mutant variant to manifest AIC. This phenomena is observed in the case 
of PCDH19-related epilepsy, where karyotypically normal females with PCDH19 variants are 
affected, while males are asymptomatic unless they are carriers of mosaic single nucleotide 
variants (Terracciano et al., 2016). Variants in genes that are known to escape X-inactivation and 
those that manifest symptoms under cellular mosaicism need to reassessed in our Aicardi exomes 




In recent years, there were increases in functional annotations of non-coding sequences from the 
ENCODE project and other large-scale GWAS studies; as well as improvements in 
computational methods used to recognise regulatory motifs (Ward et al. 2015; Smedley et al. 
2016; Abbas et al., 2016, Zhou et al., 2015). For a comprehensive analysis of non-coding 
variants, we can reanalyse the exome, genome and RNA sequencing data using updated non-
coding annotations and prediction tools.  
 
Structural Variants 
There are potentially complex or larger structural variants (SV) that may have been missed by our 
PES approach such as: dispersed duplications, unbalanced translocations, microinversions and 
fully assembled large insertions. The detection of some intrachromosomal SV were restricted by 
the length of our read pair fragment sizes, while interchromosomal SV are reliant on paired-end 
mapping; thus unbalanced translocations presenting single-anchored breakpoints were difficult to 
resolve. Furthermore the availability of benchmark SV used to filter false positive or clinically 
benign SV is scarce compared to SNP or Indels; thus prioritising and interpreting the clinical 
significance of some SV were inconclusive (Chapter 5.2.4). Nonetheless, optical mapping can 
be an alternative to PES for the detection of novel (disease-relevant) CNV and Indels up to tens 
of kilobases in length; or combined with haplotype analysis can detect SV up to hundreds of 
kilobases (Howe et al., 2015, Cao et al., 2014). Unlike the cost associated with most LRS 
technologies, optical mapping provides a more cost-effective approach for complex SV discovery 
in smaller cohort studies like ours (Goodwin et al., 2016).  
 
Non Mendelian Inheritance 
Epigenetic inheritance of AIC has only been briefly explored in a recent genome-wide 
methylation study by Piras et al. (2017). Although the study indicated differential methylation in 
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AIC probands compared to their unaffected parents and controls, there were a few caveats 
including: small sample size, conducted on peripheral blood and examined 2% of all possible 
human DNA methylation sites. Nonetheless it is important to explore the epigenome as mutations 
in epigenetic factors or aberrations to epigenetic processes are involved in many 
neurodevelopmental disorders (NDD) such as: Rubenstein-Taybi, Coffin-Lowry, ATR-X and 
Rett Syndromes. Correspondingly, some NDD are caused by genomic imprinting, which is a 
mechanism that has yet to be explored in AIC studies but has the potential to explain the female-
biased incidence. It has been suggested that some imprinted genes are sexually differentiated, 
independent of the sex chromosome (Faisal et al., 2014, Radford et al. 2012). To 
comprehensively study whether epigenetics contributes to sexual differentiation or dimorphism in 
AIC, histone modifications and RNA-associated silencing also needs to be considered in addition 
to DNA methylation. 
 
Somatic Variants 
Nonetheless the lack of paired blood-brain samples for the investigation of brain-specific 
mutations can be circumvented by: (i) increasing the sequencing coverage of blood-brain DNA to 
a minimum of 200X or (ii) sequencing cell-free DNA released post seizure (Jamuar et al., 2015, 
Liimatainen et al., 2013). Both of these options can improve the detection of brain-specific 
variants, particularly in our cohort for individuals with unresolved causes.  
 
6.3.2 Future experimental plans 
SLF1 & SZT2  
At the time of our study, the biological role of SZT2 and SLF1 was not elucidated and thus were 
not tested in vitro. We now know the role of SZT2 in the MTOR pathway in both of the gator 
arms and SLF1 in the DNA-damage repair pathway with SLF2 as a duplex. Future experimental 
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plans for the SZT2 variant could involve measuring the interaction of the mutant protein with 
other gator components such as DEPDC5, WDR59 and SESN2. Meanwhile, the SLF1 variant can 
be assessed using available patient lymphoblastoid cell lines to detect DNA instability; or 
alternatively measure the mutant response to UV or chemically-induced DNA damage. Although 
we were unable to perform the necessary assay, we recognise the importance of functional 




In vivo screening 
There were a number of practical and theoretical limitations regarding our morpholino 
knockdown approach. Firstly, we used one translation-blocking morpholino per target gene and 
the level of knockdown was not measurable due to unavailability of antibodies. Secondly, we 
were unable to perform rescue experiment of the morphants using wildtype plasmid, which 
would have consolidated the correlation between the target gene and the suspected chorioretinal 
lesions. For repeated experiments using the morpholino knockdown approach, we would utilise a 
cocktail of multiple splice blockers, of which the knockdown effect can be directly measured by 
quantifying the level of transcript.  
 
Nonetheless, the morpholino knockdown approach enabled us to prioritise genes that may be 
involved in eye or brain development, however to precisely model the functional consequence of 
our identified de novo variants, we could utilise advance organoid technologies. A transgenic 
PAX6 reporter was introduced into mouse embryonic stem cells and differentiated into retinal 
organoids, which allowed gene expression profiling at different stages of retinogenesis (Volkner 
et al., 2016). A similar experiment for implicated AIC genes would allow the study of the retinal 
pigment epithelium, which could give rise to the pathognomonic CRL. Similarly, human brain 
organoids can be generated to study perturbations to neurodevelopment that may give rise to the 
signature spectrum of MCDs observed in AIC (Lullo and Kriegstein, 2017).   
 
6.3.3 Explaining female-bias incidence 
Sexually dimorphic chorioretinal lacunae 
In light of our sequencing findings, which contradicts the X-linked hypothesis and the inability to 
recruit male AIC patients for our study, we explored other mechanisms that can lead to female-
biased traits. As mentioned before, CRL (Figure 1.1) are the pathognomonic feature that 
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distinguishes AIC from other malformation of eye-brain disorders. One possibility that has yet to 
be explored is that CRL is a female-exclusive phenotype. In proband SQC25F8, we found a 
paternally inherited variant in TCF4 in a region free of reported mutations (Sepp et al., 2012). 
Female, but not male, Tcf4 and Tead1 null mice heterozygotes show abnormal retinal 
pigmentation and retinal morphology respectively (Koscielny et al., 2014). Remarkably, both of 
these corresponding genes have been linked to either Pitt Hopkins Syndrome or Sveinsson’s 
chorioretinal atrophy, which do not have a gender-bias aspect. Unfortunately, there is a lack of 
single-sex studies of female animals compared to males at a ratio of 1 to 5.5 respectively (Beery 
et al., 2011). In addition, corresponding mouse studies for the remaining AIC candidate genes 
were unavailable to test whether pigmentation defects are present and exclusive to females. 
Nonetheless, the observed retinal defects in female mice may be attributed to the relationship 
between estrogen and retinal pathologies; the role of sex hormones in ocular tissue has been 
previously established (Bajwa et al., 2012). Notably from immunocytochemistry, the expression 
of estrogen receptor alpha (ERα) was detected in the retina and retinal pigment epithelium of 
young female eyes but not in men or postmenopausal women (Ogueta et al., 1999).  
 
Female-sex hormones  
This brings us to our next hypothesis that AIC genes are interacting or modulated by female sex 
hormones. In MCF-7 (breast cancer) cells, it has been shown that KMT2B can epigenetically 
regulate estradiol (E2) dependent transcription via ERα (Su et al., 2016). Furthermore, the 
knockdown of KMT2B can lead to the down-regulation of 195 ERα target genes that were 
upregulated by E2. Another independent study in MCF-7 cells showed that WNT8B expression 
was significantly upregulated by E2, however it is unknown whether WNT8B is one of 195 genes 
modulated by KMT2B (Saitoh et al., 2002). E2 can also regulate gene expression via membrane 
estrogen receptors such as the G-protein-coupled oestrogen receptor 1 (GPER) (Revankar et al., 
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2005). In ZR-75-30 (breast cancer) cells, it has been shown that E2 can stimulate GPER and 
regulate Hippo signalling. Furthermore, GPER-induced transcription requires TAZ and 
transcriptional factors including TEAD1 (Zhou et al., 2015). E2 can also modulate the DNA 
damage repair pathway by inducing double stranded DNA breaks and genomic instability 
(Caldon, 2014). Recently, SLF1 was identified as a DNA repair factor that forms a complex with 
SLF2 and RAD18 to recruit SMC5/6 to DNA lesions and suppress genome instability (Raschle et 
al. 2015). Collectively, we have observed the direct (KMT2B, WNT8B) and indirect (TEAD1) or 
implicated (SLF1) regulation of estrogen in female AIC patients displaying the unifying CRL 
phenotype. 
 
Sexually dimorphic signalling  
Independent of the sex hormones, others and our implicated AIC genes may be involved in 
sexually dimorphic signalling pathways. It has been previously shown that multiple tissue types, 
including the brain, exhibit sexual dimorphism as a result of highly specific patterns of gene 
expression (Yang et al., 2006, Dewing et al., 2003). From the microarray analysis of the F2 
progeny of B6.apoE-/- and C3H.apoE-/- mice, there were approximately 600 sexually dimorphic 
genes identified in the Yang et al. (2006) study; spanning both autosomes and sex chromosomes. 
In a study based on the meta-analysis of LCL gene expression from the Geuvadis consortium, 
587 sex-biased genes were identified and nine transcription factors were enriched near female-
biased genes; some of these were involved in the Wnt signalling pathway (Shen et al., 2017). 
There are known female NDD caused by Wnt-related genes such as DDX3X, USP9X and PORCN 
(Snijders Blok et al., 2015, Murtaza et al., 2015, Grzeschik et al., 2007). In our study, we 
identified a WNT8B variant that affected canonical wnt signalling; while the Schrauwen et al. 
(2015) study discovered an upregulation of the wnt receptor LRP5 and a TEAD1 variant involved 
in the hippo pathway that cross-regulates with the wnt/B-catenin pathway (Kim et al., 2014). The 
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potential role of Wnt signalling or closely related pathways can explain both the clinical and 
genetic heterogeneity of AIC, as well as the female-bias prevalence; however more collaborative 
findings from multiple Aicardi cohorts are needed for further investigation.  
 
6.4 Conclusion 
Our study provided meta-analysis and new data to shed light on the clinical and genetic 
heterogeneity of AIC, which for more than 70 years was perceived as a monogenic and likely X-
linked disorder. We highlight the importance of utilising genetic studies to guide differential 
diagnosis of syndromes like AIC that involve multiple complex traits. From our cohort, we 
identified five likely pathogenic variants in three known disease genes (HCN1, KMT2B and 
SZT2) and two potentially novel developmental genes (SLF1 and WNT8B). For five of these 
families, we provided some insight into the genetic basis of their child’s condition; which were 
unresolved from previous clinical genetic testing. More importantly, there can be immediate 
health and welfare benefits including: counselling for family planning, closure to parents of 
affected children by alleviating self-blame and opportunities for improved support through 
patient outreach services and social media groups.  
 
From a research perspective, there are challenges that remain in establishing genetic causes for 
unresolved severe disorders of the brain. Firstly, the ability to distinguish between driver and 
incidental mutations, particularly for AIC where the prevalence of 4000 individuals worldwide 
reduces the probability of finding a recurring hit in a small cohort study given the unexpected 
heterogeneity we encountered. Secondly, without cost and timely functional assessment of each 
of these likely pathogenic variants, there is a lack of acceptance and support for isolated variants 
identified in one gene in one family. To study and resolve genetically heterogeneous disorders 
like Aicardi Syndrome, it would be more valuable to concentrate efforts on identifying molecular 
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signatures, converging pathway or similar developmental expression, which may involve 
different genes but lead to the same phenotypic consequence. In conclusion, our project 
established a computational and biological pipeline that can be used to identify potential genetic 
drivers of unexplained eye and brain disorders. This will lead to better understanding of how 
these brain disorders arise, accurate genetic diagnosis and potentially gene-tailored treatments.    
  
6.5 Publication 
This chapter have been reformatted into a brief report, which will be submitted to the American 









CHAPTER VII: Appendices 
7.1 Appendix Code & Data 
Code and data files used to generate results for Chapter 4, 5 and 6 are stored in the following 
github repository: https://github.com/ThuongHa/7.1-Appendix-Data-Code.git. Directory and file 








7.2 Appendix Tables 
7.2.1 List of likely pathogenic variants identified in Aicardi Singletons 
The following variants passed our prioritisation criteria for likely pathogenicity, but the parent 
genomes of FR07958956 and FR07958917 were unavailable in these probands, thus in silico 
segregation analysis was not applicable.  
Proband Chr Start End Ref Obs Gene ExAC snp142 PP2 CADD GERP VAF DP 
FR07958956 chr1 48697786 48697786 T G SLC5A9 0.00001 0 D 28.7 6.04 0.51 22 
FR07958956 chr1 52823458 52823458 G A CC2D1B 0 0 D 25 5.41 0.3 10 
FR07958956 chr2 20130279 20130279 T A WDR35 0.00006 rs370951527 P 26.3 5.2 0.44 14 
FR07958956 chr2 32740484 32740484 C T BIRC6 0 rs61757639 D 25.6 3.64 0.5 16 
FR07958956 chr2 164467322 164467322 T G FIGN 0 0 D 23.1 4.8 0.12 4 
FR07958956 chr2 233410292 233410292 C T CHRNG 0.00002 rs199767964 D 35 4.53 0.56 14 
FR07958956 chr3 148904356 148904356 G C CP 0 0 P 23.4 4.11 0.38 11 
FR07958956 chr4 187115722 187115722 G A CYP4V2 0.00004 rs199476187 D 26.7 5.4 0.68 19 
FR07958956 chr5 141034952 141034952 G A ARAP3 0.00006 rs141682206 D 35 5.12 0.49 19 
FR07958956 chr6 3111076 3111076 T C RIPK1 0 0 P 25 5.82 0.36 8 
FR07958956 chr6 56357084 56357084 C A DST 0 0 D 34 5.54 0.5 23 
FR07958956 chr7 102944337 102944337 C T PMPCB 0 0 P 23.6 4.3 0.49 17 
FR07958956 chr8 2026889 2026889 G A MYOM2 0 0 D 25.8 4.71 0.44 11 
FR07958956 chr8 37693192 37693192 C T ADGRA2 0.00011 0 P 35 5.29 0.53 17 
FR07958956 chr8 95523525 95523525 A G KIAA1429 0 0 D 25.5 5.5 0.46 13 
FR07958956 chr8 145139436 145139436 T C GPAA1 0 0 D 25.5 5.01 0.48 14 
FR07958956 chr10 70412288 70412288 A G TET1 0.00005 0 D 24.2 3.41 0.48 21 
FR07958956 chr10 97446261 97446261 C G TCTN3 0.00002 rs147928670 P 23.5 4.46 0.49 21 
FR07958956 chr11 47469392 47469392 C A RAPSN 0 0 P 33 5.14 0.42 16 
FR07958956 chr11 56127804 56127804 T G OR8J1 0.00062 rs149173319 D 25.9 4.57 0.63 22 
FR07958956 chr12 12672907 12672907 C T DUSP16 0 0 P 26.7 5.75 0.66 19 
FR07958956 chr12 21015427 21015427 T C SLCO1B3 0.00001 0 P 23.4 3.9 0.48 22 
FR07958956 chr12 133357385 133357385 T C GOLGA3 0 0 P 25.4 5.79 0.43 12 
FR07958956 chr14 105643306 105643306 G A NUDT14 0.00004 0 D 26.7 3.08 0.48 10 
FR07958956 chr15 88576096 88576096 G A NTRK3 0 rs371590703 D 34 4.91 0.47 14 
FR07958956 chr15 89381915 89381915 T C ACAN 0 0 D 23.3 4.95 0.13 4 
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FR07958956 chr15 90764607 90764607 C A SEMA4B 0 0 D 26.8 3.59 0.15 4 
FR07958956 chr16 5083680 5083680 G C NAGPA 0 0 D 25.1 5.23 0.49 17 
FR07958956 chr16 84214746 84214746 G A TAF1C 0.00002 0 D 25.2 4.56 0.52 13 
FR07958956 chr17 8296344 8296344 C G RNF222 0 0 P 20.5 4.57 0.59 17 
FR07958956 chr17 39671917 39671917 C G KRT15 0.00036 rs79344504 D 28.5 4.74 0.55 21 
FR07958956 chr17 65163599 65163599 G A HELZ 0.00006 rs200790914 P 32 4.99 0.5 16 
FR07958956 chr18 48241536 48241536 A C MAPK4 0 0 P 25.2 5.35 0.52 17 
FR07958956 chr19 17893893 17893893 G A FCHO1 0.00004 0 P 26.1 3.84 0.46 11 
FR07958956 chr19 18179264 18179264 G A IL12RB1 0.0003 rs201548803 P 24.8 4.6 0.49 23 
FR07958956 chr19 50305813 50305813 G A AP2A1 0.00004 0 P 22 5.11 0.42 11 
FR07958956 chrX 9677703 9677703 C A TBL1X 0 0 D 24.2 4.19 0.13 3 
FR07958956 chrX 47003874 47003874 T C NDUFB11 0 0 P 24.6 4.1 0.18 4 
FR07958956 chrX 49071927 49071927 A C CACNA1F 0 0 D 25.9 3.98 0.09 3 
FR07958956 chrX 153595141 153595141 C T FLNA 0 0 D 32 5.24 0.45 14 
FR07958917 chr1 1563061 1563061 C T MIB2 0 0 D 23.4 3.8 0.78 23 
FR07958917 chr1 26357016 26357016 G A EXTL1 0.00002 rs146384192 D 34 4.61 0.52 33 
FR07958917 chr1 50884378 50884378 G C DMRTA2 0 0 D 22.2 4.46 0.63 24 
FR07958917 chr1 116206387 116206387 G A VANGL1 0 0 P 25.1 4.01 0.55 33 
FR07958917 chr1 152081033 152081033 C G TCHH 0 0 P 16.57 3.78 0.84 19 
FR07958917 chr1 155108443 155108443 C T SLC50A1 0 0 D 32 4.85 0.69 29 
FR07958917 chr1 158724876 158724876 A T OR6K6 0 0 D 23.8 5.48 0.44 41 
FR07958917 chr1 169279311 169279311 C A NME7 0 0 D 28.2 5.58 0.52 27 
FR07958917 chr1 178359240 178359240 C G RASAL2 0.00001 0 D 22.9 5.66 0.53 36 
FR07958917 chr1 227348333 227348333 T C CDC42BPA 0 0 D 25.4 5.18 0.56 36 
FR07958917 chr2 17692163 17692163 T C RAD51AP2 0.00005 0 P 25.3 5.62 0.49 41 
FR07958917 chr2 162870961 162870961 T C DPP4 0.00013 rs200348396 P 23 5.81 0.59 32 
FR07958917 chr2 172379071 172379071 T C CYBRD1 0.00003 0 P 24 3.69 0.54 24 
FR07958917 chr2 219296640 219296640 C T VIL1 0 0 D 33 5.09 0.52 31 
FR07958917 chr2 219695023 219695023 G A PRKAG3 0.00002 0 D 21.4 4.18 0.66 32 
FR07958917 chr2 219875534 219875534 G A CFAP65 0.00002 rs370054630 D 27.1 5.41 0.4 30 
FR07958917 chr2 234102524 234102524 C G INPP5D 0 0 D 24.4 5.28 0.45 33 
FR07958917 chr3 46786175 46786175 A G PRSS45 0.00002 0 P 23.4 5.83 0.61 38 
FR07958917 chr3 48664072 48664072 G A SLC26A6 0.00001 0 D 31 3.56 0.52 25 
FR07958917 chr3 129195528 129195528 C T IFT122 0 0 D 29.7 5.65 0.49 41 
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FR07958917 chr3 140140107 140140107 G C CLSTN2 0.00001 0 P 24.4 5.7 0.41 29 
FR07958917 chr3 158364655 158364655 G A GFM1 0.00015 rs200727254 D 33 5.86 0.47 43 
FR07958917 chr3 169540133 169540133 C T LRRIQ4 0.00006 0 D 22.8 4.66 0.33 33 
FR07958917 chr3 183774048 183774048 G C HTR3C 0 0 D 29.8 4.77 0.52 27 
FR07958917 chr3 186940962 186940962 C T MASP1 0.00002 0 D 35 5.88 0.49 37 
FR07958917 chr4 629697 629697 C T PDE6B 0.00005 0 P 24.4 4.25 0.38 21 
FR07958917 chr5 1243727 1243727 C A SLC6A18 0.00029 rs148220007 D 25.1 4.98 0.3 20 
FR07958917 chr5 37293060 37293060 G A NUP155 0 0 P 28.8 5.24 0.61 31 
FR07958917 chr5 80040326 80040326 C T MSH3 0.00005 0 P 28.2 4.91 0.26 34 
FR07958917 chr5 80381670 80381670 A G RASGRF2 0.00002 rs145244937 D 26.9 5.57 0.53 30 
FR07958917 chr5 101583133 101583133 C A SLCO4C1 0 0 D 33 6.17 0.7 56 
FR07958917 chr5 140256522 140256522 C G PCDHA12 0 0 D 20.9 3.43 0.53 40 
FR07958917 chr5 151046042 151046042 C A SPARC 0.00002 0 D 34 4.81 0.53 32 
FR07958917 chr5 176309040 176309040 C A HK3 0 0 D 28.4 3.27 0.43 23 
FR07958917 chr6 150184795 150184795 G A LRP11 0 0 D 33 4.03 0.17 12 
FR07958917 chr7 4172034 4172034 G C SDK1 0 0 P 21.1 5.31 0.42 26 
FR07958917 chr7 30485796 30485796 G A NOD1 0.00001 0 D 33 5.38 0.5 34 
FR07958917 chr7 44800040 44800040 C A ZMIZ2 0 0 P 32 4.4 0.48 23 
FR07958917 chr7 80374467 80374467 C T SEMA3C 0 0 P 23.2 5.56 0.26 31 
FR07958917 chr7 86539236 86539236 T C KIAA1324L 0 0 P 16.55 4.88 0.6 45 
FR07958917 chr7 100175817 100175817 C T LRCH4 0.00006 rs142600009 D 31 4.52 0.59 22 
FR07958917 chr7 135329650 135329650 A G NUP205 0 0 P 23.3 5.02 0.54 39 
FR07958917 chr8 2044236 2044236 G A MYOM2 0.00004 0 D 29.6 5.46 0.59 27 
FR07958917 chr8 10466998 10466998 G A RP1L1 0.00002 rs375128393 D 23.2 4.44 0.48 23 
FR07958917 chr8 10480518 10480518 A G RP1L1 0.00011 rs377036512 P 25.3 4.78 0.32 28 
FR07958917 chr8 87076402 87076402 C A PSKH2 0 0 P 28.3 5.1 0.5 36 
FR07958917 chr8 92139360 92139360 C T LRRC69 0.00004 0 D 25.5 5.93 0.44 41 
FR07958917 chr8 145058505 145058505 G A PARP10 0.00001 0 D 31 4.21 0.3 20 
FR07958917 chr9 100257947 100257947 G T TDRD7 0 0 P 19.4 5.19 0.36 33 
FR07958917 chr9 125330564 125330564 T A OR1L8 0 0 P 24.2 3.16 0.47 36 
FR07958917 chr9 131495774 131495774 C G ZER1 0 0 D 32 5.77 0.54 26 
FR07958917 chr10 5925019 5925019 C G ANKRD16 0.00003 0 P 23.4 5.33 0.51 35 
FR07958917 chr10 61833470 61833470 C T ANK3 0.00001 0 D 26.2 5.7 0.39 28 
FR07958917 chr10 71008260 71008260 G A HKDC1 0.00002 0 D 28.2 5.1 0.57 23 
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FR07958917 chr10 75058817 75058817 C T CFAP70 0 rs112759937 P 15.58 4.42 0.52 42 
FR07958917 chr10 99118300 99118300 T C RRP12 0 0 D 24.2 3.37 0.59 17 
FR07958917 chr10 104121626 104121626 A C GBF1 0 0 D 28.3 6.17 0.48 27 
FR07958917 chr10 106025861 106025861 C T GSTO1 0.00002 rs369551343 D 33 5.35 0.29 24 
FR07958917 chr10 126716025 126716025 G A CTBP2 0 0 P 26 3.77 0.44 34 
FR07958917 chr11 4615690 4615690 C T OR52I1 0.00009 rs202168611 D 25.2 4.04 0.44 34 
FR07958917 chr11 6519825 6519825 T C DNHD1 0 0 D 23.1 4.28 0.61 31 
FR07958917 chr11 6806288 6806288 C T OR2AG1 0 0 P 22.7 3.33 0.51 35 
FR07958917 chr11 27378978 27378978 C T CCDC34 0 0 D 35 5.61 0.4 42 
FR07958917 chr11 56143880 56143880 C A OR8U1,OR8U8 0 0 D 23 4.78 0.82 62 
FR07958917 chr11 59245546 59245546 T C OR4D10 0 0 D 23.1 4.58 0.55 33 
FR07958917 chr11 73805042 73805042 T A C2CD3 0 0 P 21.7 3.43 0.5 34 
FR07958917 chr12 30862883 30862883 T C CAPRIN2 0 0 D 23.2 5.7 0.64 39 
FR07958917 chr12 42499690 42499690 T C GXYLT1 0 rs79044728 D 25.5 4.93 0.86 43 
FR07958917 chr12 42499694 42499694 A T GXYLT1 0 0 D 25 6.07 0.86 43 
FR07958917 chr12 46320945 46320945 G A SCAF11 0 0 D 31 4.99 0.46 35 
FR07958917 chr12 53343084 53343084 G T KRT18 0 0 D 27.2 3.69 0.84 19 
FR07958917 chr12 54917227 54917227 A C NCKAP1L 0 0 P 27 5.13 0.54 39 
FR07958917 chr12 56031508 56031508 T A OR10P1 0 0 P 24 3.06 0.57 28 
FR07958917 chr12 129566452 129566452 C T TMEM132D 0.00001 0 P 22.1 3.82 0.54 28 
FR07958917 chr13 28004071 28004071 C T GTF3A 0 0 P 26.4 3.61 0.45 44 
FR07958917 chr13 35782874 35782874 A T NBEA 0.00012 rs370712135 P 25.1 5.75 0.46 37 
FR07958917 chr15 33261131 33261131 G A FMN1 0 0 D 21.6 4.22 0.44 16 
FR07958917 chr15 40586540 40586540 C T PLCB2 0 0 P 34 4.69 0.62 13 
FR07958917 chr15 81610816 81610816 G A STARD5 0 0 D 24.9 4.06 0.57 23 
FR07958917 chr16 4935248 4935248 T G PPL 0 0 P 18.9 3.21 0.4 20 
FR07958917 chr16 28495363 28495363 G A CLN3 0.00002 0 D 22.8 5.28 0.56 27 
FR07958917 chr16 57921802 57921802 G A CNGB1 0.00001 0 P 25.9 5.46 0.57 28 
FR07958917 chr16 67237752 67237752 G C ELMO3 0 0 D 23.2 4.52 0.56 18 
FR07958917 chr16 85141552 85141552 G C FAM92B 0 0 D 23.3 4.74 0.57 35 
FR07958917 chr16 89799814 89799814 G A ZNF276 0 0 P 23.2 4.92 0.52 23 
FR07958917 chr17 25909962 25909962 C T KSR1 0 0 D 27.5 5.7 0.47 15 
FR07958917 chr17 27448650 27448650 T C MYO18A 0.00001 0 D 22.5 4.61 0.61 33 
FR07958917 chr17 35900523 35900523 C T SYNRG 0.00004 0 D 26.3 5.52 0.6 30 
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FR07958917 chr17 40825840 40825840 C T PLEKHH3 0.00006 rs200439190 P 24 4.78 0.31 16 
FR07958917 chr17 48605541 48605541 G A MYCBPAP 0.00001 0 D 31 4.82 0.45 31 
FR07958917 chr17 66899494 66899494 C A ABCA8 0 0 D 24.1 4.9 0.57 47 
FR07958917 chr18 13826638 13826638 C T MC5R 0.00004 0 D 23.8 4.58 0.52 29 
FR07958917 chr18 21494814 21494814 C G LAMA3 0.00003 rs373150935 P 26.5 3.98 0.46 35 
FR07958917 chr19 464136 464136 C T ODF3L2 0 0 P 25.1 3.8 0.46 13 
FR07958917 chr19 36135689 36135689 G C ETV2 0.00002 0 D 28.6 4.7 0.62 21 
FR07958917 chr19 37488173 37488173 G A ZNF568 0 0 P 26.5 3.89 0.4 30 
FR07958917 chr20 33264826 33264826 A C PIGU 0 0 D 25.7 5.09 0.37 30 
FR07958917 chr20 62324281 62324281 G A RTEL1 0.00002 rs369357121 D 23.4 4.83 0.54 28 
FR07958917 chr22 34157457 34157457 C T LARGE 0 0 P 23.5 5.83 0.33 27 
FR07958917 chr22 37578725 37578725 C T C1QTNF6 0 0 P 20.8 4.05 0.53 19 
FR07958917 chr22 50639845 50639845 A G SELO 0 0 P 20.2 3.29 0.2 5 




7.2.2 TOPFlash experimental conditions and measurements 
The raw data that was used to generate the results from Section 4.2.5 is listed below. 
14.05.15      
Plasmids ug/uL TOPFlash RLU FOPFLash RLU TOPFlash ABS FOPFlash ABS 
pcDNA 3.1 empty vector 1.0 100.0 100.0 0.0 0.0 
WNT8B wildtype 1.0 413.0 118.3 31.2 7.6 
WNT8B mutant 1.0 204.5 115.8 3.8 4.5 
WNT8B wildtype + mutant 0.75 + 1 217.3 136.5 36.2 5.5 
      
17.05.15      
Plasmids ug/uL TOPFlash RLU TOPFlash ABS   
pcDNA 3.1 empty vector 1.0 100.0 4.9   
WNT8B wildtype 0.2 381.1 16.3   
WNT8B mutant 0.2 245.0 11.7   
WNT8B mutant 0.5 289.7 17.6   
WNT8B wildtype + mutant 0.2 + 0.2 311.6 10.1   
WNT8B wildtype + mutant 0.2 + 0.5 276.3 12.7   
      
05.07.15      
Plasmids ug/uL TOPFlash RLU TOPFlash ABS   
pcDNA 3.1 empty vector 1.0 100.0 0.1   
WNT8B wildtype 0.2 396.9 5.5   
WNT8B wildtype 0.5 368.6 0.9   
WNT8B wildtype 1.0 344.0 19.9   
WNT8B mutant 0.2 199.4 13.1   
WNT8B mutant 0.5 261.2 11.9   
WNT8B mutant 1.0 228.3 17.6   
      
14.12.16      
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Plasmids ug/uL TOPFlash RLU TOPFlash ABS   
pcDNA 3.1 empty vector 1.0 100.0 0.9   
WNT8B wildtype 0.2 674.1 0.5   
WNT8B mutant 0.2 445.9 0.8   
WNT8B mutant 0.5 458.3 4.7   
WNT8B wildtype + mutant 0.2 + 0.2 452.3 1.5   
WNT8B wildtype + mutant 0.2 + 0.5 469.8 11.0   
      
15.12.16      
Plasmids ug/uL TOPFlash RLU TOPFlash ABS   
pcDNA 3.1 empty vector 1.0 100.0 0.7   
WNT8B wildtype 0.2 417.3 4.0   
WNT8B mutant 0.2 310.7 8.2   
WNT8B mutant 0.5 351.9 32.7   
WNT8B wildtype + mutant 0.2 + 0.2 380.9 10.9   
WNT8B wildtype + mutant 0.2 + 0.5 390.9 17.6   
      
Average of N=3 Experiments      
Plasmids ug/uL TOPFlash RLU TOPFlash ABS   
pcDNA 3.1 empty vector 1.0 100.0 2.2   
WNT8B wildtype 0.2 490.8 6.9   
WNT8B mutant 0.2 333.9 6.9   
WNT8B mutant 0.5 366.6 18.3   
WNT8B wildtype + mutant 0.2 + 0.2 381.6 7.5   




7.3 Appendix Publications 
7.3.1 A mutation in COL4A2 causes autosomal dominant porencephaly with cataracts. 
Chapter 3 has been published as a clinical report in the journal American Journal of Medical 










7.3.2 Genetic heterogeneity of Aicardi Syndrome revealed through whole exome and whole 
genome sequencing. 
Chapter 4, 5 and 6 has been reformatted into a brief report, which will be submitted to the 
journal American Journal of Human Genetics under the same title as Chapter 4. Contributions of 
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Aicardi Syndrome (AIC) is a rare neurodevelopmental disorder recognized by a classical triad of 
chorioretinal lacunae, infantile spasms and agenesis of the corpus callosum. The revised 
diagnostic criteria of AIC has been broadened to include additional phenotypes outside of the 
classical triad that are frequently observed. AIC is traditionally thought to be an X-linked and 
male lethal disorder due to an almost exclusive prevalence in females. There have been numerous 
genetic and genomic investigations into AIC, however an X-linked cause has yet to be 
established. In this study, we performed whole exome and whole genome sequencing on a cohort 
of 13 females diagnosed with or suspected of AIC based on the current criteria. In five unrelated 
individuals, we identified de novo variants in HCN1, KMT2B, SLF1, SZT2 and WNT8B 
respectively. Notably, a comprehensive genomic analyses of coding, non-coding and structural 
variation highlighted a distinct lack of X-linked candidates. Next, we assessed the likely 
pathogenicity of the autosomal variants we identified using a combination of: pre-existing in 
vitro assays (HCN1 and WNT8B), published expression and phenotype studies in human or mice 
and morpholino knockdown in zebrafish (Danio rerio) embryos. Our findings show that causes 




Aicardi Syndrome (MIM 304050; AIC) is an early infantile epileptic encephalopathy syndrome 
estimated to affect 4000 individuals worldwide (Kroner et al. 2008, Aicardi 2005). The 
diagnostic criteria for the disorder encompasses: a recognizable spectrum of malformations of 
cortical development including agenesis of the corpus callosum, intracranial cysts and white 
matter abnormalities; early onset infantile spasms and/or focal seizures within three to four 
months; and finally chorioretinal lacunae (CRL; Figure 1.1), which is the most consistently 
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observed phenotype among affected individuals to date (Aicardi 2005; Fruhman et al. 2012). In 
the absence of CRL, alternative eye phenotypes (coloboma and microphthalmia) can satisfy the 
phenotypic requirements for an AIC diagnosis provided that the accompanying onset and type of 
seizures and patterns of malformation of cortical development are typical of AIC (Aicardi 2005). 
In a meta-analysis of 405 cases, 83% of patients without CRL were not clinically diagnosed with 
AIC, despite sufficing the current diagnostic criteria (Aicard 2005, Kroner et al. 2008). This 
highlights the difficulty in recognising AIC, which requires combined expertise in neurology and 
ophthalmology and thus reiterates the need for identification of genetic causes to aid clinical 
examinations (Fruhman et al. 2012). 
 
Unfortunately, genetic testing for AIC is currently unavailable because the cause(s) underlying 
AIC have yet to be identified. Early investigations into the genetics of AIC were predominantly 
focused on chromosome X for two reasons (Neidich et al. 1990; Nielsen et al. 1991; Hoag et al. 
1997; Yilmaz et al. 2007; Eble et al. 2009; Pai et al. 2013). Firstly, the first chromosomal 
aberration reported in a suspected AIC female was an X/3 translocation (Ropers et al. 1982). 
Secondly, an X-linked male-lethal cause would best explain the predominance of the disease in 
females, which are represented in more than 99% of cases reported in literature. Despite 70 years 
of genetic and genomic investigations, an X-linked cause has yet to be established. By reviewing 
the genetic loci of variants reported in AIC thus far, we have yet to observe a recurring gene hit 
or subchromosomal overlap (Table 1.7).  
 
The clinical presentations and diagnosis of AIC in the cases we reviewed from literature and our 
cohort are highly variable. There are three observable subgroups of patients in ours and published 
cases based on the presentation of: (i) the complete classical triad (undisputed diagnosis; Figure 
1.1), (ii) one or two missing classical features replaced with major features that suffice the 
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Aicardi (2005) criteria (supported diagnosis) and two or more missing classical features replaced 
with minor features that do not meet the criteria (suspected diagnosis) (Table 1.1). In addition to 
the variable phenotypes, the efficacy of reported anti-epileptic treatments in Aicardi patients are 
also highly variable; which suggests diverse origins (post-synaptic processes and neuronal 
structures) of seizure development in AIC (Table 1.5). Based on the genetic and clinical 
variability observed thus far, we hypothesized that AIC is genetically heterogeneous. 
 
Patient consent was obtained for all patients enrolled in this study. The clinical characteristics of 
the individuals in our AIC cohort are summarised in Table - Clinical, while the full phenotypic 
spectrum is described in Table 4.2. Serological tests for congenital viruses and metabolic levels, 
performed antenatally were negative for all probands. 9/12 probands had no family history of 
neurodevelopmental disorders, while 10/12 had unremarkable pregnancy and delivery.  No 
genomic or genetic abnormalities were detected through prior clinical genetic testing for some of 
the patients that underwent karyotyping (1/12), array-based CNV screening (5/12) and candidate 
gene sequencing (1/12).  
 
We performed whole exome sequencing (WES) on 13 patients (and parents if available) using the 
Agilent SureSelect EZ human exome version v3 capture kit (Agilent) and sequencing on the 
HiSeq2500 (Illumina) platform. Fastq files were processed, annotated and analysed as previously 
described (S Figure - Pipeline) (Ha et al. 2015). WES achieved a median coverage depth of 30X 
across 97.27% of the target capture (Figure 4.3 & Table 4.3). On average, approximately 60,000 
SNP and Indels were called per exome and then filtered using the following selection criteria: (i) 
absent from unrelated in-house or published healthy cohorts, (ii) predicted deleterious by CADD 
and Polyphen2, (iii) transmitted in a de novo or recessive manner and (iv) associated with eye or 
cortical development. Four de novo variants remained after manual evaluation and Sanger 
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validation in the following genes: HCN1, SLF1, SZT2 and WNT8B (Table 4.4) (Kircher et al. 
2014; Adzhubei et al. 2010).  
 
For the remaining cohort with ambiguous or no variant hits, we proceeded with whole genome 
sequencing (WGS) using the HiSeqXTen (Illumina) platform. Sequence reads were processed 
and variants called by the Australian Genome Research Facility, using Genome analysis toolkit 
(GATK) v3.5-0 best practices guidelines (Auwera et al. 2013). Variants within protein-coding 
regions were annotated and analysed equivalently to WES. WGS achieved a median coverage 
depth of 38X across 99.74% of the Human genome genome build 19 (Hg19) (Figure 4.3 & 
Table 4.3). On average, approximately 5 million SNP and Indels were called per genome. For 
our first parse, we analysed variants in protein-coding regions that may have been missed from 
WES. Here, an average of 42,000 exonic variants remained per proband and a further 82 fulfilled 
our disease-variant filtering criteria (Table 4.6). From our parent-proband trios (n=5), after we 
applied inheritance-based filtering, only one de novo variant, in KMT2B, validated via Sanger 
sequencing (Table 4.5). For the remaining two singletons, we compiled a list of potential variant 
hits that require segregation when parent DNA is available (Appendix 7.2.1).  
 
We also screened for putative causative structural variants (SV; larger than 50bp) using four 
widely used programs: Delly, Lumpy, Manta and Retroseq (Rausch et al. 2012; Layer et al. 2014; 
Chen et al. 2015; Keane et al. 2012). We validated our SV discovery pipeline (Figure 5.6) using 
the Genome in a Bottle benchmark genome ‘NA12878’ (Figure 5.7 & Figure 5.9) (Zook et al. 
2016) and applied it to 17 AIC genomes (5 proband-parent trios and two singletons) and 
approximately 100 unrelated in-house genomes Combining the variants from all the SV callers, 
there were approximately 82,000 SV per genome (Table 5.2). SV were automatically filtered 
using a custom bash script and the following parameters: unrelated in-house genomes, read 
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quality scores, benign SV from published datasets and assumed inheritance models (Table 5.2). 
After prioritising for variants that flanked Hg19 canonical transcripts or regulatory elements, 
none of these variants appeared de novo in silico (Table 5.2). As RNA sequencing data was 
unavailable for these probands, we were unable to prioritise regulatory variants.  
 
Of the five putative candidate genes identified, HCN1 and WNT8B had pre-existing in vitro 
assays that we could employ to test the effect of each variant on protein function. For HCN1, 
encoding the hyperpolarization-activated cyclic nucleotide-gated channel 1, we investigated the 
effect of the HCN1 (c1625G>T; p.Cys542Phe; NM_021072) variant on membrane conductivity 
using voltage-clamp assay in frog (Xenopus laevis) oocytes. We found that oocytes expressing 
HCN1 (p.Cys542Phe) variant left-shifted the voltage dependence of activation suggesting a loss 
of channel function (Figure 4.6). These findings contrast with the gain of function or dominant 
negative effects of pathogenic HCN1 variants described by Nava et al. (2014). While most of the 
published variants reside in the transmembrane or intracellular domain of HCN1, the 
p.Cys542Phe variant is located in the cyclic nucleotide binding domain that is responsible for the 
direct regulation of the channel function (Wainger 2001). Previously reported individuals with 
mutations in HCN1 have a Dravet-like syndrome with normal brain MRI and seizure onset 
between 4 and 13 years of age (Nava et al. 2014). The discovery of the HCN1 (p.Cys542Phe) 
variant also helped redefine the diagnosis for proband V from an AIC-like syndrome to Early 
Infantile Epileptic Encephalopathy (EIEE) 24 (MIM 615871). 
 
To assess the effect of the WNT8B (c.209T>C; p.Leu70Pro; NM_003393) variant that was found 
in proband III (Table - Clinical; Figure - In vitro) on canonical WNT signalling we performed a 
TOPFlash assay in human embryonic kidney 293T cells. We observed that in the presence of 
wild-type WNT8B, the mutant had a dominant negative effect indicated by a significant 
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reduction in luciferase reporter gene activity (Figure 4.7). The mechanism by which WNT8B 
mutant interferes with the wildtype WNT signalling was not followed up in our study. We 
observed that the WNT8B mutant was consistently lower in abundance compared to the wildtype 
at equivalent levels of transfected plasmid, potentially indicating a loss of protein stability 
(Figure 4.7). WNT8B has yet to be implicated in any human inherited disorder however, the 
demonstrated roles for the zebrafish and mouse WNT8B orthologues in specifying the anterior 
neuroectoderm, regulating axon guidance and specification of retinal progenitor cells, suggest 
this gene as a very plausible candidate for AIC (Kim et al. 2002; Cavodeassi et al. 2005; 
Hofmeister & Key 2013, Liu 2012). 
 
For the remaining genes that did not have established molecular or biochemical assays and are 
yet to be implicated in both eye and brain development, we used morpholino knockdown in 
zebrafish (Danio rerio) embryos to screen for phenotypes that were reminiscent of AIC. We 
included tead1, which is the only other previously identified gene implicated AIC that is 
conserved in zebrafish. We designed a study in which the morpholino injections and data analysis 
were carried out under blinded conditions and morphant classification counts were verified by 
three independent researchers. More than 90% of uninjected and scrambled morpholino control 
group displayed normal embryonic development with or without minor body abnormalities such 
as bent tail (Figure 4.8). In contrast, our experimental morphants displayed a spectrum of 
developmental abnormalities including: lack of eye pigmentation, body curvatures, pericardial 
oedema, tail defects and head malformations (Figure 4.8). The most consistent phenotype among 
the slf1, tead1 and wnt8b morphants was the lack of eye pigmentation, which was patchy in 
appearance and often unilateral (Figure 4.8). A lack of eye pigmentation was also observed in 
szt2 morphants, however as 72 hours post fertilization (hpf) szt2 morphants often resembled 48 
hpf morphants, this may be attributed to developmental delay. There are known limitations to 
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disease modeling in zebrafish (Kok et al. 2015) and the morpholino knockdown approach models 
a loss of function whereas our de novo variants are likely to be dominant negative. Nonetheless, 
we showed a unifying morphant phenotype of AIC-like eye and brain defects among at least 3/5 
genes tested. 
 
We identified likely pathogenic variants in different autosomal genes from five unrelated 
individuals. The lack of X-linked candidates identified from others and our genetic studies may 
be attributed to the paired-end sequencing (PES) approach, which has limited resolution for 
variants in repetitive DNA sequences, regions with high or low GC bias and non-random DNA 
fragmentation bias (Treangen et al. 2011; Aird et al. 2011). Structural variant detection from PES 
is reliant on balanced and paired-end mapping, which may miss larger or complex structural 
variants such as: dispersed duplications, unbalanced translocations, microinversions, large 
insertions and repeat expansion mutations. Our 38X average sequencing coverage was also 
inadequate for detecting somatic variants with low levels of mosaicism (less than 5% of allelic 
fraction); which could be disguised as false positives. In addition, a majority of our sequencing 
was based on peripheral blood DNA, thus we were unable to comprehensively screen for brain-
specific variants. Finally, due to the lack of paired WGS and RNA sequencing data, we were 
unable to prioritise and interpret the significance of some non-coding variants; especially in 
regions lacking functional annotations. For the remaining unresolved individuals in our cohort, an 
X-linked cause may still be possible. 
 
The most enigmatic aspect and least understood aspect of AIC is the almost exclusive female 
prevalence. In light of our genetic data that opposes the X-linked-male-lethal hypothesis and lack 
of  males affected by AIC in our study, we explored other potential mechanisms that can lead to 
female-biased traits. One possibility would be the participation of the implicated AIC genes in a 
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sexually dimorphic pathway such as Wnt signalling, which has been linked to female 
neurodevelopmental disorders in X-linked Wnt-related genes such as DDX3X, USP9X and 
PORCN (Shen et al. 2017; Snijders et al. 2015; Murtaza et al. 2015; Grzeschik et al. 2007). In our 
study, we identified a WNT8B variant that affected canonical wnt signalling; while the Shrauwen 
et al. (2015) study showed upregulation of the wnt receptor LRP5 by RNA-Seq and also 
discovered a pathogenic variant in TEAD1.  While TEAD1 is involved in the hippo pathway, 
there is evidence for cross-regulation between the hippo and wnt/β-catenin pathways (Kim & Jho 
2014).  
 
Another hypothesis would be the interaction with or modulation by female sex hormones and our 
candidate AIC genes. In MCF-7 (breast cancer) cells, it has been shown that KMT2B can 
epigenetically regulate estradiol (E2) dependent transcription via estrogen receptor alpha (ERα) 
(Su et al. 2012). Meanwhile in an independent study in MCF-7 cells, WNT8B expression was 
significantly upregulated by E2 (Saitoh et al. 2002). It is interesting to note that the expression of 
ERα was detected in the retinal pigment epithelium (RPE) of young female eyes but not in men 
or postmenopausal women (Ogueta et al. 1999). The role of estrogen in retinal pathologies are 
well established and it is tempting to speculate that CRL (the pathognomonic feature of AIC) 
may be a sex-limited trait that appears in an excess of females compared to males (Gupta et al. 
2005; Wagner et al. 2008). Nonetheless, more transcriptomic and epigenomic data is needed to 
assess whether E2 directly or indirectly regulate ours and future implicated AIC genes.  Other 
sex-limited traits that overlap with AIC, such as early infantile epileptic encephalopathy and 
isolated ACC, have been reported in affected females with autosomal mutations in FOXG1 
(14q12), YWHAG (7q11.23), HCN1 (5p12) and DCC (18q21.2) (Mitter et al. 2017; Guella et al. 
2017; Marsh et al. 2017; Nava et al. 2014). 
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Overall, our genetic findings highlight the importance of proband-parent trio analysis for 
unresolved and clinically heterogeneous disorders like Aicardi Syndrome. We were able to 
provide a differential diagnosis for proband T22352 and expand the phenotype spectrum of 
HCN1 variants. We also identified two new variants in known neurodevelopmental disorder 
genes, SZT2 and KMT2B. Although these variants have good bioinformatic support for 
pathogenicity, the inheritance of the SZT2 variant in proband T25217 and the phenotype of 
proband T22842 with the KMT2B variant do not match with the published cases reported thus far 
(Table - De novo & S Table - Recurrence). Further functional validation is needed to establish 
whether these variants are true drivers of the Aicardi phenotypes in the respective individuals or 
incidental findings. We also discovered likely pathogenic variants in WNT8B and SLF1 in 
probands T22101 and T17262 respectively.  These two genes have yet to be implicated in human 
neurodevelopmental disorders (Table - 4.5 & Table 4.6). Although both of these genes are 
biologically distinct (Table 4.7), they share similarities in their zebrafish morphant phenotype 
(Figure 4.8) and expression in embryonic mouse brain (Figure 4.14 & Figure 4.15). Both of the 
individuals with the WNT8B and SLF1 variant display the classical triad (diagnostic for AIC; 
Figure 1.1) with overlapping accompanying phenotypes including: ventriculomegaly, atrophy of 
cerebellar hemisphere, developmental delay, scoliosis and skeletal abnormalities (Table 4.1 & 
Table 4.2). Based on our in vivo findings and published expression studies, WNT8B and SLF1 
appear to be good candidates for AIC that strongly suggest that this enigmatic disorder is 
genetically heterogeneous and that not all cases will be X-linked.  
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